U.S. patent application number 09/833917 was filed with the patent office on 2002-01-03 for hydrazide and alkoxyamide angiogenesis inhibitors.
Invention is credited to Ba-Maung, Nwe, Craig, Richard A., Kawai, Megumi, Lynch, Linda M., Patel, Jyoti R., Sheppard, George S., Wang, Jieyi, Yang, Fan.
Application Number | 20020002152 09/833917 |
Document ID | / |
Family ID | 26892708 |
Filed Date | 2002-01-03 |
United States Patent
Application |
20020002152 |
Kind Code |
A1 |
Craig, Richard A. ; et
al. |
January 3, 2002 |
Hydrazide and alkoxyamide angiogenesis inhibitors
Abstract
Compounds having the formula 1 are methionine aminopeptidase
type 2 (MetAP2) inhibitors and are useful for inhibiting
angiogenesis. Also disclosed are MetAP2-inhibiting compositions and
methods of inhibiting angiogenesis in a mammal.
Inventors: |
Craig, Richard A.; (Racine,
WI) ; Kawai, Megumi; (Libertyville, IL) ;
Lynch, Linda M.; (Pleasant Prairie, WI) ; Patel,
Jyoti R.; (Libertyville, IL) ; Sheppard, George
S.; (Wilmette, IL) ; Wang, Jieyi; (Gurnee,
IL) ; Yang, Fan; (Highwood, IL) ; Ba-Maung,
Nwe; (Niles, IL) |
Correspondence
Address: |
Steven F. Weinstock
Abbott Laboratories
AP6D/D-377
100 Abbott Park Road
Abbott Park
IL
60064-6050
US
|
Family ID: |
26892708 |
Appl. No.: |
09/833917 |
Filed: |
April 12, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60197262 |
Apr 14, 2000 |
|
|
|
Current U.S.
Class: |
514/159 ;
514/330; 514/614; 546/159; 546/221; 564/149 |
Current CPC
Class: |
C07D 213/86 20130101;
C07C 2601/14 20170501; C07C 243/34 20130101; C07C 243/38 20130101;
C07D 213/81 20130101; C07C 255/44 20130101; C07D 213/42 20130101;
C07D 211/98 20130101; C07D 207/50 20130101; C07D 307/84 20130101;
C07C 2601/18 20170501; C07D 333/68 20130101; C07C 259/06 20130101;
C07D 295/15 20130101; C07B 2200/07 20130101; C07D 277/54 20130101;
C07D 317/68 20130101; C07D 215/42 20130101; C07D 207/416 20130101;
C07D 277/56 20130101; C07D 333/72 20130101; C07C 2601/02 20170501;
C07C 323/63 20130101; C07D 277/82 20130101; C07C 2601/08 20170501;
C07D 241/44 20130101; C07C 281/02 20130101; C07D 213/87 20130101;
C07C 323/60 20130101; C07D 239/42 20130101; C07D 239/28 20130101;
C07D 261/18 20130101; C07D 333/38 20130101; C07C 251/86 20130101;
C07D 307/68 20130101; C07D 213/77 20130101; C07D 237/20 20130101;
C07D 295/32 20130101; C07C 255/57 20130101; C07C 323/48 20130101;
C07D 209/14 20130101; C07D 231/38 20130101 |
Class at
Publication: |
514/159 ;
514/614; 514/330; 546/159; 564/149; 546/221 |
International
Class: |
A61K 031/47; A61K
031/166; C07C 243/10; C07D 215/38 |
Claims
What is claimed is:
1. A compound of formula (I), 8or a therapeutically acceptable salt
or prodrug thereof, wherein R.sup.1 is selected from the group
consisting of alkyl, aryl, arylalkyl, cycloalkyl,
(cycloalkyl)alkyl, (heterocycle)alkyl, and R.sup.5S-(alkylene)-;
wherein each group is drawn with its right-hand end being the end
that is attached to the parent molecular moiety; R.sup.3 is
selected from the group consisting of hydrogen, alkyl, and
arylalkyl; R.sup.4 is selected from the group consisting of
--NR.sup.6R.sup.7, and --OR wherein each group is drawn with its
left-hand end being the end that is attached to the parent
molecular moiety; R.sup.5 is selected from the group consisting of
alkyl, aryl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl; R.sup.6
and R.sup.7 are independently selected from the group consisting of
hydrogen, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl,
alkoxycarbonylalkyl, alkyl, alkylsulfanylalkyl, aryl, arylalkanoyl,
arylalkoxyalkyl, arylalkoxycarbonyl, arylalkyl, aryloxyalkyl,
(aryl)oyl, arylsulfonyl, carboxyalkyl, cycloalkyl,
(cycloalkyl)alkyl, (cycloalkyl)alkanoyl, (cycloalkyl)oyl,
haloalkanoyl, haloalkyl, heterocycle, (heterocycle)alkanoyl,
(heterocycle)oyl, hydroxyalkyl, a nitrogen protecting group, and
--C(O)NR.sup.9R.sup.10; or R.sup.6 and R.sup.7 together are
arylalkylidene; or R.sup.6 and R.sup.7, together with the nitrogen
atom to which they are attached, form a heterocycle; R.sup.8 is
selected from the group consisting of hydrogen, alkanoylalkyl,
alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl,
arylalkoxycarbonylalkyl, (aryl)oylalkyl, carboxyalkyl, and
(cycloalkyl)alkyl; and R.sup.9 and R.sup.10 are independently
selected from the group consisting of hydrogen, alkyl and aryl.
2. A compound according to claim 1, wherein R.sup.1 is selected
from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl,
arylalkyl, and (heterocycle)alkyl.
3. A compound according to claim 2, wherein R.sup.4 is
--OR.sup.8.
4. A compound according to claim 3 selected from the group
consisting of
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-phenoxybutanamide;
(2RS,3R)-3-amino-N-(benzyloxy)-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-N-(methoxy)-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-N-(tert-butoxy)-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-4-cyclohexyl-N-ethoxy-2-hydroxybutanamide;
(2RS,3R)-N-(allyloxy)-3-amino-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-isobutoxybutanamide;
(2RS,3R)-3-amino-4-cyclohexyl-N,2-dihydroxybutanamide;
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N-phenoxypropanamide;
(2RS,3R)-3-amino-5-phenyl-2-hydroxy-N-phenoxypentanamide;
(2RS,3R)-3-amino-3-cyclooctyl-2-hydroxy-N-phenoxypropanamide,
(2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N-phenoxypentanamide; ethyl
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate;
benzyl
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)aceta-
te;
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetic
acid; ethyl
(2S)-2-((((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)a-
mino)oxy)acetyl)amino)propanoate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy--
N-(2-oxo-2-((2-phenylethyl)amino)ethoxy)butanamide;
(2RS,3R)-3-amino-N-(benzyloxy)-3-cyclohexyl-2-hydroxypropanamide;
and
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-phenylpentanamide.
5. A compound according to claim 2 wherein R.sup.4 is --NR.sup.6
R.sup.7.
6. A compound according to claim 5 wherein one of R.sup.6 and
R.sup.7 is hydrogen and the other is (aryl)oyl.
7. A compound according to claim 6 selected from the group
consisting of
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-ethoxybenzohydrazi-
de;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethoxybenz-
ohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-chlorob-
enzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-brom-
obenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-me-
thoxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)--
2,5-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybut-
anoyl)-2-methoxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydrox-
ybutanoyl)-3-chlorobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hyd-
roxybutanoyl)-3-methylbenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2--
hydroxybutanoyl)-2,4-dihydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclo-
hexyl-2-hydroxybutanoyl)-2,5-dimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methylbenzohydrazi-
de;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-nitrobenzohydra-
zide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-naphthohydraz-
ide; N'-((2
RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-chlorobenzohy-
drazide;
(2RS,3R)-3-amino-N'-benzoyl-4-cyclohexyl-2-hydroxybutanohydrazide-
;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-bromobenzohydrazi-
de;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-tert-butylbenzo-
hydrazide; N'
((2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoyl)-3-chlorob-
enzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-3-chlorob-
enzohydrazide;
N'-((2RS,3R)-3-amino-3-cyclooctyl-2-hydroxypropanoyl)-3-chl-
orobenzohydrazide;
N'-((2RS,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-
-chlorobenzohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N'-(1-naphthyl)-
pentanohydrazide;
N'-((2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoyl)-2--
naphthohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-n-
aphthohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hy-
droxy-2-naphthohydrazide;
N'-((2S,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-
-1-naphthohydrazide;
N'-((2S,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-3-hy-
droxy-2-naphthohydrazide;
N'-((2S,3R,4RS)-3-amino-4-ethyl-2-hydroxyoctanoy-
l)-3-chlorobenzohydrazide; N'-((2S
,3R)-3-amino-5-cyclohexyl-2-hydroxypent-
anoyl)-3-chlorobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-
butanoyl)-2-hydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hyd-
roxybutanoyl)-2-methylbenzohydrazide;
2-amino-N'-((2RS,3R)-3-amino-4-cyclo-
hexyl-2-hydroxybutanoyl)benzohydrazide;
4-amino-N'-((2RS,3R)-3-amino-4-cyc-
lohexyl-2-hydroxybutanoyl)benzohydrazide;
3-amino-N'-((2RS,3R)-3-amino-4-c-
yclohexyl-2-hydroxybutanoyl)benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohe-
xyl-2-hydroxybutanoyl)-3-hydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyc-
lohexyl-2-hydroxybutanoyl)-4-hydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methoxybenzohydraz-
ide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-fluorobenzohyd-
razide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-fluorobenzo-
hydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-fluorobe-
nzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-bromo-
benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-eya-
nobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-c-
yanobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-
-(dimethylamino)benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydrox-
ybutanoyl)-4-(dimethylamino)benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohe-
xyl-2-hydroxybutanoyl)-3-(trifluoromethyl)benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(trifluoromethyl)b-
enzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(tri-
fluoromethoxy)benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxyb-
utanoyl)-4-phenoxybenzohydrazide;
N'-((2RS,3R)-3-arnino-4-cyclohexyl-2-hyd-
roxybutanoyl)-2,4-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexy-
l-2-hydroxybutanoyl)-2,5-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-4-cy-
clohexyl-2-hydroxybutanoyl)-3,4-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethylbenzohyd-
razide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethoxy-
benzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3
,4-dimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybu-
tanoyl)-3,4,5-trimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl--
2-hydroxybutanoyl)-2,3-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cycl-
ohexyl-2-hydroxybutanoyl)-2,4-dichlorobenzohydrazide;
N'-((2RS,3R)-3-arnino-4-cyclohexyl-2-hydroxybutanoyl)-3
,4-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybut-
anoyl)-3,5-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hyd-
roxybutanoyl)-2,3-dimethylbenzohydrazide;
(2S,3R)-3-amino-N'-(3-chlorobenz-
oyl)-2-hydroxy-5-phenylpentanohydrazide; and
(2S,3R)-3-amino-N'-(3-chlorob-
enzoyl)-2-hydroxy-5-(1H-indol-3-yl)pentanohydrazide.
8. A compound according to claim 5 wherein one of R.sup.6and
R.sup.7 is selected from the group consisting of hydrogen, alkyl,
and aryl; and the other is selected from the group consisting of
hydrogen, aryl, and arylalkyl.
9. A compound according to claim 8 selected from the group
consisting of
(2RS,3R)-3-amino-N'-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N'-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-phenylethyl)butanohydrazide-
;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-methyl-N'-phenylbutanohydrazi-
de;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-methylphenyl)butanohydra-
zide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-methoxyphenyl)butanohy-
drazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(1-naphthyl)butanohydr-
azide; (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2,4-difluorophenyl)-2-hydroxybutanohydr-
azide;
4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)ben-
zenesulfonamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenylbutanohy- drazide;
(2RS,3R)-3-amino-N'-(4-bromophenyl)-4-cyclohexyl-2-hydroxybutanoh-
ydrazide;
(2RS,3R)-3-amino-N'-(2-chlorophenyl)-4-cyclohexyl-2-hydroxybutan-
ohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(3-(trifluoromethyl-
)phenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-iod-
ophenyl)butanohydrazide;
(2RS,3R)-3-amino-N'-(3-chlorophenyl)-4-cyclohexyl-
-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(3-m-
ethoxyphenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(3,5-dichlo-
rophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N'-(3-bromophenyl)-4--
cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydro-
xy-N'-(3,-methoxyphenyl)butanohydrazide;
(2RS,3R)-3-amino-N'-(3-chloro-4-m-
ethylphenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-(trifluoromethoxy)phenyl)bu-
tanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(4-fluorophenyl)-2-hydroxy-
butanohydrazide;
(2RS,3R)-3-amino-N'-(4-chlorophenyl)-4-cyclohexyl-2-hydro-
xybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-ethylphenyl)-2-hydr-
oxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(3-fluorophenyl)-2-hy-
droxybutanohydrazide;
(2RS,3R)-3-arnino-N'-(4-chloro-2-methylphenyl)-4-cyc-
lohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy--
N'-mesitylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-(-
(E)-2-(2-pyridinyl)ethenyl)phenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cycl-
ohexyl-N'-(2-fuorophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-(trifluoromethyl)phenyl)but-
anohydrazide;
(2RS,3R)-3-amino-N'-(2-chloro-6-fluorophenyl)-4-cyclohexyl-2-
-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2,5-difluorophe-
nyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N'-(3-chloro-4-fluoropheny-
l)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N'-(2-chloroben-
zyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl--
2-hydroxy-N'-phenyl-N'-(3-phenylpropyl)butanohydrazide;
(2RS,3R)-3-amino4-cyclohexyl-2-hydroxy-N'-isobutyl-N'-phenylbutanohydrazi-
de; (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-
entyl-N'-phenylbutanohydra- zide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((2RS)-2-methylbutyl)-N'--
phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-isopenty-
l-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-hexyl-2-hydro-
xy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((-
2RS)-2-methylpentyl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohex-
yl-2-hydroxy-N'-((3RS)-3-methylpentyl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(3
,3-dimethylbutyl)-2-hydroxy-N'-phenyl- butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-ethylbutyl)-2-hydroxy-
-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-dodecyl-2-hydr-
oxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-p-
henyl-N'-((3RS)-3,5,5-trimethylhexyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-octyl-N'-phenylbutanohydrazide-
;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-propylbutanohydrazi-
de;
(2RS,3R)-3-amino-4-cyclohexyl-N'-heptyl-2-hydroxy-N'-phenylbutanohydra-
zide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-ethyl-2-hydroxy-N'-phenylbutanohydr-
azide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-(4-methylphenyl)ethyl-
)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-((2RS)-2-ethy-
lhexyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-N'-((2RS)-2-(-
4-chlorophenyl)-2-cyanoethyl)-4-cyclohexyl-2-hydroxy-N'-phenylbutanohydraz-
ide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-((2RS)-2-phenylp-
ropyl)butanohydrazide;
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N'-(4-methy-
lphenyl)propanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N'-(4-methyl-
phenyl)pentanohydrazide;
(2S,3R)-3-amino-3-cyclooctyl-2-hydroxy-N'-(4-meth-
ylphenyl)propanohydrazide;
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-
-2-hydroxy-N'-(4-methylphenyl)butanohydrazide;
(2RS,3R)-3-amino-3-cyclohex-
yl-2-hydroxy-N'-(1-naphthyl)propanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-
-phenyl-N'-(1-naphthyl)pentanohydrazide;
(2RS,3R)-3-amino-3-cyclooctyl-2-h-
ydroxy-N'-(1-naphthyl)propanohydrazide;
(2RS,3R)-3-amino-5-cyclohexyl-2-hy-
droxy-N'-(4-methylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-cyclohexyl-2-
-hydroxy-N'-(1-naphthyl)pentanohydrazide; and
(2S,3R)-3-amino-4-cyclohexyl- -2-hydroxybutanohydrazide.
10. A compound according to claim 5 wherein one of R.sup.6 and
R.sup.7 is selected from the group consisting of hydrogen, alkyl,
and aryl; and the other is selected from the group consisting of
alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl,
alkoxycarbonylalkyl, alkylsulfanylalkyl, aryloxyalkyl,
arylalkoxycarbonyl, arylsulfonyl, carboxyalkyl,
--C(O)R.sup.9R.sup.10, cycloalkyl, (cycloalkyl)alkyl, haloalkanoyl,
haloalkyl, heterocycle, (heterocycle)oyl, and hydroxyalkyl.
11. A compound according to claim 10 selected from the group
consisting of
(2RS,3R)-3-amino-N'-(7-chloro-4-quinolinyl)-4-cyclohexyl-2-hydroxybutanoh-
ydrazide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-iodophe-
nyl)hydrazinecarboxamide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutan-
oyl)-2,4,6-trimethylbenzenesulfonohydrazide; ethyl
(2-((2RS,3R)-3-amino-4--
cyclohexyl-2-hydroxybutanoyl)hydrazino)acetate trifluoroacetate;
benzyl
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazinecarboxylate;
ethyl
3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-3--
oxopropanoate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2,2,2-trifluoro-
ethyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-methyl-N-
'-(3-nitro-2-pyridinyl)butanohydrazide;
(2RS,3R)-3-amino-N',4-dicyclohexyl- -2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-p-
yridinyl)butanohydrazide;
(2RS,3R)-3-amino-N'-(6-chloro-3-pyridazinyl)-4-c-
yclohexyl-2-hydroxy-N'-methylbutanohydrazide;
(2RS,3R)-3-amino-N'-(5-chlor- o-1-methyl-6-oxo-1
,6-dihydro-4-pyridazinyl)-4-cyclohexyl-2-hydroxy-N'-met-
hylbutanohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1
,3-benzodioxole-5-carbohydrazide; methyl
2-(2-((2RS,3R)-3-amino-4-cyclohe-
xyl-2-hydroxybutanoyl)hydrazino)-4-(trifluoromethyl)-5-pyrimidinecarboxyla-
te;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((2RS)-2-hydroxy-3-(3-(trif-
luoromethyl)phenoxy)propyl)-N'-methylbutanohydrazide; methyl
3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-2-thioph-
enecarboxylate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-pyridinylcar-
bonyl)butanohydrazide; ethyl
3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-
butanoyl)hydrazino)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-
-1-carboxylate; (2RS,3R)-3-amino-N'-(1
,3-benzothiazol-2-yl)-4-cyclohexyl-- 2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(trif-
luoroacetyl)butanohydrazide;
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybu-
tanoyl)-3-chloro-1-benzothiophene-2-carbohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-quinoxalinyl)butanohydrazid-
e;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-methyl-N'-(5-(trifluoromethy-
l)-2-pyridinyl)butanohydrazide; (2RS,3R)-3-amino-4-cyclohexyl-N'-(1
,3-dimethyl-4-nitro-1H-pyrazol-5-yl)-2-hydroxybutanohydrazide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-phenylhydrazinecarb-
oxamide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-chloro-2-
-methoxyphenyl)hydrazinecarboxamide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hy-
droxybutanoyl)-N-(3-fluorophenyl)hydrazinecarboxamide;
N-((1R)-1-((2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-
carbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethyl)benzamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-thienylcarbonyl)butanohydra-
zide; 4-chlorobenzyl
2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl-
)hydrazino)-4-(trifluoromethyl)-5-pyrimidinecarboxylate;
(2RS,3R)-3-amino-N'-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxybutano-
hydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((3RS)-3-(methylsulf-
anyl)butyl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cy-
clopropylmethyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-N'-(2-(benzyloxy)ethyl)-4-cyclohexy1-2-hydroxy-N'-phenyl-
butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-(2,2-
,5-trichloropentyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydrox-
y-N'-(3-(methylsulfanyl)propyl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclopentylmethyl)-2-hydroxy-N'-phenylb-
utanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(5-hydroxypenty-
l)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-((2R)-2,3-di-
hydroxypropyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cycl-
ohexyl-N'-(2,2-dichlorohexyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((3RS)-7-methoxy-3,7-dimethylo-
ctyl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclooct-
ylmethyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexy-
l-N'-((11Z)-11-hexadecenyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N
phenyl-N'-tridecylbutanohydrazi- de;
4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-phenylhydrazi-
no)butanoic acid;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((6Z)-6-nonen-
yl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-((4Z)-4-dec-
enyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2--
hydroxy-N'-(4-pentenyl)-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclo-
hexyl-N'-((3RS)-3,7-dimethyl-6-octenyl)-2-hydroxy-N'-phenylbutanohydrazide-
;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-(4,4,4-trifluorobut-
yl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((3RS)-3-hy-
droxybutyl)-N'-95 phenylbutanohydrazide;
(2RS,3R)-3-amino4-cyclohexyl-N'-(- 2-(((3RS)-3
,7-dimethyl-6-octenyl)oxy)ethyl)-2-hydroxy-N'-phenylbutanohydr-
azide;
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-((1RS)-3,3-dimethylcyclohexyl)e-
thyl)-2-hydroxy-N'-phenylbutanohydrazide;
(2RS,3R)-3-amino-N'-((4S)-6-brom-
o-4-methylhexyl)-4-cyclohexyl-2-hydroxy-N'-phenylbutanohydrazide;
and
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclohexylmethyl)-2-hydroxy-N'-phenylbu-
tanohydrazide.
12. A compound according to claim 5 wherein R.sup.6and
R.sup.7together are arylalkylidene.
13. A compound according to claim 12 which is
(2RS,3R)-3-amino-N'-((E)-(4--
chlorophenyl)methylidene)-4-cyclohexyl-2-hydroxybutanohydrazide.
14. A compound according to claim 5 wherein R.sup.6 and R.sup.7,
together with the nitrogen atom to which they are attached, form a
heterocycle.
15. A compound according to claim 14 selected from the group
consisting of
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2S)-2-(methoxymethyl)pyrrolid-
inyl)butanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-pyrrolidinyl-
)butanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(4-oxo-2-thioxo-1,3-
-thiazolidin-3-yl)butanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-
-piperidinyl)butanamide; and
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2-
R)-2-(methoxymethyl)pyrrolidinyl)butanamide.
16. A compound according to claim 1 wherein R.sup.1 is
R.sup.5S-(alkylene)-.
17. A compound according to claim 16 wherein R.sup.4 is
--OR.sup.8.
18. A compound according to claim 17 selected from the group
consisting of
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-phenoxypentamide;
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N-phenoxybutanamide;
(2RS,3S)-3-amino-2-hydroxy-N-phenoxy-4-(propylsulfanyl)butanamide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-phenoxypentanamide;
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-phenoxybutanamide;
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-phenoxybutana-
mide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-benzyloxypentanamide;
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)pentanamide-
;
(2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide;
(2S,3S)-3-amino-N-(cyclohexylmethoxy)-2-hydroxy-4-(isobutylsulfanyl)butan-
amide;
(2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-(mesitylmethoxy)bu-
tanamide;
(2RS,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)-N-((1RS)-1-phenylet-
hoxy)pentanamide;
(2S,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfa-
nyl)-N-methylbutanamide; (2RS,3S
)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isop-
ropylsulfanyl)-N-methylpentanamide; and
(2RS,3R)-3-amino-2-hydroxy-5-(isop-
ropylsulfanyl)-N-((1RS)-1-phenylethoxy)pentanamide.
19. A compound according to claim 18 wherein R.sup.4 is
--NR.sup.6R.sup.7.
20. A compound according to claim 19 wherein one of R.sup.6 and
R.sup.7 is hydrogen and the other is (aryl)oyl.
21. A compound according to claim 20 wherein the aryl(oyl) is
unsubstituted.
22. A compound according to claim 21 selected from the group
consisting of
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-naphthohydra-
zide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzohydra-
zide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-isopropylsulfanylpentanoyl)-2-napht-
hohydrazide;
N'-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)--
2-naphthohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentan-
oyl)-1-naphthohydrazide; and
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsu-
lfanyl)pentanoyl)-1-naphthohydrazide.
23. A compound according to claim 20 wherein the aryl(oyl) is
substituted with one substituent.
24. A compound according to claim 23 wherein the substituent is at
the 2-position.
25. A compound according to claim 24 selected from the group
consisting of
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-chlorobenzoh-
ydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-hyd-
roxy-2-naphthohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxyp-
entanoyl)-2-methylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-
-hydroxypentanoyl)-2-aminobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsul-
fanyl)-2-hydroxypentanoyl)-2-hydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-fluorobenzoh-
ydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-bro-
mobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pent-
anoyl)-2-methylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropyl-
sulfanyl)pentanoyl)-2-methoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydrox-
y-5-(isopropylsulfanyl)pentanoyl)-2-fluorobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chlorobe-
nzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoy-
l)-2-bromobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfa-
nyl)pentanoyl)-2-ethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(i-
sopropylsulfanyl)pentanoyl)-2-benzylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-anilinob-
enzohydrazide; and
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pen-
tanoyl)-2-(2-phenylethyl)benzohydrazide.
26. A compound according to claim 23 wherein the substituent is at
the 3-position.
27. A compound according to claim 23 selected from the group
consisting of
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-chlorobenzoh-
ydrazide;
N'-((2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxybutanoyl)-3-chlo-
robenzohydrazide;
N'-((2RS,3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoy-
l)-3-chlorobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulf-
anyl)pentanoyl)-3-chlorobenzohydrazide;
N'-((2RS,3S)-3-amino-2-hydroxy-4-(-
isobutylsulfanyl)butanoyl)-3-chlorobenzohydrazide;
N'-((2RS,3S)-3-amino-4--
((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)-3-chlorobenzohydrazide;
N'-((2S,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl-3-chlorobenz-
ohydrazide;
N'-((2R,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-ch-
lorobenzohydrazide;
N'-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pen-
tanoyl)-3-chlorobenzohydrazide;
3-(2-aminoethyl)-N'-((2S,3S)-3-amino-2-hyd-
roxy-4-(isobutylsulfanyl)butanoyl)benzohydrazide;
N'-((2S,3S)-3-amino-2-hy-
droxy-4-(isobutylsulfanyl)butanoyl)-3-propoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-trifluoromet-
hylsulfanylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydrox-
ypentanoyl)-3-methylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-
-2-hydroxypentanoyl)-3-aminobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethyls-
ulfanyl)-2-hydroxypentanoyl)-3-hydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methoxybenzo-
hydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-fl-
uorobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentan-
oyl)-3-(dimethylamino)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfany-
l)-2-hydroxypentanoyl)-3-(trifluoromethyl)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluorome-
thoxy)benzohydrazide;
(2RS,3R)-3-amino-N'-(3-(2-aminoethoxy)phenyl)-2-hydr-
oxy-5-(isopropylsulfanyl)pentanohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsu-
lfanyl)-2-hydroxypentanoyl)-3-bromobenzohydrazide;
N'-((2RS,3R)-3-amino-5--
(ethylsulfanyl)-2-hydroxypentanoyl)-3-cyanobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-hydroxyb-
enzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentano-
yl)-3-methylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsul-
fanyl)pentanoyl)-3-methoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-
-(isopropylsulfanyl)pentanoyl)-3-fluorobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-bromoben-
zohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl-
)-3-(methylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isop-
ropylsulfanyl)pentanoyl)-3-(ethylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(propyls-
ulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfany-
l)pentanoyl)-3-(butylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydro-
xy-5-(isopropylsulfanyl)pentanoyl)-3-(hexylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isoprop-
ylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulf-
anyl)pentanoyl)-3-(isobutylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentnoyl)-3-((4-methy-
lpentyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isoprop-
ylsulfanyl)pentanoyl)-3-(sec-butylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(neopent-
ylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulf-
anyl)pentanoyl)-3-(cyclohexylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((cycloh-
exylmethyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isop-
ropylsulfanyl)pentanoyl)-3-(benzylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((2-phen-
ylethyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isoprop-
ylsulfanyl)pentanoyl)-3-((3-phenylpropyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(((1,1
'-biphenyl)-4-ylmethyl)sulfanyl)benzohydrazide; and
(2RS,3R)-3-amino-N'-(3-(2,3-dihydroxypropoxy)benzoyl)-2-hydroxy-5-(isopro-
pylsulfanyl)pentanohydrazide.
28. A compound according to claim 23 wherein the substituent is at
the 4-position.
29. A compound according to claim 28 selected from the group
consisting of
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzoh-
ydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-ami-
nobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoy-
l)-4-,hydroxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydr-
oxypentanoyl)-4-methoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfan-
yl)-2-hydroxypentanoyl)-4-fluorobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(et-
hylsulfanyl)-2-hydroxypentanoyl)-4-bromobenzohydrazide;N'-((2RS,3R)-3-amin-
o-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-propoxybenzo-
hydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(m-
ethylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hyd-
roxypentanoyl)-4-isopropoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsu-
lfanyl)-2-hydroxypentanoyl)-4-(diethylamino)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-butoxybenzoh-
ydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-chl-
orobenzohydrazide;
N'-((2RS,3R)-3-amno-5-(ethylsulfanyl)-2-hydroxypentanoy-
l)-4-(dimethylamino)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-
-2-hydroxypentanoyl)-4-(trifluoromethyl)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-phenoxybenzo-
hydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(p-
henoxymethyl)benzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydr-
oxypentanoyl)-4-cyanobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(iso-
propylsulfanyl)pentanoyl)-4-methylbenzohydrazide;
N'-((2RS,3R)-3-aniino-2--
hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-methoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-fluorobe-
nzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoy-
l)-4-chlorobenzohydrazide;
N'-((2RS,3R)-3-aniino-2-hydroxy-5-(isopropylsul-
fanyl)pentanoyl)-4-bromobenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(-
isopropylsulfanyl)pentanoyl)-4-ethylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propylbe-
nzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoy-
l)-4-isopropylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropyls-
ulfanyl)pentanoyl)-4-ethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy--
5-(isopropylsulfanyl)pentanoyl)-4-tert-butylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propoxyb-
enzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentano-
yl)-4-isopropoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropy-
lsulfanyl)pentanoyl)-4-(methylsulfonyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(methyls-
ulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfany-
l)pentanoyl)-4-(ethylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydro-
xy-5-(isopropylsulfanyl)pentanoyl)-4-(propylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(butylsu-
lfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl-
)pentanoyl)-4-(hexylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydrox-
y-5-(isopropylsulfanyl)pentanoyl)-4-(isopropylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isobuty-
lsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfa-
nyl)pentanoyl)-4-((4-methylpentyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(sec-but-
ylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulf-
anyl)pentanoyl)-4-(neopentylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(cyclohe-
xylsulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsul-
fanyl)pentanoyl)-4-((cyclohexylmethyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(benzyls-
ulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfany-
l)pentanoyl)-4-((2-phenylethyl)sulfanyl)benzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((3-phen-
ylpropyl)sulfanyl)benzohydrazide; and
N'-((2RS,3R)-3-amino-2-hydroxy-5-(is-
opropylsulfanyl)pentanoyl)-4-(((1,1
'-biphenyl)-4-ylmethyl)sulfanyl)benzoh- ydrazide.
30. A compound according to claim 20 wherein the aryl(oyl) is
substituted with two or three substituents.
31. A compound according to claim 30 selected from the group
consisting of
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-diethoxybe-
nzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-
,3-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydrox-
ypentanoyl)-2,4-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfa-
nyl)-2-hydroxypentanoyl)-2,5-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4,5-dimethylbe-
nzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3
,5-dimethylbenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydro-
xypentanoyl)-2,3-dimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsul-
fanyl)-2-hydroxypentanoyl)-2,4-dimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dimethoxyb-
enzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)--
3,4-dimethoxybenzohydrazide;
N'-((2RS,3R)-3-arnino-5-(ethylsulfanyl)-2-hyd-
roxypentanoyl)-3,5-dimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethyls-
ulfanyl)-2-hydroxypentanoyl)-3,4,5-trimethoxybenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dichlorobe-
nzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-
,4-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydrox-
ypentanoyl)-2,5-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfa- nyl)-2-hydroxypentanoyl)-3
,4-dichlorobenzohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dichlorobe-
nzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoy-
l)-2,3-dichlorobenzohydrazide;N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropyls-
ulfanyl)pentanoyl)-3-fluoro-2-methylbenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-difluo-
robenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pent-
anoyl)-5-chloro-2-methoxybenzohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5--
(isopropylsulfanyl)pentanoyl)-2-chloro-5-(methylsulfanyl)benzohydrazide;
and
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3,4-di-
ethoxybenzohydrazide.
32. A compound according to claim 19 wherein one of R.sup.6 and
R.sup.7 is hydrogen; and the other is selected from the group
consisting of aryl, arylalkanoyl, arylalkoxycarbonyl, and
arylsulfonyl.
33. A compound according to claim 32 selected from the group
consisting of benzyl
2-((2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutano-
yl)hydrazinecarboxylate; benzyl
2-((2RS,3S)-3-amino-2-hydroxy-4-(propylsul-
fanyl)butanoyl)hydrazinecarboxylate;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2--
hydroxy-N'-(4-methylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulf-
anyl)-2-hydroxy-N'-(4-methoxyphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(1-naphthyl)pentanohydraz-
ide;
(2RS,3R)-3-arino-5-(ethylsulfanyl)-2-hydroxy-N'-(4-iodophenyl)pentano-
hydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-chloropheiyl-
)pentanohydrazide; (2R S
,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-me-
thoxyphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-
-N'-(2-chlorophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-
-hydroxy-N'-(3-trifluoromethylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(4-isopropyl)pentanohydra-
zide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-chloro-4-methylph-
enyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3--
fluorophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydrox-
y-N'-(2-ethylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-
-hydroxy-N'-(4-fluorophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsul-
fanyl)-2-hydroxy-N'-(4-trifluoromethoxyphenyl)pentanohydrazide;
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N'-(4-methylphenyl)butanohyd-
razide;
(2RS,3S)-3-amino-2-hydroxy-N'-(4-methylphenyl)-4-(propylsulfanyl)b-
utanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-(4-met-
hylphenyl)pentanohydrazide;
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl-
)-N'-(4-methylphenyl)butanohydrazide;
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-
-hydroxy-N'-(1-naphthyl)butanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(iso-
propylsulfanyl)-N'-(1-naphthyl)pentanohydrazide;
(2RS,3S)-3-amino-2-hydrox-
y-4-(isobutylsulfanyl)-N'-(1-naphthyl)butanohydrazide;
(2RS,3S)-3-amino-2-hydroxy-N'-(1-naphthyl)-4-(propylsulfanyl)butanohydraz-
ide;
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N'-(1-napht-
hyl)butanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(phen-
ylacetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-
-((2-methoxyphenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfa-
nyl)-2-hydroxy-N'-((3-methoxyphenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-((4-methoxyphenyl)acetyl)-
pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-((2-chlo-
rophenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hyd-
roxy-N'-((3-chlorophenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethy-
lsulfanyl)-2-hydroxy-N'-((4-chlorophenyl)acetyl)pentanohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1,1
'-biphenyl)-4-ylacetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2--
hydroxypentanoyl)-2-(4-dimethylaminophenyl)acetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1-naphthyl)-
acetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-
-2-(2-naphthyl)acetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hy-
droxypentanoyl)benzenesulfonohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfa-
nyl)-2-hydroxypentanoyl)-3-chlorobenzenesulfonohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthalenes-
ulfonohydrazide; and
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypenta-
noyl)-4-methylbenzenesulfonohydrazide.
34. A compound according to claim 19 wherein one of R.sup.6 and
R.sup.7 is hydrogen; and the other is selected from the group
consisting of alkanoyl, cycloalkyl, cycloalkylalkanoyl,
(cycloalkyl)oyl, (heterocycle)alkanoyl, and (heterocycle)oyl.
35. A compound according to claim 34 selected from the group
consisting of
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-cyclopentylpentanohydrazi-
de;
(2RS,3R)-N'-acetyl-3-amino-5-(ethylsulfanyl)-2-hydroxypentanohydrazide-
;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-isobutyrylpentanohydrazi-
de;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-methylbutanoyl)pent-
anohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-N'-heptanoyl-2-hydroxypen-
tanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(tetrahydro-
-2-furanylcarbonyl)pentanohydrazide;
(2RS,3R)-3-amino-N'-(cyclohexylacetyl-
)-5-(ethylsulfanyl)-2-hydroxyheptanohydrazide;
N'-((2RS,3R)-3-amino-5-(eth-
ylsulfanyl)-2-hydroxypentanoyl)-2-furohydrazide;
N'-((2RS,3R)-3-amino-5-(e-
thylsulfanyl)-2-hydroxypentanoyl)-3-furohydrazide;
N'-((2RS,3R)-3-amino-5--
(ethylsulfanyl)-2-hydroxypentanoyl)-2-thiophenecarbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-thiophenecar-
bohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3H-
-pyrrole-2-carbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydrox-
ypentanoyl)-1,3-thiazole-2-carbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsu-
lfanyl)-2-hydroxypentanoyl)-1,3-thiazole-4-carbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-5-
-carbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl-
)-1H-pyrazole-5-carbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-h-
ydroxypentanoyl)-1H-pyrazole-4-carbohydrazide;
N'-((2RS,3R)-3-amino-5-(eth-
ylsulfanyl)-2-hydroxypentanoyl)-5-isoxazolecarbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyridinecarb-
ohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(-
2-pyridinyl)acetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydro-
xypentanoyl)-3-pyridinecarbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfan-
yl)-2-hydroxypentanoyl)-2-(3-pyridinyl)acetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pyridinecarb-
ohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(-
4-pyridinyl)acetohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydro-
xypentanoyl)-3-pyridazinecarbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulf-
anyl)-2-hydroxypentanoyl)-4-pyrimidinecarbohydrazide;
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyrazinecarb-
ohydrazide;
(2RS,3R)-3-amino-N'-((2RS,3S)-3-amino-2-hydroxy-5-(isopropylsu-
lfanyl)pentanoyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide;N'-((2RS-
,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-benzodioxole-5-carb-
ohydrazide;(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-(tetrahydro-
-2-furanylcarbonyl)pentanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isoprop-
ylsulfanyl)-N'-(tetrahydro-3-furanylcarbonyl)pentanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-cyclopentylpentanohyd-
razide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-c-
yclopentylacetohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-
-N'-cyclohexylpentanohydrazide;
N'-((2RS,3R)-3-arnino-2-hydroxy-5-(isoprop-
ylsulfanyl)pentanoyl)-2-cyclohexylacetohydrazide;
N'-((2RS,3R)-3-amino-2-h-
ydroxy-5-(isopropylsulfanyl)pentanoyl)-2-furohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-furohydr-
azide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,5--
dimethyl-3-furohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfa-
nyl)pentanoyl)-2-thiophenecarbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-
-(isopropylsulfanyl)pentanoyl)-3-thiophenecarbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methyl-2-
-thiophenecarbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfa-
nyl)pentanoyl)-5-methyl-2-thiophenecarbohydrazide;
N'-((2RS,3R)-3-amino-2--
hydroxy-5-(isopropylsulfanyl)pentanoyl)-1H-pyrrole-2-carbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1-methyl-1-
H-pyrrole-2-carbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsul- fanyl)pentanoyl)-1
,3-thiazole-2-carbohydrazide; N'-((2RS,3R)-3-amino-2-hy-
droxy-5-(isopropylsulfanyl)pentanoyl)-1,3-thiazole-4-carbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-isopropylpentanoyl)-2-pyridinecarbohydra-
zide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-6-chl-
oro-2H-chromene-3-carbohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopro-
pylsulfanyl)pentanoyl)-2-(4-morpholinyl)acetohydrazide;
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-(4-methy-
l-1-piperazinyl)acetohydrazide; and
1-acetyl-N'-((2RS,3R)-3-amino-2-hydrox-
y-5-(isopropylsulfanyl)pentanoyl)-4-piperidinecarbohydrazide.
36. A compound according to claim 19 wherein R.sup.6 and R.sup.7,
together with the nitrogen atom to which they are attached, form a
heterocycle.
37. A compound according to claim 36 which is
(2RS,3R)-3-amino-5-(ethylsul-
fanyl)-2-hydroxy-N-(1-piperidinyl)pentanamide.
38. A pharmaceutical composition comprising a compound of claim 1
or a therapeutically acceptable salt or prodrug thereof, in
combination with a therapeutically acceptable carrier.
39. A method of inhibiting angiogenesis in a mammal in recognized
need of such treatment comprising administering to the mammal a
therapeutically acceptable amount of a compound of claim 1.
40. A compound which is N'-((2S
,3R)-3-amino-2-hydroxy-5-(isopropylsulfany-
l)pentanoyl)-3-chlorobenzoyl hydrazide.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional patent
application 60/197,262, filed April 14, 2000, which is hereby
incorporated by reference.
TECHNICAL FIELD
[0002] The present invention relates to substituted hydrazides and
N-alkoxyamides which are useful for preventing angiogenesis,
methods of making the compounds, compositions containing the
compounds, and methods of treatment using the compounds.
BACKGROUND OF THE INVENTION
[0003] Angiogenesis, the fundamental process by which new blood
vessels are formed, is essential to a variety of normal body
activities (such as reproduction, development and wound repair).
Although the process is not completely understood, it is believed
to involve a complex interplay of molecules which both stimulate
and inhibit the growth of endothelial cells, the primary cells of
the capillary blood vessels. Under normal conditions, these
molecules appear to maintain the microvasculature in a quiescent
state (i.e., one of no capillary growth) for prolonged periods
which may last for as long as weeks or in some cases, decades. When
necessary, however, (such as during wound repair), these same cells
undergo rapid proliferation and turnover within a 5 day period.
(The Journal of Biological Chemistry, 267:10931-10934 (1987),
Science, 235:442-447 (1987)).
[0004] Although angiogenesis is a highly regulated process under
normal conditions, many diseases (characterized as "angiogenic
diseases") are driven by persistent unregulated angiogenesis. For
example, ocular angiogenesis has been implicated as the most common
cause of blindness and dominates approximately 20 eye diseases. In
certain existing conditions such as arthritis, newly formed
capillary blood vessels invade the joints and destroy cartilage. In
diabetes, new capillaries formed in the retina invade the vitreous,
bleed, and cause blindness. Growth and metastasis of solid tumors
are also angiogenesis-dependent (Cancer Research, 46:467-473
(1986), Journal of the National Cancer Institute, 82:4-6 (1989).
Because the pivotal role played by angiogenesis in tumor formation,
metastasis, other disease conditions such as arthritis,
inflammation, macular degeneration of age, and diabetic
retinopathy, agents which inhibit angiogenesis have been the
subject of active current research for their clinical
potential.
[0005] In Proc. Natl. Acad. Sci. USA, 94:6099-6103 (1997) and
Chemistry and Biology, 4(6): 461-471 (1997) it is reported that
both AGM-1470 and ovalicin, a sequiterpene isolated from the fungus
Pseudorotium ocalis have been found to covalently inactivate a
common bifunctional protein, type 2-methionine aminopeptidase
(MetAP2) and is concluded that MetAP2 plays a critical role in the
proliferation of endothelial cells and may serve as a promising
target for the development of new anti-angiogenic drugs. The
literature has thus established a casual link between inhibition of
MetAP2 and the resultant inhibition of endothelial cell
proliferation and angiogenesis. There is a need for discovery of
new agents which inhibit MetAP2 for their potential as new drugs in
combating angiogenesis and disease conditions which depend upon
angiogenesis for their development.
SUMMARY OF THE INVENTION
[0006] In its principle embodiment, the present invention provides
a compound of formula (I), 2
[0007] or a therapeutically acceptable salt or prodrug thereof,
wherein
[0008] R.sup.1 is selected from the group consisting of alkyl,
aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl,
and R.sup.5S-(alkylene)-;
[0009] wherein each group is drawn with its right-hand end being
the end that is attached to the parent molecular moiety;
[0010] R.sup.3 is selected from the group consisting of hydrogen,
alkyl, and arylalkyl;
[0011] R.sup.4 is selected from the group consisting of
-NR.sup.6R.sup.7, and --OR.sup.8;
[0012] wherein each group is drawn with its left-hand end being the
end that is attached to the parent molecular moiety;
[0013] R.sup.5 is selected from the group consisting of alkyl,
aryl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl;
[0014] R.sup.6 and R.sup.7 are independently selected from the
group consisting of hydrogen, alkanoyl, alkenyl, alkenyloxyalkyl,
alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylsulfanylalkyl, aryl,
arylalkanoyl, arylalkoxyalkyl, arylalkoxycarbonyl, arylalkyl,
aryloxyalkyl, (aryl)oyl, arylsulfonyl, carboxyalkyl, cycloalkyl,
(cycloalkyl)alkyl, (cycloalkyl)alkanoyl, (cycloalkyl)oyl,
haloalkanoyl, haloalkyl, heterocycle, (heterocycle)alkanoyl,
(heterocycle)oyl, hydroxyalkyl, a nitrogen protecting group, and
--C(O)NR .sup.9R.sup.10 ; or R.sup.6 and R.sup.7 together are
arylalkylidene; or
[0015] R.sup.6 and R.sup.7, together with the nitrogen atom to
which they are attached, form a heterocycle;
[0016] R.sup.8 is selected from the group consisting of hydrogen,
alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl,
aryl, arylalkyl, arylalkoxycarbonylalkyl, (aryl)oylalkyl,
carboxyalkyl, and (cycloalkyl)alkyl; and
[0017] R.sup.9 and R.sup.10 are independently selected from the
group consisting of hydrogen, alkyl and aryl.
[0018] In another embodiment, the present invention provides a
compound of formula (II) 3
[0019] or a therapeutically acceptable salt or prodrug thereof,
wherein R.sup.1, R.sup.3, R.sup.6, and R.sup.7 are as previously
defined.
[0020] In a preferred embodiment, the present invention provides a
compound of formula (II) wherein R.sup.1 is R.sup.5S-(alkylene)-,
R.sup.3 is hydrogen, one of R.sup.6 and R.sup.7 is hydrogen, and
the other is (aryl)oyl.
[0021] In another embodiment, the present invention provides a
compound of formula (III) 4
[0022] or a therapeutically acceptable salt or prodrug thereof,
wherein R.sup.1 and R.sup.3 are as previously defined and R.sup.A
is selected from the group consisting of aryl, alkyl, and
arylalkyl.
[0023] In another embodiment, the present invention provides a
pharmaceutical composition comprising a compound of formula (I) or
a therapeutically acceptable salt or prodrug thereof, in
combination with a therapeutically acceptable carrier.
[0024] In another embodiment, the present invention provides a
method of inhibiting angiogenesis in a mammal in recognized need of
such treatment comprising adminstering to the mammal a
therapeutically acceptable amount of a compound of formula (I).
DETAILED DESCRIPTION OF THE INVENTION
[0025] Compounds of the present invention comprise hydrazines and
hydroxylamines substituted with substituted 2-hydroxy-3-amino
alkanoic acids.
[0026] Compounds of the present invention exist as stereoisomers,
wherein asymmetric or chiral centers are present. These compounds
are designated by the symbols "R" or "S" depending on the
configuration of substituents around the chiral carbon atom. The
present invention contemplates various stereoisomers and mixtures
thereof. Stereoisomers include enantiomers and diastereomers, and
mixtures of enantiomers or diastereomers are designated (RS).
Individual stereoisomers of compounds of the present invention may
be prepared synthetically from commercially available starting
materials which contain asymmetric or chiral centers or by
preparation of racemic mixtures followed by resolution well-known
to those of ordinary skill in the art. These methods of resolution
are exemplified by (1) attachment of a mixture of enantiomers to a
chiral auxiliary, separation of the resulting mixture of
diastereomers by recrystallization or chromatography and liberation
of the optically pure product from the auxiliary or (2) direct
separation of the mixture of optical enantiomers on chiral
chromatographic columns.
[0027] Because carbon-carbon double bonds may exist in the present
compounds, the invention contemplates various geometric isomers and
mixtures thereof resulting from the arrangement of substituents
around these carbon-carbon double bonds. These substituents are
designated as being in the E or Z configuration wherein the term
"E" represents higher order substituents on opposite sides of the
carbon-carbon double bond, and the term "Z" represents higher order
substituents on the same side of the carbon-carbon double bond.
[0028] When used throughout this specification and the appended
claims, the following terms have the meanings indicated:
[0029] The term "alkanoyl" refers to an alkyl group attached to the
parent molecular moiety through a carbonyl group. The alkanoyl
groups of this invention can be unsubstituted or substituted with
one, two, or three substituents independently selected from the
group consisting of alkoxycarbonyl, alkylsulfanyl, amino, and
hydroxy.
[0030] The term "alkanoylalkyl" refers to an alkanoyl group
attached to the parent molecular moiety through an alkyl group.
[0031] The term "alkenyl" refers to a monovalent straight or
branched chain groups having from two to fourteen carbon atoms
containing at least one carbon-carbon double bond.
[0032] The term "alkenyloxy" refers to an alkenyl group attached to
the parent molecular moiety through an oxygen atom.
[0033] The term "alkenyloxyalkyl" refers to an alkenyloxy group
attached to the parent molecular moiety through an alkyl group.
[0034] The term "alkoxy" refers to an alkyl group attached to the
parent molecular moiety through an oxygen atom.
[0035] The term "alkoxyalkyl" refers to an alkoxy group attached to
the parent molecular moiety through an alkyl group.
[0036] The term "alkoxycarbonyl" refers to an alkoxy group attached
to the parent molecular moiety through a carbonyl group.
[0037] The term "alkoxycarbonylalkyl" refers to an alkoxycarbonyl
group attached to the parent molecular moiety through an alkyl
group.
[0038] The term "alkyl" refers to a monovalent group derived from a
straight or branched chain saturated hydrocarbon having from one to
fourteen carbons by the removal of a single hydrogen atom.
[0039] The term "alkylene" refers to a saturated divalent
hydrocarbon group derived from a straight or branched chain
saturated hydrocarbon having from one to fourteen carbons by the
removal of two hydrogen atoms.
[0040] The term "alkylsulfanyl" refers to an alkyl group attached
to the parent molecular moiety through a sulfur atom.
[0041] The term "alkylsulfanylalkyl" refers to an alkylsulfanyl
group attached to the parent molecular moiety through an alkyl
group.
[0042] The term "alkylsulfonyl" refers to an alkyl group attached
to the parent molecular moiety through a sulfonyl group.
[0043] The term "amido" refers to an amino group attached to the
parent molecular moiety through a carbonyl group.
[0044] The term "amidoalkyl" refers to an amido group attached to
the parent molecular moiety through an alkyl group.
[0045] The term "amino" refers to --NR.sup.aR.sup.b, wherein
R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen, unsubstituted alkanoyl,
alkoxycarbonylalkyl, alkyl, aryl, arylalkyl, (aryl)oyl, cycloalkyl,
and (cycloalkyl)alkyl. The aryl and the aryl part of the arylalkyl
and the (aryl)oyl can be unsubstituted or substituted with one,
two, three, four, or five substituents independently selected from
the group consisting of alkoxy, alkoxycarbonyl, cyano, halo,
haloalkoxy, haloalkyl, and nitro.
[0046] The term "aminoalkoxy" refers to an amino group attached to
the parent molecular moiety through an alkoxy group.
[0047] The term "aminoalkyl" refers to an amino group attached to
the parent molecular moiety through an alkyl group.
[0048] The term "aminosulfonyl" refers to an amino group attached
to the parent molecular moiety through a sulfonyl group.
[0049] The term "aryl" refers to phenyl, naphthyl, dihydronaphthyl,
tetrahydronaphthyl, indanyl, and indenyl. Aryl groups having an
unsaturated or partially saturated ring fused to an aromatic ring
can be attached through either the saturated or unsaturated part of
the group. The aryl groups of this invention can be unsubstituted
or substituted with one, two, three, four, or five substituents
independently selected from the group consisting of alkanoyl,
alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl,
alkylsulfanyl, alkylsulfanylalkyl, amino, aminoalkoxy, aminoalkyl,
aminosulfonyl, carboxy, cyano, (cycloalkyl)alkylsulfanyl,
cycloalkylsulfanyl, halo, haloalkoxy, haloalkyl, haloalkylsulfanyl,
(heterocycle)alkenyl, hydroxy, hydroxyalkoxy, nitro, oxo, and
thioxo. The aryl groups of this invention can be further
substituted with an additional aryl group or an arylalkyl,
arylalkylsulfanyl, aryloxy, aryloxyalkyl, heterocycle, or
(heterocycle)alkenyl group, wherein the aryl, the aryl part of the
arylalkyl, the arylalkylsulfanyl, the aryloxy, and the
aryloxyalkyl, the heterocycle, and the heterocycle part of the
(heterocycle)alkenyl can be further substituted with one, two,
three, four, or five substituents independently selected from the
group consisting of alkanoyl, alkoxy, alkoxycarbonyl, alkyl,
carboxy, cyano, haloalkoxy, haloalkyl, and nitro.
[0050] The term "arylalkanoyl" refers to an aryl group attached to
the parent molecular moiety through an alkanoyl group.
[0051] The term "arylalkoxy" refers to an aryl group attached to
the parent molecular moiety through an alkoxy group.
[0052] The term "arylalkoxyalkyl" refers to an arylalkoxy group
attached to the parent molecular moiety through an alkyl group.
[0053] The term "arylalkoxycarbonyl" refers to an arylalkoxy group
attached to the parent molecular moiety through a carbonyl
group.
[0054] The term "arylalkoxycarbonylalkyl" refers to an
arylalkoxycarbonyl group attached to the parent molecular moiety
through an alkyl group.
[0055] The term "arylalkyl" refers to an aryl group attached to the
parent group through an alkyl group. The alkyl part of the
arylalkyl can be unsubstituted or substituted with a cyano
group.
[0056] The term "arylalkylidene" refers to =CHRC, wherein Rc is
aryl.
[0057] The term "arylalkylsulfanyl" refers to an arylalkyl group
attached to the parent molecular moiety through a sulfur atom.
[0058] The term "aryloxy" refers to an aryl group attached to the
parent molecular moiety through an oxygen atom.
[0059] The term "aryloxyalkyl" refers to an aryloxy group attached
to the parent molecular moiety through an alkyl group. The alkyl
part of the aryloxyalkyl can be unsubstituted or substituted with a
hydroxy group.
[0060] The term "(aryl)oyl" refers to an aryl group attached to the
parent molecular moiety through a carbonyl group.
[0061] The term "(aryl)oylalkyl" represnts an (aryl)oyl group
attached to the parent molecular moiety through an alkyl group.
[0062] The term "arylsulfonyl" refers to an aryl group attached to
the parent molecular moiety through a sulfonyl group.
[0063] The term "carbonyl" refers to --C(O)--.
[0064] The term "carboxy" refers to --CO.sub.2H.
[0065] The term "carboxyalkyl" refers to a carboxy group attached
to the parent molecular moiety through an alkyl group.
[0066] The term "cyano" refers to --CN.
[0067] The term "cycloalkyl" refers to a monovalent saturated
cyclic hydrocarbon having from three to ten carbon atoms.
[0068] The term "cycloalkylalkanoyl" refers to a cycloalkyl group
attached to the parent molecular moiety through an alkanoyl
group.
[0069] The term "(cycloalkyl)alkyl" refers to a cycloalkyl group
attached to the parent molecular moiety through an alkyl group.
[0070] The term "(cycloalkyl)alkylsulfanyl" refers to a
(cycloalkyl)alkyl group attached to the parent molecular moiety
through a sulfur atom.
[0071] The term "(cycloalkyl)oyl" refers to a cycloalkyl group
attached to the parent molecular moiety through a carbonyl
group.
[0072] The term "cycloalkylsulfanyl" refers to a cycloalkyl group
attached to the parent molecular moiety through a sulfur atom.
[0073] The term "halo" or "halogen" refers to F, Cl, Br, or I.
[0074] The term "haloalkanoyl" refers to a haloalkyl group attached
to the parent molecular moiety through a carbonyl group.
[0075] The term "haloalkoxy" refers to a haloalkyl group attached
to the parent molecular moiety through an oxygen atom.
[0076] The term "haloalkyl" refers to an alkyl group substituted by
one, two, three, or four halogen atoms.
[0077] The term "haloalkylsulfanyl" refers to a haloalkyl group
attached to the parent molecular moiety through a sulfur atom.
[0078] The term "heterocycle" refers to a five-, six- or
seven-membered ring containing one, two or three heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulfur. The five-membered ring has zero to two double
bonds and the six- and seven-membered rings have zero to three
double bonds. The term "heterocycle" also includes bicyclic groups
in which the heterocycle ring is fused to a phenyl group or a
cycloalkyl group. The heterocycle groups of the present invention
can be attached through a carbon atom or a nitrogen atom in the
group. Examples of heterocycles include, but are not limited to,
benzodioxolyl, benzothiazolyl, benzothienyl, chromenyl,
dihydropyridazinyl, furyl, isoxazolyl, morpholinyl, piperazinyl,
piperidinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl,
pyrimidinyl, pyrrolidinyl, pyrrolyl, quinolinyl, quinoxolinyl,
tetrahydrobenzothienyl, tetrahydrofuryl, thiazolidinyl, thiazolyl,
thienyl, and the like. The heterocycle groups of this invention can
be unsubstituted or substituted with one, two, three, or four,
substituents independently selected from the group consisting of
alkanoyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl,
alkylsulfanylalkyl, amino, aminosulfonyl, carboxy, halo,
haloalkoxy, haloalkyl, hydroxy, nitro, oxo, and thioxo. The
heterocycle groups of this invention can be further substituted
with an aryl, arylalkyl, aryloxy, aryloxycarbonyl, or
(heterocycle)alkenyl group, wherein the aryl, the aryl portion of
the aryloxy, the arylalkyl, and the aryloxycarbonyl, and the
heterocycle portion of the (heterocycle)alkenyl can be further
substituted with one, two, three, four, or five substituents
independently selected from the group consisting of alkanoyl,
alkoxy, alkoxycarbonyl, alkyl, carboxy, cyano, haloalkoxy,
haloalkyl, and nitro.
[0079] The term "(heterocycle)alkanoyl" refers to a heterocycle
group attached to the parent molecular moiety through an alkanoyl
group.
[0080] The term "(heterocycle)alkenyl" refers to a heterocycle
group attached to the parent molecular moiety through an alkenyl
group.
[0081] The term "(heterocycle)alkyl" refers to a heterocycle group
attached to the parent molecular moiety through an alkyl group.
[0082] The term "(heterocycle)oyl" refers to a heterocycle group
attached to the parent molecular moiety through a carbonyl
group.
[0083] The term "hydroxy" refers to --OH.
[0084] The term "hydroxyalkoxy" refers to a hydroxyalkyl group
attached to the parent molecular moiety through an oxygen atom.
[0085] The term "hydroxyalkyl" refers to an alkyl group substituted
with one, two, or three hydroxy groups.
[0086] The term "nitro" refers to --NO.sub.2.
[0087] The term "nitrogen protecting group" refers to groups
intended to protect an amino group against undersirable reactions
during synthetic procedures. Common N-protecting groups comprise
acyl groups such as formyl, acetyl, propionyl, pivaloyl,
tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl,
trichloroacetyl, phthalyl, ortho-nitrophenoxyacetyl,
.alpha.-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl,
and 4-nitrobenzoyl; sulfonyl groups such as benzenesulfonyl, and
para-toluenesulfonyl; carbamate forming groups such as
benzyloxycarbonyl, para-chlorobenzyloxycarbonyl,
p-methoxybenzyloxycarbonyl, tert-butyloxycarbonyl (Boc),
benzyloxycarbonyl (Cbz), and the like.
[0088] The term "oxo" refers to (.dbd.O).
[0089] The term "sulfonyl" refers to --SO.sub.2--.
[0090] The term "thioxo" refers to (.dbd.S).
[0091] The compounds of the present invention can exist as
therapeutically acceptable salts. The term "therapeutically
acceptable salt," as used herein, represents salts or zwitterionic
forms of the compounds of the instant invention which are water or
oil-soluble or dispersible, which are suitable for treatment of
diseases without undue toxicity, irritation, and allergic response;
which are commensurate with a reasonable benefit/risk ratio, and
which are effective for their intended use. The salts can be
prepared during the final isolation and purification of the
compounds or separately by reacting an amino group with a suitable
acid. Representative acid addition salts include acetate, adipate,
alginate, citrate, aspartate, benzoate, benzenesulfonate,
bisulfate, butyrate, camphorate, camphorsulfonate, digluconate,
glycerophosphate, hemisulfate, heptanoate, hexanoate, formate,
fumarate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethansulfonate (isethionate), lactate, maleate,
mesitylenesulfonate, methanesulfonate, naphthylenesulfonate,
nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate,
persulfate, 3-phenylproprionate, picrate, pivalate, propionate,
succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate,
glutamate, bicarbonate, para-toluenesulfonate, and undecanoate.
Also, amino groups in the compounds of the present invention can be
quatemized with methyl, ethyl, propyl, and butyl chlorides,
bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl
sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides,
and iodides; and benzyl and phenethyl bromides. Examples of acids
which can be employed to form therapeutically acceptable addition
salts include inorganic acids such as hydrochloric, hydrobromic,
sulfuric, and phosphoric, and organic acids such as oxalic, maleic,
succinic, and citric.
[0092] Basic addition salts can be prepared during the final
isolation and purification of the compounds by reacting a carboxy
group with a suitable base such as the hydroxide, carbonate, or
bicarbonate of a metal cation or with ammonia or an organic
primary, secondary, or tertiary amine. The cations of
therapeutically acceptable salts include lithium, sodium,
potassium, calcium, magnesium, and aluminum, as well as nontoxic
quaternary amine cations such as ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine, tributylamine, pyridine,
N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine,
dicyclohexylamine, procaine, dibenzylamine,
N,N-dibenzylphenethylamine, 1-ephenamine, and
N,N'-dibenzylethylenediamine. Other representative organic amines
useful for the formation of base addition salts include
ethylenediamine, ethanolamine, diethanolamine, piperidine, and
piperazine.
[0093] The present compounds can also exist as therapeutically
acceptable prodrugs. The term "therapeutically acceptable prodrug,"
refers to those prodrugs or zwitterions which are suitable for use
in contact with the tissues of patients without undue toxicity,
irritation, and allergic response, are commensurate with a
reasonable benefit/risk ratio, and are effective for their intended
use. The term "prodrug," refers to compounds which are rapidly
transformed in vivo to parent compounds of formula (I) for example,
by hydrolysis in blood.
[0094] In accordance with methods of treatment and pharmaceutical
compositions of the invention, the compounds can be administered
alone or in combination with other anti-angiogenesis agents. When
using the compounds, the specific therapeutically effective dose
level for any particular patient will depend upon factors such as
the disorder being treated and the severity of the disorder; the
activity of the particular compound used; the specific composition
employed; the age, body weight, general health, sex, and diet of
the patient; the time of administration; the route of
administration; the rate of excretion of the compound employed; the
duration of treatment; and drugs used in combination with or
coincidently with the compound used. The compounds can be
administered orally, parenterally, osmotically (nasal sprays),
rectally, vaginally, or topically in unit dosage formulations
containing carriers, adjuvants, diluents, vehicles, or combinations
thereof. The term "parenteral" includes infusion as well as
subcutaneous, intravenous, intramuscular, and intrasternal
injection.
[0095] Parenterally adminstered aqueous or oleaginous suspensions
of the compounds can be formulated with dispersing, wetting, or
suspending agents. The injectable preparation can also be an
injectable solution or suspension in a diluent or solvent. Among
the acceptable diluents or solvents employed are water, saline,
Ringer's solution, buffers, monoglycerides, diglycerides, fatty
acids such as oleic acid, and fixed oils such as monoglycerides or
diglycerides.
[0096] The anti-angiogenesis effect of parenterally administered
compounds can be prolonged by slowing their absorption. One way to
slow the absorption of a particular compound is administering
injectable depot forms comprising suspensions of crystalline,
amorphous, or otherwise water-insoluble forms of the compound. The
rate of absorption of the compound is dependent on its rate of
dissolution which is, in turn, dependent on its physical state.
Another way to slow absorption of a particular compound is
administering injectable depot forms comprising the compound as an
oleaginous solution or suspension. Yet another way to slow
absorption of a particular compound is administering injectable
depot forms comprising microcapsule matrices of the compound
trapped within liposomes, microemulsions, or biodegradable polymers
such as polylactide-polyglycolide, polyorthoesters or
polyanhydrides. Depending on the ratio of drug to polymer and the
composition of the polymer, the rate of drug release can be
controlled.
[0097] Transdermal patches can also provide controlled delivery of
the compounds. The rate of absorption can be slowed by using rate
controlling membranes or by trapping the compound within a polymer
matrix or gel. Conversely, absorption enhancers can be used to
increase absorption.
[0098] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In these solid dosage forms,
the active compound can optionally comprise diluents such as
sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide,
calcium silicates, polyamide powder, tableting lubricants, and
tableting aids such as magnesium stearate or microcrystalline
cellulose. Capsules, tablets and pills can also comprise buffering
agents, and tablets and pills can be prepared with enteric coatings
or other release-controlling coatings. Powders and sprays can also
contain excipients such as talc, silicic acid, aluminum hydroxide,
calcium silicate, polyamide powder, or mixtures thereof. Sprays can
additionally contain customary propellants such as
chlorofluorohydrocarbons or substitutes therefor.
[0099] Liquid dosage forms for oral administration include
emulsions, microemulsions, solutions, suspensions, syrups, and
elixirs comprising inert diluents such as water. These compositions
can also comprise adjuvants such as wetting, emulsifying,
suspending, sweetening, flavoring, and perfuming agents.
[0100] Topical dosage forms include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants, and
transdermal patches. The compound is mixed under sterile conditions
with a carrier and any needed preservatives or buffers. These
dosage forms can also include excipients such as animal and
vegetable fats, oils, waxes, paraffins, starch, tragacanth,
cellulose derivatives, polyethylene glycols, silicones, bentonites,
silicic acid, talc and zinc oxide, or mixtures thereof.
Suppositories for rectal or vaginal administration can be prepared
by mixing the compounds with a suitable non-irritating excipient
such as cocoa butter or polyethylene glycol, each of which is solid
at ordinary temperature but fluid in the rectum or vagina.
Ophthalmic formulations comprising eye drops, eye ointments,
powders, and solutions are also contemplated as being within the
scope of this invention.
[0101] The total daily dose of the compounds administered to a host
in single or divided doses can be in amounts from about 0.1 to
about 200 mg/kg body weight or preferably from about 0.25 to about
100 mg/kg body weight. Single dose compositions can contain these
amounts or submultiples thereof to make up the daily dose.
DETERMINATION OF BIOLOGICAL ACTIVITY
[0102] Assays for the inhibition of catalytic activities of MetAP2
were performed in 96-well microtiter plates. Compounds to be tested
were dissolved in dimethyl-sulfoxide at 10 mM and diluted ten-fold
in assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl). Ten microliters
of solution of each compound to be tested for inhibition were
introduced into each cell of the plate. Zero inhibition of enzyme
activity was taken to be the result obtained in cells in which 10
mL of assay buffer was placed. A mixture totaling 90 mL per well
and made up of of 84 mL of assay buffer containing 100 mM
MnCl.sub.2, 1 mL of L-amino acid oxidase (Sigma Catalog No. A-9378,
.about.11 mg/mL), 1 mL of horseradish peroxidase (Sigma Catalog No.
P-8451, dissolved in assay buffer at a concentration of 10 mg/mL),
1 mL of the tripeptide Met-Ala-Ser (Bachem) dissolved in assay
buffer at concentration of 50 mM, 1 mL of ortho-dianisidine (Sigma
Catalog No. D-1954, freshly made solution in water at a
concentration of 10 mg/mL), and MetAP1 at final concentration of 6
mg/ml or MetAP2 at a final concentration of 1.5 mg/mL was rapidly
mixed and added to each cell containing test or control compound.
The absorbence at 450 nanometers was measured every 20 seconds over
a period of twenty minutes using an automaic plate reader
(Molecular Devices, CA, USA). The Vmax in mOD/min, calculated for
each well, was used to represent MetAP1 or MetAP2 activity. The
IC.sub.50 for each inhibitor was obtained by plotting the remaining
activity versus inhibitor concentrations. All of the compounds of
the invention displayed IC.sub.50's below 15 .mu.M. Preferred
compounds of the invention displayed IC.sub.50's below 1 .mu.M, and
most preferred compounds displayed IC.sub.50's below 0.1 .mu.M.
Thus, the compounds are useful for treating diseases caused or
exacerbated by angiogenesis.
SYNTHETIC METHODS
[0103] Abbreviations which have been used in the descriptions of
the scheme and the examples that follow are: THF for
tetrahydrofuran, PDC for pyridinium dichromate, DMSO for
dimethylsulfoxide, DME for 1,2-dimethoxyethane, DCC for
1,3-diicyclohexylcarbodiimide, DIC for 1,3-diisopropylcarbodiimide,
HOBT for 1-hydroxybenzotriazole, HOAT for
1-hydroxy-7-azabenzotriazole, EDCI for
1-(3-dimethylaminopropyl)-3-ethylc- arbodiimide hydrochloride,
PyBOP for benzotriazol-1-yloxytripyrrolidinopho- sphonium
hexafluorophosphate, DBU for 1,8-diazabicyclo(5.4.0)undec-7-ene,
NMM for N-methylmorpholine, DMA for N,N-dimethylacetamide, NMP for
N-methylpyrrolidinone, BOC-ON for
(2-(tert-butoxycarbonyloxyimino)-2-phen- ylacetonitrile, and DMF
for N,N dimethylformaide.
[0104] The compounds and processes of the present invention will be
better understood in connection with the following synthetic
schemes which illustrate the methods by which the compounds of the
invention may be prepared. Starting materials can be obtained from
commercial sources or prepared by well-established literature
methods known to those of ordinary skill in the art. The groups
R.sup.1, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are defined above.
It will be readily apparent to one of ordinary skill in the art
that the compounds defined above can be synthesized by substitution
of the appropriate reactants and agents in the syntheses shown
below. 5
[0105] As shown in Scheme 1, compounds of formula (1) (R.sup.2 is a
nitrogen protecting group) can be converted to compounds of formula
(2) by treatment with a reducing agent. Representative reducing
agents include sodium borohydride, calcium borohydride, lithium
borohydride, zinc borohydride, lithium aluminum hydride, borane,
sodium cyanoborohydride, diisobutylaluminum hydride, and sodium
bis(2-methoxyethoxy)aluminum hydride (Red-Al.RTM.). Examples of
solvents used in these reactions include toluene, dichloromethane,
ethanol, THF, dioxane, diethyl ether, or mixtures thereof. The
reaction temperature is about -78.degree. C. to 60.degree. C. and
depends on the method chosen. Reaction times are typically about
0.5 to 24 hours.
[0106] Compounds of formula (2) can be converted to compounds of
formula (3) by treatment with an oxidizing reagent. Representative
oxidizing agents include Dess-Martin periodinane, PDC, MnO.sub.2,
DMSO/oxalyl chloride, and DMSO/SO.sub.3-pyridine/triethylamine.
Examples of solvents used in these reactions include DMSO,
dichloromethane, chloroform, and THF. The reaction temperature is
about -78.degree. C. to 60.degree. C. and depends on the method
chosen. Reaction times are typically about 0.5 to 24 hours.
[0107] Conversion of compounds of formula (3) to compounds of
formula (4) can be accomplished by the addition of sodium
bisulfite, followed by the addition of sodium cyanide or potassium
cyanide. Examples of solvents used in these reactions include
water, ethyl acetate, and acetonitrile. The reaction temperature is
about -10.degree. C. to 60.degree. C. and depends on the method
chosen. Reaction times are typically about 2-36 hours.
[0108] Compounds of formula (4) can be converted to compounds of
formula (5) by hydrolysis with aqueous acid or by hydrolysis with
aqueous base followed by acidification. Representative aqueous
acids include HBr, HCl, HOAc, and H.sub.2SO.sub.4, and
representative aqueous bases include NaOH, KOH, and Ba(OH).sub.2.
Examples of solvents used in these reactions include dioxane,
water, ethylene glycol, and DME. The reaction temperature is about
25.degree. C. to 150.degree. C. and depends on the method chosen.
Reaction times are typically about 2-36 hours.
[0109] Conversion of compounds of formula (5) to compounds of
formula (6) can be accomplished by coupling with substituted
hydrazines (HNR.sup.3NR.sup.6R.sup.7) in the presence of a carbonyl
activating group such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP, and
base. Representative bases include NMM, diisopropylethylamine, and
DBU. Examples of solvents used in these reactions include
dichloromethane, chloroform, DMA, THF, and NMP. The reaction
temperature is about -10.degree. C. to 60.degree. C. and depends on
the method chosen. Reaction times are typically about 2-72 hours.
6
[0110] A method for the preparation of compounds of formula (11) is
shown in Scheme 2. Aldehydes of formula (7) can be reacted with
compounds of formula (8) (R.sup.d is alkyl or arylalkyl) in the
presence of a base and lithium bromide to provide compounds of
formula (9). Examples of bases include triethyl amine and
diisopropylethylamine. Representative solvents include THF, diethyl
ether, and methyl tert-butyl ether. The reaction is conducted at
about 25 to about 30.degree. C. for about 12 to about 24 hours.
[0111] Compounds of formula (9) can be treated with an
appropriately substituted amine or amide in the presence of
tert-butylhypochlorite and base, then treated with potassium osmate
dihydrate and hydroquini dine 1 ,4-phathalazinediyl diether to
provide compounds of formula (10) (R .sup.2is a nitrogen protecting
group). Examples of bases include sodium hydroxide, potassium
hydroxide, and lithium hydroxide. Representative solvents include
water, 1-propanol, isopropanol, acetonitrile, and mixtures thereof.
The reaction is typically conducted at about 0 to about 30.degree.
C. for about 30 minutes to about 4 hours.
[0112] Conversion of compounds of formula (10) to compounds of
formula (5) can be accomplished by treatment with hydrogen peroxide
in the presence of hydroxide such as lithium hydroxide. Examples of
solvents include THF, water, and mixtures thereof. The reaction is
conducted at about 0 to about 25.degree. C. for about 1 to about 6
hours.
[0113] Compounds of formula (5) can be converted to compounds of
formula (12) (Re is aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl,
heterocycle, or (heterocycle)alkyl) either by the methods desribed
in Schemes 1 and 3, or by sequentially coupling the carboxylic acid
with hydrazine and then coupling with an appropriately substituted
carboxylic acid. Conditions for these couplings are similar to
those described in Scheme 1 and are known to those of ordinary
skill in the art. 7
[0114] As shown in Scheme 3, compounds of formula (5) (made as
described in Scheme 1) can be converted to compounds of formula
(12) by coupling with substituted hydroxylamines
(HNR.sup.3OR.sup.4) in the presence of a carbonyl activating group
such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP, and base.
Representative bases include NMM, diisopropylethylamine, and DBU.
Examples of solvents used in these reactions include
dichloromethane, chloroform, DMA, THF, and DMF. The reaction
temperature is about -10.degree. C. to 60.degree. C. and depends on
the method chosen. Reaction times are typically about 2-72 hours.
In a preferred embodiment, compounds of formula (5) are treated
with HOBT, NMM, EDCI, and a substituted hydroxylamine in
dichloromethane/DMF at room temperature for 16 hours to provide
compounds of formula (12).
[0115] The present invention will now be described in connection
with certain preferred embodiments which are not intended to limit
its scope. On the contrary, the present invention covers all
alternatives, modifications, and equivalents as can be included
within the scope of the claims. Thus, the following examples, which
include preferred embodiments, will illustrate the preferred
practice of the present invention, it being understood that the
examples are for the purposes of illustration of certain preferred
embodiments and are presented to provide what is believed to be the
most useful and readily understood description of its procedures
and conceptual aspects.
[0116] Compounds of the invention were named by ACD/ChemSketch
version 4.01 (developed by Advanced Chemistry Development, Inc.,
Toronto, ON, Canada) or were given names which appeared to be
consistent with ACD nomenclature.
EXAMPLE 1
(2RS,3R)-3-amino-N'-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide
EXAMPLE 1A
tert-butyl (1R)-2-cyclohexyl-1-(hydroxymethyl)ethylcarbamate
[0117] A solution of
(2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropa- noic acid
(30.4 g,112 mmol) in toluene (300 mL) at 0.degree. C. was treated
with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al.RTM.) (115
mmol) over 45 minutes. The mixture was stirred for 30 minutes,
warmed to room temperature, stirred for 1 hour, treated with
aqueous Rochelle salt, and extracted with diethyl ether. The
extract was washed with brine and aqueous NaHCO.sub.3, dried
(MgSO.sub.4), filtered, and concentrated to provide the desired
product.
EXAMPLE 1B
tert-butyl (1R)-2-cyclohexyl-1-formylethylcarbamate
[0118] A solution of Example 1A (25.8 g,100 mmol), sulfur trioxide
pyridine complex (79.6 g, 500 mmol), and triethylamine (69.7 mL,
500 mmol) in DMSO (70 mL) at room temperature was stirred for 30
minutes, cooled to 0.degree. C., treated with water and saturated
aqueous KHSO.sub.4, and extracted with ethyl acetate. The extract
was washed with saturated aqueous KHSO.sub.4 and brine, dried
(MgSO.sub.4), filtered, and concentrated to provide the desired
product.
EXAMPLE 1C
(2RS,3R)-3-((tert-butoxycarbonyl)amino)-4-cyclohexyl-2-hydroxybutanoic
acid
[0119] A solution of Example 1B (19.7 g, 77.1 mmol) and sodium
bisulfite (8.0 g, 77.1 mmol) in water (500 mL) at 5.degree. C. was
stirred for 24 hours, warmed to room temperature, treated with a
solution of potassium cyanide (5.1 g, 78.8 mmol) in ethyl acetate
(350 mL), and stirred for 5 hours. The aqueous phase was separated
and extracted with ethyl acetate. The combined extracts were washed
with water and brine, dried (MgSO.sub.4), filtered, and
concentrated to provide tert-butyl
(1R)-2-cyano-1-(cyclohexylmethyl)-2-hydroxyethylcarbamate.
[0120] The concentrate was dissolved in dioxane (150 mL), treated
with 12N HCl (150 mL), heated to reflux, stirred for 21 hours, and
cooled to room temperature. The mixture was concentrated, dissolved
in a mixture of water (30 mL) and acetone (200 mL), adjusted to pH
5.5 with 1N NaOH, treated with acetone (3.5 L), and cooled to
0.degree. C. for 4 hours. The resulting precipitate was collected
by filtration and dried to provide
(3R)-3-amino-4-cyclohexyl-2-hydroxybutanoic acid. A solution of the
acid, BOC-ON (1.2 eq.), and triethylamine (2 eq.) in 1:1
water/dioxane at 45.degree. C. was stirred for 15 hours, treated
with 10% aqueous KHS0.sub.4, and extracted with ethyl acetate. The
extract was washed with water and brine, dried (MgSO.sub.4),
filtered, and concentrated to provide the desired product.
EXAMPLE 1D
(2RS,3R)-3-amino-N'-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide
[0121] A solution of Example 1C (50 mg, 0.17 mmol),
1-hydroxybenzotriazole hydrate (30 mg, 0.22mmol), and
N-methylmorpholine (0.07 mL, 0.63 mmol) in
5:1/dichloromethane:N,N-dimethylacetamide (2 mL) at 0.degree. C.
was treated with 1,3-diisopropylcarbodiimide (0.03 mL, 0.21 mmol),
and stirred for 5 minutes. The solution was treated with
1-benzylhydrazine dihydrochloride (0.05 g, 0.25 mmol), stirred for
2 hours, and warmed to room temperature over 44 hours. The reaction
was washed with 2N HCl and saturated NaHCO.sub.3, and concentrated.
The concentrate was purified by silica gel chromatography with
3:1/hexanes:ethyl acetate then 1:1/hexanes:ethyl acetate, then
dissolved in 4N HCl in dioxane (1 mL), stirred for 1 hour, and
concentrated, then purified by HPLC to provide the desired
product.
[0122] MS(APCI) m/e 306 (M+H).sup.+;
[0123] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.43-7.26 (m, 5H),
4.13 (d, 1H), 4.01 (s, 2H), 3.53 (m, 1H), 3.39 (s, 1H), 1.80-1.67
(m, 5H), 1.57-1.51 (m, 1H), 1.46-1.17 (m, 5H), 1.00-0.90 (m,
2H).
EXAMPLE 2
(2RS,3R)-3-amino-N'-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide
[0124] The desired product was prepared by substituting
diphenylhydrazine for 1-benzylhydrazine dihydrochloride in Example
1.
[0125] MS(APCI) m/e 368 (M+H).sup.+;
[0126] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.32-7.26 (m, 4H),
7.16-7.13 (m, 4H), 7.06-7.01 (m, 211), 4.26 (d, 1H), 3.52 (m, 1H),
1.72-1.12 (m, 13H).
EXAMPLE 3
(2RS,3R)-3-amino-N'-(7-chloro-4-quinolinyl)-4-cyclohexyl-2-hydroxybutanohy-
drazide
[0127] The desired product was prepared by substituting
7-chloro-4-hydrazinoquinoline for 1-benzylhydrazine dihydrochloride
in Example 1.
[0128] MS(APCI) m/e 377 (M+H).sup.+;
[0129] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.51 (d, 1H), 8.35
(d, 1H), 7.96 (d, 1H), 7.76 (dd, 1H), 6.96 (d, 1H), 4.47 (d, 1H),
3.70 (m, 1H), 1.86-0.98 (m, 13H).
EXAMPLE 4
(2RS
3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-phenylethyl)butanohydrazide
[0130] The desired product was prepared by substituting
1-(2-phenethyl)hydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0131] MS(APCI) m/e 320 (M+H).sup.+;
[0132] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.30-7.21 (m, 5H),
4.16 (d, 1H), 3.59 (m, 1H), 3.09 (t, 2H), 2.82 (t, 2H), 1.81-0.91
(m, 13H).
EXAMPLE 5
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-methyl-N'-phenylbutanohydrazide
[0133] The desired product was prepared by substituting
1-methyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0134] MS(APCI) m/e 306 (M+H).sup.+;
[0135] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.21-7.26 (m, 2H),
6.82-6.91 (m, 3H), 4.28 (d, 1H), 3.63 (m, 1H), 3.16 (s, 3H),
1.68-1.88 (m, 6H), 1.48-1.58 (m, 2H), 1.19-1.38 (m, 3H), 0.92-1.08
(m, 2H).
EXAMPLE 6
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide
[0136] The desired product was prepared by substituting
1-naphthohydrazide for 1-benzylhydrazine dihydrochloride in Example
1.
[0137] MS(APCI) m/e 370 (M+H).sup.+;
[0138] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.37 (m, 1H), 8.05
(d, 1H), 7.95 (m, 1H), 7.77 (dd, 1H), 7.57 (m, 3H), 4.42 (d, 1H),
3.77 (m, 1H), 1.90-0.97 (m, 13H).
EXAMPLE 7
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-methylphenyl)butanohydrazide
[0139] The desired product was prepared by substituting
1-(4-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0140] MS(APCI) m/e 306 (M+H).sup.+;
[0141] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.01 (d, 2H), 6.76
(d, 2H), 4.27 (d, 1H), 3.61 (m, 1H), 2.23 (s, 3H), 1.85-1.64 (m,
6H), 1.54-1.42 (m, 2H), 1.36-1.15 (m, 3H), 1.06-0.89 (m, 2H).
EXAMPLE 8
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-iodophenyl)hydraz-
inecarboxamide
[0142] The desired product was prepared by substituting
N-(4-iodophenyl)hydrazinecarboxamide for 1-benzylhydrazine
dihydrochloride in Example 1.
[0143] MS(APCI) m/e 461 (M+H).sup.+;
[0144] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.59 (d, 2H), 7.23
(d, 2H), 4.33 (d, 1H), 3.68 (m, 1H), 1.85-1.65 (m, 6H), 1.59-1.19
(m, 5H), 1.09-0.93 (m, 2H).
EXAMPLE 9
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4,6-trimethylbenzen-
esulfonohydrazide
[0145] The desired product was prepared by substituting
2,4,6-trimethylbenzenesulfonohydrazide for 1-benzylhydrazine
dihydrochloride in Example 1.
[0146] MS(APCI) m/e 398 (M+H).sup.+;
[0147] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.01 (s, 2H), 4.01
(d, 1H), 3.36 (m, 1H), 2.67 (s, 6H), 2.29 (s, 3H), 1.78-1.65 (m,
4H), 1.47-1.20 (m, 7H), 1.00-0.78 (m, 2H).
EXAMPLE 10
ethyl
(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)acetat-
e
[0148] The desired product was prepared by substituting ethyl
hydrazinoacetate for 1-benzylhydrazine dihydrochloride in Example
1.
[0149] MS(APCI) m/e 302 (M+H).sup.+;
[0150] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.20 (q, 2H), 4.18
(d, 1H), 3.62 (d, 2H), 3.60 (m, 1H), 1.82-1.57 (m, 7H), 1.56-1.20
(m, 4H), 1.28 (t, 3H), 1.05-0.90 (m, 2H).
EXAMPLE 11
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-methoxyphenyl)butanohydrazid-
e
[0151] The desired product was prepared by substituting
1-(4-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0152] MS(APCI) m/e 322 (M+H).sup.+;
[0153] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 6.82 (m, 4H), 4.27
(d, 1H), 3.72 (s, 3H), 3.61 (m, 1H), 1.85-1.62 (m, 6H), 1.55-1.18
(m, 5H), 1.08-0.90 (m, 2H).
EXAMPLE 12
[0154]
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(1-naphthyl)butanohydraz-
ide
[0155] The desired product was prepared by substituting
1-(1-naphthyl)hydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0156] MS(APCI) m/e 342 (M+H).sup.+;
[0157] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.06 (m, 1H), 7.82
(m, 1H), 7.48 (m, 2H), 7.41-7.29 (m, 2H), 6.91 (dd, 1H), 4.38 (d,
1H), 3.68 (m, 1H), 1.89-1.66 (m, 6H), 1.60-1.47 (m, 2H), 1.19-1.31
(m, 3H), 1.09-0.92 (m, 2H).
EXAMPLE 13
benzyl
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazinecarboxy-
late
EXAMPLE 13A
benzyl
2-((2RS,3R)-3-((tert-butoxvcarbonyl)amino)-4-cyclohexyl-2-hydroxybu-
tanoyl)hydrazinecarboxylate
[0158] A solution of Example 1 C (1.10 g, 3.65 mmol) in
dichloromethane at 0.degree. C. was treated with
dicyclohexylcarbodiimide (0.83 g, 4.02 mmol), stirred for 30
minutes, treated with benzyl carbazate (0.69 g, 4.02 mmol), warmed
to room temperature, and stirred for 32 hours. The mixture was
filtered, and concentrated, and the concentrate was purified by
flash column chromatography on silica gel with ethyl acetate in
hexanes to provide the desired product.
EXAMPLE 13B
benzyl 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)h
drazinecarboxylate
Example 13A (0.09 g, 0.2 mmol) was treated with 4N HCl in dioxane,
stirred for 4 hours, concentrated, and precipitated from diethyl
ether to provide the desired product.
[0159] MS(APCI) m/e 350 (M+H).sup.+;
[0160] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.23 (m, 1H),
10.08 (m, 1H), 9.32 (m, 1H), 7.85 (m, 2H), 7.38 (m, 5H), 6.51 (m,
1H), 5.18 (s, 1H), 5.10 (s, 1H), 4.07 (m, 1H), 3.69 (m, 1H), 3.49
(m 1H), 3.23 (m, 1H), 1.63 (m, 5H), 1.47 (m, 3H), 1.19 (m, 2H).
EXAMPLE 14
(2RS,3R)-3-amino-N'-((E)-(4-chlorophenyl)methylidene)-4-cyclohexyl-2-hydro-
xybutanohydrazide
EXAMPLE 14A
tert-butyl
(1R,2RS)-1-(cyclohexylmethyl)-3-hydrazino-2-hydroxy-3-oxopropyl-
carbamate
[0161] A solution of Example 13A (0.37 g, 0.82 mmol) in methanol
(15mL) was treated with Pd-carbon (0.05 g), stirred under a
hydrogen atmosphere for 16 hours, filtered, and concentrated to
provide the desired product.
EXAMPLE 14B
(2RS,3R)-3-amino-N'-((E)-(4-chlorophenvl)methylidene)-4-cyclohexyl-2-hydro-
xybutanohydrazide
[0162] A solution of Example 14A (0.064 g, 0.20 mmol) in ethanol (3
mL) was treated with pyridine (2 mL) and 4-chlorobenzaldehyde
(0.033 mL, 0.23 mmol), heated to 85.degree. C., stirred for 16
hours, and concentrated. The concentrate was purified by flash
column chormatography on silica gel with ethyl acetate in hexanes,
and the purified concntrate was treated with 4N HCl in dioxane,
stirred for 4 hours, concentrated, precipitated from diethyl ether,
and collected by filtration to provide the desired product.
[0163] MS(APCI) m/e 336 (M-H).sup.-;
[0164] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.11.60 (m, 1H),
8.42 (m, 1H), 7.83 (m, 2H), 7.71 (m, 2H), 7.53 (m, 2H), 6.61 (m,
1H), 4.18 (m, 1H), 4.12 (m, 1H), 3.70 (m, 1H), 1.66 (m, 5H), 1.43
(m, 3H), 1.19 (m, 2H).
EXAMPLE 15
ethyl
3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-3-o-
xopropanoate
[0165] A solution of Example 14A (0.096 g, 0.30 mmol) in
dichloromethane (8 mL) at 0.degree. C. was treated with
N-methylmorpholine (0.094 mL, 0.67 mmol) and ethyl-3-chloro-3-oxo
propionate (0.049 mL, 0.38 mmol), stirred for 30 minutes, warmed to
room temperature and stirred for 16 hours. The mixture was treated
with dichloromethane, washed sequentially with 0.5M HCl, water, and
brine, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with ethyl acetate in hexanes, and the purified concentrate was
treated with 4N HCl in dioxane, stirred for 4 hours, concentrated,
precipitated from diethyl ether, and collected by filtration to
provide the desired product.
[0166] MS(APCI) m/e 330 (M+H).sup.+;
[0167] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.10.24 (m, 1H),
7.71 (m, 2H), 6.53 (m, 1H), 4.10 (m, 5H), 3.70 (m, 1H), 3.49 (m,
2H), 3.37 (m, 1H), 1.65 (m, 5H), 1.43 (m, 3H), 1.20 (m, 5H).
EXAMPLE 16
benzyl 2-((2RS,
3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutano-
yl)hydrazinecarboxylate
EXAMPLE 16A
(2S)-2-((tert-butoxycarbonyl)amino)-3-((cyclohexylmethyl)sulfanyl)propanoi-
c acid
[0168] A solution of D-cysteine hydrochloride (4.78 g, 39.4 mmol)
in liquid ammonia (250 mL) at -70.degree. C. was slowly treated
with sodium (3.78 g, 161 mmol), stirred for 30 minutes, treated
with (bromomethyl)cyclohexane (6.33 mL, 45.4 mmol), warmed to room
temperature, and stirred until the ammonia evaporated. The residue
was treated with water(75 mL), isopropanol (50 mL) and
di-tert-butyl dicarbonate (9.97 mL, 43.3 mmol), stirred for 24
hours, and concentrated. The concentrate was dissolved in water
(150 mL), cooled to 0.degree. C., adjusted to pH<7 with 3N HCl,
and extracted with diethyl ether. The combined extracts were washed
with brine, dried (MgSO.sub.4), filtered, and concentrated to
provide the desired product.
[0169] MS(APCI) m/e 318 (M+H).sup.+.
EXAMPLE 16B
(2RS,3R)
3-(tert-butoxycarbonylamino)-2-hydroxy-4-(cyclohexylmethylthio)bu-
tanoic acid
[0170] The desired product was prepared by substituting Example 16A
for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid
in Examples 1A-1C.
[0171] MS(APCI) m/e 346 (M+H).sup.+.
EXAMPLE 16C
benzyl 2-((2RS,
3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutano-
yl)hydrazinecarboxylate
[0172] The desired product was prepared by substituting Example 16B
for Example 1C in Example 13.
[0173] MS(APCI) m/e 396 (M+H).sup.+;
[0174] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.9.32 (m, 1H),
7.97 (m, 2H), 7.38 (m, 5H), 6.63 (m, 1H), 5.10 (m, 2H), 4.23 (m,
1H), 3.69 (m, 3H), 2.43 (m, 2H), 1.83-1.58 (m, 6H), 1.18 (m,
5H).
EXAMPLE 17
benzyl 2-((2RS,
3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)hydrazine-
carboxylate
EXAMPLE 17A
N-(tert-butoxycarbonyl)-S -propyl-D-cysteine
[0175] The desired product was prepared by substituting
1-bromopropane for (bromomethyl)cyclohexane in Example 16.
[0176] MS(APCI) m/e 264 (M+H).sup.+.
EXAMPLE 17B
(2RS,3R)
3-(tert-butoxycarbonylamino)-2-hydroxy-4-(propylthio)butanoic
acid
[0177] The desired product was prepared by substituting Example 17A
for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid
in Examples 1A-1C.
[0178] MS(APCI) m/e 294 (M+H).sup.+.
EXAMPLE 17C
benzyl 2-((2RS,
3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)hydrazine-
carboxylate
[0179] The desired product was prepared by substituting Example 17B
for Example 1C in Example 13.
[0180] MS(APCI) m/e 342 (M+H).sup.+;
[0181] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 9.30 (m, 1H),
8.12 (m, 2H), 7.38 (m, 1H), 6.63 (m, 1H), 5.10 (m, 2H), 4.28 (m,
1H), 3.70 (m, 2H), 3.49(m, 1H), 2.84 (m, 1H), 2.48 (m, 1H), 1.52
(m, 2H), 0.95 (m, 3H).
EXAMPLE 18
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2,2,2-trifluoroethyl)butanohyd-
razide
[0182] The desired product was prepared by substituting
1-(2,2,2-trifluoroethyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0183] MS(APCI) m/e 298 (M+H).sup.+;
[0184] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.17 (d, 1H), 3.48
(t, 2H), 3.68 (m, 1H), 1.84-0.90 (m, 13H).
EXAMPLE 19
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide
[0185] The desired product was prepared by substituting tert-butyl
hydrazinecarboxylate for 1-benzylhydrazine dihydrochloride in
Example 1.
[0186] MS(APCI) m/e 216 (M+H).sup.+;
[0187] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.39 (d, 1H), 3.68
(m, 1H), 1.84-0.92 (m, 13H).
EXAMPLE 20
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-methyl-N'-(3-nitro-2-pyridinyl)-
butanohydrazide
[0188] The desired product was prepared by substituting
2-(1-methylhydrazino)-3-nitropyridine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0189] MS(APCI) m/e 352 (M+H).sup.+;
[0190] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.39 (dd, 1H),
8.01 (d, 1H), 6.99 (dd, 1H), 4.14 (d, 1H), 3.66 (s, 3H), 3.53 (m,
1H), 1.84-0.92 (m, 13H).
EXAMPLE 21
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2S)-2-(methoxymethyl)pyrrolidi-
nyl)butanamide
[0191] The desired product was prepared by substituting
(2S)-2-(methoxymethyl)-1-pyrrolidinamine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0192] MS(APCI) m/e 314 (M+H).sup.+;
[0193] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.33 (d, 1H), 4.21
(m, 1H), 3.68 (m, 2H), 3.60-3.42 (m, 2H), 3.34 (m, 5H), 1.98 (m,
2H), 1.88-1.65 (m, 7H), 1.52 (t, 2H), 1.37-1.20 (m, 4H), 1.60-0.89
(m, 2H).
EXAMPLE 22
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-pyrrolidinyl)butanamide
[0194] The desired product was prepared by substituting
1-pyrrolidinamine for 1-benzylhydrazine dihydrochloride in Example
1.
[0195] MS(APCI) m/e 270 (M+H).sup.+;
[0196] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.43 (d, 1H),
3.78-3.63 (m, 5H), 2.19 (m, 4H), 1.84-0.92 (m, 13H).
EXAMPLE 23
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2,4-difluorophenyl)-2-hydroxybutanohydra-
zide
[0197] The desired product was prepared by substituting
1-(2,4-difluorophenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0198] MS(APCI) m/e 328 (M+H).sup.+;
[0199] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 6.98-6.88 (m, 2H),
6.81 (m, 1H), 4.30 (d, 1H), 3.60 (m, 1H), 1.83-1.65 (m, 6H),
1.55-1.41 (m, 2H), 1.38-1.20 (m, 3H), 1.08-0.92 (m, 2H).
EXAMPLE 24
(2RS,3R)-3-amino-N',4-dicyclohexvl-2-hydroxybutanohydrazide
[0200] The desired product was prepared by substituting
1-cyclohexylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0201] MS(APCI) m/e 298 (M+H).sup.+;
[0202] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.42 (d, 1H), 3.79
(m, 1H), 3.67 (m, 1H), 2.14-2.05 (m, 2H), 1.95-1.86 (m, 2H),
1.81-1.68 (m, 6H), 1.55-1.25 (m, 11H), 1.08-0.92 (m, 2H).
EXAMPLE 25
4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)benzenesul-
fonamide
[0203] The desired product was prepared by substituting
4-hydrazinobenzenesulfonamide for 1-benzylhydrazine dihydrochloride
in Example 1.
[0204] MS(APCI) m/e 371 (M+H).sup.+;
[0205] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.72 (d, 2H), 6.90
(d, 2H), 4.34 (d, 1H), 3.67 (m, 1H), 1.88-1.65 (m, 6H), 1.60-1.47
(m, 2H), 1.37-1.21 (m, 3H), 1.02-0.92 (m, 2H).
EXAMPLE 26
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenylbutanohydrazide
[0206] The desired product was prepared by substituting
1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example
1.
[0207] MS(APCI) m/e 292 (M+H).sup.+;
[0208] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.19 (m, 2H), 6.83
(m, 3H), 4.29 (d, 1H), 3.61 (m, 1H), 1.84-1.64 (m, 6H), 1.56-1.42
(m, 2H), 1.38-1.17 (m, 3H), 1.18-0.90 (m, 2H).
EXAMPLE 27
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-pyridinyl)butanohydrazide
[0209] The desired product was prepared by substituting
2-hydrazinopyridine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0210] MS(APCI) m/e 293 (M+H).sup.+;
[0211] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.01 (m, 1H), 7.78
(m, 1H), 6.93 (m, 2H), 4.39 (d, 1H), 3.68 (m, 1H), 1.85-0.98 (m,
13H).
EXAMPLE 28
N'((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-ethoxybenzohydrazide
[0212] The desired product was prepared by substituting
4-ethoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0213] MS(APCI) m/e 364 (M+H).sup.+;
[0214] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.86 (d, 2H), 7.00
(d, 2H), 4.35 (d, 1H), 4.11 (q, 2H), 3.69 (m, 1H), 1.88-1.70 (m,
6H), 1.66-1.52 (m, 2H), 1.41 (t, 3H), 1.37-1.20 (m, 3H), 1.10-0.96
(m, 2H).
EXAMPLE 29
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(4-oxo-2-thioxo-1,3-thiazolidin--
3-yl)butanamide
[0215] The desired product was prepared by substituting
3-amino-2-thioxo-1,3-thiazolidin-4-one for 1-benzylhydrazine
dihydrochloride in Example 1.
[0216] MS(APCI) m/e 332 (M+H).sup.+;
[0217] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.38 (d, 1H), 4.25
(br s, 1H), 3.74 (m, 1H), 1.86-0.96 (m, 13H).
EXAMPLE 30
(2RS
3R)-3-amino-N'-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxy-N'-met-
hylbutanohydrazide
[0218] The desired product was prepared by substituting
3-chloro-6-(1-methylhydrazino)pyridazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0219] MS(APCI) m/e 342 (M+H).sup.+;
[0220] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.57 (d, 1H), 7.33
(d, 1H), 4.40 (d, 1H), 3.64 (m, 1H), 3.40 (s, 3H), 1.86-1.67 (m,
6H), 1.64-1.16 (m, 5H), 1.08-0.92 (m, 2H).
EXAMPLE 31
(2RS,3R)-3-amino-N'-(5-chloro-1-methyl-6-oxo-1,6-dihydro-4-pyridazinyl)-4--
cyclohexyl-2-hydroxy-N'-methylbutanohydrazide
[0221] The desired product was prepared by substituting
4-chloro-2-methyl-5-(1-methylhydrazino)-3(2H)-pyridazinone for
1-benzylhydrazine dihydrochloride in Example 1.
[0222] MS(APCI) m/e 372 (M+H).sup.+.
EXAMPLE 32
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-piperidinyl)butanamide
[0223] The desired product was prepared by substituting
1-aminopiperidine for 1-benzylhydrazine dihydrochloride in Example
1.
[0224] MS(APCI) m/e 284 (M+H).sup.+;
[0225] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.47 (d, 1H),
3.75-3.58 (m, 2H), 3.54-3.40 (m, 3H), 1.86-1.50 (m, 13H), 1.47-1.37
(m, 1H), 1.37-1.16 (m, 3H), 1.06-0.89 (m, 2H).
EXAMPLE 33
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethoxybenzohyd-
razide
[0226] The desired product was prepared by substituting
3,5-dimethoxybenzohydrazide for 1-benzylhydrazine dihydrochloride
in Example 1.
[0227] MS(APCI) m/e 380 (M+H).sup.+;
[0228] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.03 (m, 2H), 6.70
(m, 1H), 4.36 (d, 1H), 3.81 (m, 611), 3.68 (m, 1H), 1.87-1.68 (m,
6H), 1.63-1.41 (m, 2H), 1.38-1.19 (m, 3H), 1.10-0.93 (m, 2H).
EXAMPLE 34
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1,3-benzodioxole-5-ca-
rbohydrazide
[0229] The desired product was prepared by substituting
1,3-benzodioxole-5-carbohydrazide for 1-benzylhydrazine
dihydrochloride in Example 1.
[0230] MS(APCI) m/e 364 (M+H).sup.+;
[0231] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.50 (dd, 1H),
7.35 (d, 1H), 6.92 (d, 1H), 4.35 (d, 1H), 4.27 (d, 1H), 3.80 (s,
2H), 3.61 (m, 1H), 1.86-1.18 (m, 11H), 1.10-0.92 (m, 2H).
EXAMPLE 35
(2RS,3R)-3-amino-N'-(4-bromophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
[0232] The desired product was prepared by substituting
1-(4-bromophenyl)hydrazine for 1-benzylhydrazine in Example 1.
[0233] MS(APCI) m/e 371(M+H).sup.+;
[0234] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.30 (d. 2H), 6.77
(d, 2H), 4.29 (d, 1H), 3.62 (m, 1H), 1.86-1.64 (m, 6H), 1.56-1.16
(m, 5H), 1.07-0.98 (m, 2H).
EXAMPLE 36
(2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N'-(4-methylphenyl)pentanohydra-
zide
[0235] The desired product was prepared by substituting
(2R)-2-((tert-butoxycarbonyl)amino)-4-(ethylsulfanyl)butanoic acid
and 1-(4-methylphenyl)hydrazine for
(2R)-2-((tert-butoxycarbonyl)amino)-3-cyc- lohexylpropanoic acid
and 1-benzylhydrazine dihydrochloride, respectively, in Example
1.
[0236] MS(ESI) m/e 298 (M+H).sup.+;
[0237] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.04 (bs, 1H),
7.87 (bs, 1H), 6.95 (d, 2H), 6.68 (d, 2H), 4.13 (t, 1H), 3.43 (m,
1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 2.18 (s, 3H), 1.98-1.78 (m,
2H), 1.21 (t, 3H).
EXAMPLE 37
(2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N'-(4-methoxyphenyl)pentanohydr-
azide
[0238] The desired product was prepared by substituting
1-(4-methoxyphenyl)hydrazine for 1-(4-methylphenyl)hydrazine in
Example 36.
[0239] MS(ESI) m/e 314 (M+H).sup.+;
[0240] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.03 (bs, 1H),
7.86 (bs, 1H), 6.74 (m, 4H), 4.13 (m, 1H), 3.37 (s, 3H), 3.40 (m,
1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 1.98-1.78 (m, 2H), 1.21 (t,
3H).
EXAMPLE 38
(2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N'-(1-naphthyl)pentanohydrazide
[0241] The desired product was prepared by substituting
1-(1-naphthyl)hydrazine for 1-(4-methylphenyl)hydrazine in Example
36.
[0242] MS(ESI) m/e 334 (M+H).sup.+;
[0243] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.27 (bs, 1H),
8.21 (m, 1H), 7.92 (bs, 1H), 7.83 (m, 1H), 7.48 (m, 2H), 7.32 (m,
1H), 6.80-6.72 (m, 2H), 4.25 (t, 1H), 3.48 (m, 1H), 2.73-2.60 (m,
2H), 2.56 (q, 2H), 1.98-1.78 (m, 2H), 1.21 (t, 3H).
EXAMPLE 39
methyl
2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-4--
(trifluoromethyl)-5-pyrimidinecarboxylate
[0244] The desired product was prepared by substituting methyl
2-hydrazino-4-(trifluoromethyl)-5-pyrimidinecarboxylate for
1-benzylhydrazine dihydrochloride in Example 1.
[0245] MS(APCI) m/e 420 (M+H).sup.+.
EXAMPLE 40
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-methylphenyl)butanohydrazide
[0246] The desired product was prepared by substituting
1-(2-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0247] MS(APCI) m/e 306 (M+H).sup.+;
[0248] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.10-7.02 (m, 2H),
6.85-6.73 (m, 2H), 4.32 (d, 1H), 3.75 (m, 1H), 2.25 (s, 3H),
1.88-1.65 (m, 6H), 1.58-1.46 (m, 2H), 1.38-1.18 (m, 3H), 1.09-0.92
(m, 2H).
EXAMPLE 41
(2RS,3R)-3-amino-N'-(2-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
[0249] The desired product was prepared by substituting
1-(2-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0250] MS(APCI) m/e 326 (M+H).sup.+;
[0251] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.28 (dd, 1H),
7.18 (m, 1H), 7.93 (dd, 1H), 6.82 (m, 1H), 4.34 (d, 1H), 3.66 (m,
1H), 1.86-1.66 (m, 6H), 1.58-1.18 (m, 5H), 1.06-0.89 (m, 2H).
EXAMPLE 42
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(3-(trifluoromethyl)phenyl)buta-
nohydrazide
[0252] The desired product was prepared by substituting
1-(2-(trifluoromethyl)phenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0253] MS(APCI) m/e 360 (M+H).sup.+;
[0254] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.36 (m, 1H), 7.08
(m, 3H), 4.32 (d, 1H), 3.62 (m, 1H), 1.88-1.62 (m, 6H), 1.58-1.16
(m, 5H), 1.08-0.87 (m, 2H).
EXAMPLE 43
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-hydroxy-3-(3-(trifluoromethy-
l)phenoxy)propyl)-N'-methylbutanohydrazide
[0255] The desired product was prepared by substituting
1-(1-methylhydrazino)-3-(3-(trifluoromethyl)phenoxy)-2-propanol for
1-benzylhydrazine dihydrochloride in Example 1.
[0256] MS(APCI) m/e 448 (M+H).sup.+;
[0257] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.49 (m, 1H),
7.28-7.18 (m, 3H), 4.40 (dd, 1H), 4.33 (m, 1H), 4.10 (m, 2H), 3.58
(m, 1H), 3.34 (d, 3H), 3.12 (d, 2H), 1.84-1.62 (m, 6H), 1.58-1.20
(m, 5H), 1.06-0.87 (m, 2H).
EXAMPLE 44
methyl
3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-2--
thiophenecarboxylate
[0258] The desired product was prepared by substituting methyl
3-hydrazino-2-thiophenecarboxylate for 1-benzylhydrazine
dihydrochloride in Example 1.
[0259] MS(APCI)m/e 356 (M+H).sup.+;
[0260] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.52 (d, 1H), 6.78
(d, 1H), 4.32 (d, 1H), 3.83 (s, 3H), 3.68 (m, 1H), 1.86-1.62 (m,
6H), 1.55-1.12 (m, 5H), 1.05-0.91 (m, 2H).
EXAMPLE 45
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-pyrndinylcarbonyl)butanohydr-
azide
[0261] The desired product was prepared by substituting
2-pyridinecarbohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0262] MS(APCI) m/e 321 (M+H).sup.+;
[0263] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.81 (m, 1H), 8.33
(m, 2H), 7.88 (m, 1H), 4.40 (d, 111), 3.71 (m, 1H), 1.88-1.64 (m,
6H), 1.64-1.42 (m, 2H), 1.42-1.22 (m, 3H), 1.10-0.94 (m, 2H).
EXAMPLE 46
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-chlorobenzohydrazid-
e
[0264] The desired product was prepared by substituting
2-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0265] MS(APCI) m/e 354 (M+H).sup.+;
[0266] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta.7.62 (m, 1H), 7.50
(m, 2H), 7.42 (m, 1H), 4.37 (d, 1H), 3.72 (m, 1H), 1.86-1.63 (m,
6H), 1.63-1.40 (m, 2H), 1.40-1.16 (m, 3H), 1.10-0.92 (m, 2H).
EXAMPLE 47
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-bromobenzohydrazide
[0267] The desired product was prepared by substituting
3-bromobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0268] MS(APCI) m/e 399 (M+H).sup.+;
[0269] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.06 (t, 1H), 7.87
(m, 1H), 7.78 (m, 1H), 7.45 (t, 1H), 4.38 (d, 1H), 3.69 (m, 1H),
1.88-1.66 (m, 6H), 1.62-1.42 (m, 2H), 1.38-1.18 (m, 3H), 1.10-0.95
(m, 2H).
EXAMPLE 48
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-methoxybenzohydrazi-
de
[0270] The desired product was prepared by substituting
3-methoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0271] MS(APCI) m/e 350 (M+H).sup.+;
[0272] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.48 (d, 1H), 7.42
(q, 2H), 7.17 (d, 1H), 4.37 (d, 1H), 3.86 (s, 3H), 3.70 (m, 1H),
1.88-1.67 (m, 6H), 1.63-1.40 (m, 2H), 1.40-1.18 (m, 3H), 1.10-0.95
(m, 2H).
EXAMPLE 49
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dichlorobenzohydr-
azide
[0273] The desired product was prepared by substituting
2,5-dichlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0274] MS(APCI) m/e 389 (M+H).sup.+;
[0275] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.67 (m, 1H), 7.52
(d, 2H), 4.36 (d, 1H), 3.68 (m, 1H), 1.87-1.67 (m, 6H), 1.62-1.50
(m, 1H), 1.50-1.40 (m, 1H), 1.40-1.20 (m, 3H), 1.10-0.95 (m,
2H).
EXAMPLE 50
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methoxybenzohydrazi-
de
[0276] The desired product was prepared by substituting
2-methoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0277] MS(APCI) m/e 350 (M+H).sup.+;
[0278] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.99 (dd, 1H),
7.57 (dt, 1H), 7.20 (d, 1H), 7.10 (t, 1H), 4.38 (d, 1H), 4.01 (s,
3H), 3.71 (m, 1H), 1.88-1.68 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40
(m, iH), 1.38-1.17 (m, 3H), 1.10-0.96 (m, 2H).
EXAMPLE 51
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-chlorobenzohydrazid-
e
[0279] The desired product was prepared by substituting
3-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0280] MS(APCI) m/e 354 (M+H).sup.+;
[0281] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.91 (m, 1H), 7.82
(m, 1H), 7.62 (m, 1H), 7.51 (t, 1H), 4.38 (d, 1H), 3.69 (m, 1H),
1.88-1.68 (m, 6H), 1.62-1.52 (m, 1H), 1.52-1.40 (m, 1H), 1.38-1.20
(m, 3H), 1.10-0.94 (m, 2H).
EXAMPLE 52
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-methylbenzohydrazid-
e
[0282] The desired product was prepared by substituting
3-methylbenzohydrazide for 1-benzylhydrazide dihydrochloride in
Example 1.
[0283] MS(APCI) m/e 334 (M+H).sup.+;
[0284] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.75-7.66 (m, 2H),
7.48-7.34 (m, 2H), 4.37 (d, 1H), 3.69 (m, 1H), 2.41 (s, 3H),
1.88-1.67 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40 (m, 1H), 1.40-1.18
(m, 3H), 1.10-0.94 (m, 2H).
EXAMPLE 53
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dihydroxybenzohyd-
razide
[0285] The desired product was prepared by substituting
2,4-dihydroxybenzohydrazide for 1-benzylhydrazine dihydrochloride
in Example 1.
[0286] MS(APCI) m/e 352 (M+H).sup.+;
[0287] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.72 (d, 1H), 6.38
(dt, 2H), 4.37 (d, 1H), 3.67 (m, 1H), 1.87-1.65 (m, 6H), 1.62-1.52
(m, 1H), 1.52-1.49 (m, 1H), 1.39-1.18 (m, 3H), 1.10-0.97 (m,
2H).
EXAMPLE 54
ethyl
3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-6,6-
-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate
[0288] The desired product was prepared by substituting ethyl
3-hydrazino-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carb-
oxylate for 1-benzylhydrazine dihydrochloride in Example 1.
[0289] MS(APCI) m/e 466 (M+H).sup.+;
[0290] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.38 (d, 1H), 4.28
(q, 2H), 3.67 (m, 1H), 2.54 (d, 2H), 2.39 (s, 2H), 1.90-1.71 (m,
6H), 1.71-1.43 (m, 2H), 1.40-1.16 (m, 6H), 1.08 (s, 3H), 1.06 (s,
3H), 1.10-0.94 (m, 2H).
EXAMPLE 55
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-iodophenyl)butanohydrazide
[0291] The desired product was prepared by substituting
1-(4-iodophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0292] MS(APCI) m/e 418 (M+H).sup.+;
[0293] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.47 (d, 2H), 6.66
(d, 2H), 4.28 (d, 1H), 3.62 (m, 1H), 1.85-1.62 (m, 6H), 1.55-1.42
(m, 2H), 1.37-1.17 (m, 3H), 1.08-0.88 (m, 2H).
EXAMPLE 56
(2RS,3R)-3-amino-N'-(1,3-benzothiazol-2-yl)-4-cyclohexyl-2-hydroxybutanohy-
drazide
[0294] The desired product was prepared by substituting
2-hydrazino-1,3-benzothiazole for 1-benzylhydrazine dihydrochloride
in Example 1.
[0295] MS(APCI) m/e 349 (M+H).sup.+;
[0296] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.76 (dd, 1H),
7.51 (m, 2H), 7.33 (m, 1H), 3.87 (d, 1H), 3.78 (m, 1H), 1.82-1.60
(m, 6H), 1.48-1.16 (m, 5H), 1.16-0.91 (m, 2H).
EXAMPLE 57
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dimethoxybenzohyd-
razide
[0297] The desired product was prepared by substituting
2,5-dimethoxybenzohydrazide for 1-benzylhydrazine dihydrochloride
in Example 1.
[0298] MS(APCI) m/e 380 (M+H).sup.+;
[0299] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.54 (m, 1H), 7.14
(m, 2H), 4.38 (d, 1H), 3.96 (s, 3H), 3.79 (s, 3H), 3.71 (m, 1H),
1.88-1.67 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40 (m, 1H), 1.38-1.18
(m, 3H), 1.10-0.93 (m, 2H).
EXAMPLE 58
(2RS,3R)-3-amnino-N'-(3-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazid-
e
[0300] The desired product was prepared by substituting
1-(3-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0301] MS(APCI) m/e 326 (M+H).sup.+;
[0302] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.15 (t, 1H),
6.84-6.73 (m, 2H), 4.30 (d, 1H), 3.62 (m, 1H), 1.88-1.64 (m, 6H),
1.58-1.42 (m, 2H), 1.37-1.17 (m, 3H), 1.08-0.87 (m, 2H).
EXAMPLE 59
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(3-methoxyphenyl)butanohydrazid-
e
[0303] The desired product was prepared by substituting
1-(3-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0304] MS(APCI) m/e 322 (M+H).sup.+;
[0305] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.12-7.05 (m, 1H),
6.46-6.39 (m, 2H), 4.27 (d, 1H), 3.73 (s, 3H), 3.61 (m, 1H),
1.84-1.63 (m, 6H), 1.56-1.40 (m, 2H), 1.40-1.25 (m, 3H), 1.08-0.96
(m, 2H).
EXAMPLE 60
(2RS,3R)-3-amino-4-cyclohexyl-N'-(3,5-dichlorophenyl)-2-hydrox
butanohvdrazide
[0306] The desired product was prepared by substituting
1-(3,5-dichlorophenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0307] MS(APCI) m/e 361 (M+H).sup.+;
[0308] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 6.82 (m, 1H), 6.77
(m, 2H), 4.30 (d, 1H), 3.61 (m, =1H), 1.88-1.63 (m, 6H), 1.57-1.43
(m, 2H), 1.28-1.17 (m, 3H), 1.09-0.98 (m, 2H).
EXAMPLE 61
(2RS,3R)-3-amino-N'-(3-bromophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
[0309] The desired product was prepared by substituting
1-(3-bromophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0310] MS(APCI) m/e 371 (M+H).sup.+;
[0311] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.09 (t, 1H),
7.00-6.91 (m, 2H), 6.81 (m, 1H), 4.29 (d, 1H), 3.62 (m, 1H),
1.87-1.63 (m, 6H), 1.56-1.43 (m, 2H), 1.37-1.18 (m, 3H), 1.09-0.90
(m, 2H).
EXAMPLE 62
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(trifluoroacetyl)butanohvdrazid-
e
[0312] The desired product was prepared by substituting
2,2,2-trifluoroacetohydrazide for 1-benzylhydrazine dihydrochloride
in Example 1.
[0313] MS(APCI) m/e 312 (M+H).sup.+;
[0314] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.36 (d, 1H), 3.68
(m, 1H), 1.85-1.67 (m, 6H), 1.59-1.18 (m, 5H), 1.08-0.93 (m,
2H).
EXAMPLE 63
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-isopropylphenyl)butanohydraz-
ide
[0315] The desired product was prepared by substituting
1-(4-isopropylphenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0316] MS(APCI) m/e 334 (M+H).sup.+;
[0317] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.12 (d, 2H), 6.78
(d, 2H), 4.29 (d, 1H), 3.61 (m, 1H), 2.83 (m, 1H), 1.82-0.95 (m,
19H).
EXAMPLE 64
(2RS,3R)-3-amino-N'-(3-chloro-4-methylphenyl)-4-cyclohexyl-2-hydroxybutano-
hydrazide
[0318] The desired product was prepared by substituting
1-(3-chloro-4-methylphenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0319] MS(APCI) m/e 340 (M+H).sup.+;
[0320] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.91 (d, 1H), 7.85
(s, 1H), 6.73 (d, 1H), 4.28 (d, 1H), 3.62 (m, 1H), 2.25 (s, 3H),
1.83-1.00 (m, 13H).
EXAMPLE 65
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-(trifluoromethoxy)phenyl)but-
anohydrazide
[0321] The desired product was prepared by substituting
1-(4-(trifluoromethoxy)phenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0322] MS(APCI) m/e 376 (M+H).sup.+;
[0323] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.11 (d, 2H), 6.93
(m, 2H), 4.28 (d, 1H), 3.62 (m, 1H), 1.80-1.02 (m,13H).
EXAMPLE 66
(2RS,3R)-3-amino-4-cyclohexyl-N'-(4-fluorophenyl)-2-hydroxybutanohydrazide
[0324] The desired product was prepared by substituting
1-(4-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0325] MS(APCI) m/e 310 (M+H).sup.+;
[0326] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 6.94 (m, 4H), 4.31
(d, 1H), 3.58 (m, 1H), 1.83-0.97 (m,13H).
EXAMPLE 67
(2RS,3R)-3-amino-N'-(4-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
[0327] The desired product was prepared by substituting
1-(4-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0328] MS(APCI) m/e 326 (M+H).sup.+;
[0329] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (d, 2H), 6.83
(d, 2H), 4.29 (d, 1H), 3.61 (m, 1H), 1.80-1.00 (m,13H).
EXAMPLE 68
(2RS,3R)-3-amino-4-cvclohexyl-N'-(2-ethylphenyl)-2-hydroxybutanohydrazide
[0330] The desired product was prepared by substituting
1-(2-ethylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0331] MS(APCI) m/e 320 (M+H).sup.+;
[0332] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.10 (m, 2H), 6.82
(m, 2H), 4.31 (d, 1H), 3.58 (m, 1H), 2.61 (q, 2H), 1.80-1.00 (m,
16H).
EXAMPLE 69
(2RS,3R)-3-amino-4-cyclohexyl-N'-(3-fluorophenyl)-2-hydroxybutanohydrazide
[0333] The desired product was prepared by substituting
1-(3-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0334] MS(APCI) m/e 310 (M+H).sup.+;
[0335] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.17 (m, 1H), 6.62
(m, 3H), 4.30 (d, 1H), 3.61 (m, 1H), 2.63 (q, 2H), 1.80-1.00 (m,
13H).
EXAMPLE 70
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-chloro-1-benzothiop-
hene-2-carbohydrazide
[0336] The desired product was prepared by substituting
3-chloro-1-benzothiophene-2-carbohydrazide for 1-benzylhydrazine
dihydrochloride in Example 1.
[0337] MS(APCI) m/e 410 (M+H).sup.+;
[0338] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.01 (d, 2H), 7.60
(d, 2H), 4.38 (d, 1H), 3.71 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 71
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methylbenzohydrazid-
e
[0339] The desired product was prepared by substituting
4-methylbenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0340] MS(APCI) m/e 334 (M+H).sup.+;
[0341] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.80 (d, 2H), 7.32
(d, 2H), 4.39 (d, 1H), 3.70 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 72
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-nitrobenzohydrazide
[0342] The desired product was prepared by substituting
4-nitrobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0343] MS(APCI) m/e 365 (M+H).sup.+;
[0344] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.42 (d, 2H), 8.08
(d, 2H), 4.42 (d, 1H), 3.73 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 73
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-naphthohydrazide
[0345] The desired product was prepared by substituting
2-naphthohydrazide for 1-benzylhydrazine dihydrochloride in Example
1.
[0346] MS(APCI) mle 370 (M+H).sup.+;
[0347] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.53 (s, 1H), 8.01
(m, 5H), 7.59 (m, 2H), 4.38 (d, 1H), 3.72 (m, 1H),1.80-1.00 (m,
13H).
EXAMPLE 74
(2RS,3R)-3-amino-N'-(4-chloro-2-methylphenyl)-4-cyclohexyl-2-hydroxybutano-
hydrazide
[0348] The desired product was prepared by substituting
1-(4-chloro-2-methylphenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0349] MS(APCI) m/e 340 (M+H).sup.+;
[0350] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.08-7.01 (m, 2H),
6.77 (d, 1H), 4.33 (d, 1H), 3.66 (m, 1H), 2.23 (s, 3H), 1.86-1.64
(m, 6H), 1.57-1.44 (m, 2H), 1.37-1.22 (m, 3H), 1.05-0.92 (m,
2H).
EXAMPLE 75
(2RS,3R)-3-amino-4-cvclohexvl-2-hydroxy-N'-mesitylbutanohydrazide
[0351] The desired product was prepared by substituting
1-mesitylhydrazine for 1-benzylhydrazine dihydrochloride in Example
1.
[0352] MS(APCI) m/e 334 (M+H).sup.+;
[0353] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 6.77 (bs, 1H),
6.74 (bs, 1H), 4.14 (d, 1H), 3.52 (m, 1H), 2.32 (d, 6H), 2.18 (d,
3H), 1.78-1.61 (m, 6H), 1.48-1.14 (m, 5H), 1.02-0.75 (m, 2H).
EXAMPLE 76
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-((E)-2-(2-pyridinyl)ethenyl)-
phenyl)butanohydrazide
[0354] The desired product was prepared by substituting
2-((1E)-3-(4-hydrazinophenyl)-1-propenyl)pyridine for
1-benzylhydrazine dihydrochloride in Example 1.
[0355] MS(APCI) m/e 395 (M+H).sup.+.
EXAMPLE 77
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-fluorophenyl)-2-hydroxybutanohydrazide
[0356] The desired product was prepared by substituting
1-(2-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0357] MS(APCI) m/e 310 (M+H).sup.+;
[0358] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.04 (dt, 1H),
7.00 (dd, 1H), 6.94 (dt, 1H), 6.82 (m, 1H), 4.31 (d, 1H), 3.64 (m,
1H), 1.86-1.64 (m, 6H), 1.57-1.42 (m, 2H), 1.42-1.17 (m, 3H),
1.08-0.92 (m, 2H).
EXAMPLE 78
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-quinoxalinyl)butanohydrazide
[0359] The desired product was prepared by substituting
2-hydrazinoquinoxaline for 1-benzylhydrazine dihydrochloride in
Example 1.
[0360] MS(APCI) m/e 344 (M+H).sup.+;
[0361] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.71 (s, 1H), 8.03
(d, 1H), 7.93 (d, 1H), 7.78 (t, 1H), 7.66 (t, 1H), 4.55 (d, 1H),
3.77 (m, 1H), 1.87-1.65 (m, 6H), 1.65-1.44 (m, 2H), 1.44-1.16 (m,
3H), 1.10-0.94 (m, 2H).
EXAMPLE 79
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-(trifluoromethyl)phenyl)buta-
nohydrazide
[0362] The desired product was prepared by substituting
1-(4-(trfluoromethyl)phenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0363] MS(APCI) m/e 360 (M+H).sup.+;
[0364] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.07 (d, 2H), 7.84
(d, 2H), 4.39 (d, 1H), 3.70 (m, 1H), 1.87-1.67 (m, 6H), 1.62-1.52
(m, 1H), 1.52-1.42 (m, 1H), 1.42-1.16 (m, 3H), 1.10-0.94 (m,
2H).
EXAMPLE 80
(2RS,3R)-3-amino-N'-(2-chloro-6-fluorophenyl)-4-cyclohexyl-2-hydroxybutano-
hydrazide
[0365] The desired product was prepared by substituting
1-(2-chloro-6-fluorophenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0366] MS(APCI) m/e 344 (M+H).sup.+;
[0367] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.16 (dt, 1H),
7.07-6.99 (m, 1H), 6.92 (dt, 1H), 4.20 (d, 1H), 3.55 (m, 1H),
1.80-1.66 (m, 6H), 1.50-1.35 (m, 2H), 1.35-1.18 (m, 3H), 1.03-0.87
(m, 2H).
EXAMPLE 81
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-methyl-N'-(5-(trifluoromethyl)--
2-pyridinyl)butanohydrazide
[0368] The desired product was prepared by substituting
2-(1-methylhydrazino)-5-(trifluoromethyl)pyridine for
1-benzylhydrazine dihydrochloride in Example 1.
[0369] MS(APCI) m/e 375 (M+H).sup.+;
[0370] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.42 (bs, 1H),
8.11 (dd, 1H), 7.25 (d, 1H), 4.50 (d, 1H), 3.72 (m, 1H), 3.48 (s,
3H), 1.87-1.66 (m, 6H), 1.62-1.52 (m, 1H), 1.52-1.45 (m, 1H),
1.38-1.21 (m, 3H), 1.08-0.93 (m, 2H).
EXAMPLE 82
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2,5-difluorophenyl)-2-hydroxybutanohydra-
zide
[0371] The desired product was prepared by substituting
1-(2,5-difluorophenyl)hydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0372] MS(APCI) m/e 328 (M+H).sup.+;
[0373] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.01 (m, 1H), 6.67
(m, 1H), 6.50 (m, 1H), 4.33 (d, 1H), 3.65 (m, 1H), 1.86-1.65 (m,
6H), 1.58-1.44 (m, 2H), 1.38-1.18 (m, 3H), 1.06-0.92 (m, 2H).
EXAMPLE 83
(2RS,3R)-3-amino-4-cyclohexyl-N'-(1,3-dimethyl-4-nitro-1
H-pyrazol-5-yl)-2-hydroxybutanohydrazide
[0374] The desired product was prepared by substituting
5-hydrazino-1,3-dimethyl-4-nitro-1H-pyrazole for 1-benzylhydrazine
dihydrochloride in Example 1.
[0375] MS(APCI) m/e 355 (M+H).sup.+;
[0376] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.39 (d, 1H), 3.74
(s, 3H), 3.67 (m, 1H), 2.40 (s, 3H), 1.83-1.64 (m, 611), 1.55-1.17
(m, 5H), 1.08-0.90 (m, 2H).
EXAMPLE 84
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-phenylhydrazinecarbo-
xamide
[0377] The desired product was prepared by substituting
N-phenylhydrazinecarboxamide for 1-benzylhydrazine dihydrochloride
in Example 1.
[0378] MS(APCI) m/e 335 (M+H).sup.+;
[0379] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.41 (d, 2H), 7.28
(t, 2H), 7.03 (t, 1H), 4.33 (d, 1H), 3.68 (m, 1H), 1.87-1.67 (m,
6H), 1.60-1.50 (m, 1H), 1.50-1.38 (m, 1H), 1.37-1.18 (m, 3H),
1.08-0.97 (m, 2H).
EXAMPLE 85
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-chloro-2-methoxyp-
henyl)hydrazinecarboxamide
[0380] The desired product was prepared by substituting
N-(4-chloro-2-methoxyphenyl)hydrazinecarboxamide for
1-benzylhydrazine dihydrochloride in Example 1.
[0381] MS(APCI) m/e 399 (M+H).sup.+;
[0382] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.10 (d, 1H), 6.96
(d, 2H), 4.34 (d, 1H), 3.90 (s, 3H), 3.68 (m, 1H), 1.86-1.66 (m,
6H), 1.62-1.50 (m, 1H), 1.50-1.38 (m, 1H), 1.38-1.17 (m, 3H),
1.11-0.93 (m, 2H).
EXAMPLE 86
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(3-fluorophenyl)hydr-
azinecarboxamide
[0383] The desired product was prepared by substituting
N-(3-fluorophenyl)hydrazinecarboxamide for 1-benzylhydrazine
dihydrochloride in Example 1.
[0384] MS(APCI) m/e 353 (M+H).sup.+;
[0385] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.41 (d, 1H), 7.26
(q, 1H), 7.09 (d, 1H), 6.75 (t, 1H), 4.34 (d, 1H), 3.68 (m, 1H),
1.87-1.66 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.48 (m, 1H), 1.48-1.18
(m, 3H), 1.00-0.93 (m, 2H).
EXAMPLE 87
N-((1R)-1-((2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)c-
arbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethyl)benzamide
[0386] The desired product was prepared by substituting
N-((1R)-1-(hydrazinocarbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethy-
l)benzarnide for 1-benzylhydrazine dihydrochloride in Example
1.
[0387] MS(APCI) m/e 519 (M+H).sup.+;
[0388] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.05 (d, 2H), 7.79
(d, 2H), 4.31 (d, 1H), 3.81 (q, 1H), 3.65 (m, 1H), 2.68 (m, 2H),
2.30-2.15 (m, 2H), 2.12 (s, 3H), 1.84-1.63 (m, 6H), 1.58-1.48 (m,
1H), 1.48-1.36 (m, 1H), 1.36-1.20 (m, 3H), 1.06-0.95 (m, 2H).
EXAMPLE 88
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-thienylcarbonyl)butanohydraz-
ide
[0389] The desired product was prepared by substituting
2-thiophenecarbohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0390] MS(APCI) m/e 326 (M+H).sup.+;
[0391] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.81 (dd, 2H),
7.18 (d, 1H), 4.42 (d, 1H), 3.73 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 89
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-chlorobenzohydrazid-
e
[0392] The desired product was prepared by substituting
4-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0393] MS(APCI) m/e 354 (M+H).sup.+;
[0394] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.91 (d, 2H), 7.55
(d, 2H), 4.43 (d, 1H), 3.68 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 90
(2RS,3R)-3-amino-N'-benzovl-4-cyclohexyl-2-hydroxybutanohydrazide
[0395] The desired product was prepared by substituting
benzohydrazide for 1-benzylhydrazine dihydrochloride in Example
1.
[0396] MS(APCI) m/e 320 (M+H).sup.+;
[0397] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.91 (d, 2H), 7.58
(m, 3H), 4.42 (d, 1H), 3.68 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 91
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-bromobenzohydrazide
[0398] The desired product was prepared by substituting
3-bromobenzohydrazide for 1-benzylhydrazine dihydrochloride in
Example 1.
[0399] MS(APCI) m/e 400 (M+H).sup.+;
[0400] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.81 (d, 2H), 7.72
(d, 2H), 4.37 (d, iH), 3.69 (m, 1H), 1.80-1.00 (m, 13H).
EXAMPLE 92
N
'-((2RS,3R)-3-amino-4-cyclohexvl-2-hydroxybutanoyl)-4-tert-butylbenzohyd-
razide
[0401] The desired product was prepared by substituting for
1-benzylhydrazine dihydrochloride in Example 1.
[0402] MS(APCI) m/e 376 (M+H).sup.+;
[0403] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.83 (d, 2H), 7.55
(d, 2H), 4.41 (d, 1H), 3.73 (m, 1H), 1.80-1.00 (m, 22H).
EXAMPLE 93
4-chlorobenzyl
2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydra-
zino)-4-(trifluoromethyl)-5-pyrimidinecarboxylate
[0404] The desired product was prepared by substituting
4-chlorobenzyl
2-hydrazino-4-(trifluoromethyl)-5-pyrimidinecarboxylate for
1-benzylhydrazine dihydrochloride in Example 1.
[0405] MS(APCI) m/e 530 (M+H).sup.+;
[0406] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.96 (bs, 1H),
7.41 (m, 4H), 4.34 (d, 1H), 3.62 (m, 1H), 1.85-1.67 (m, 6H),
1.62-1.40 (m, 2H), 1.40-1.17 (m, 3H), 1.08-0.93 (m, 2H).
EXAMPLE 94
(2RS,3R)-3-amino-N'-(3-chloro-4-fluorophenyl)-4-cyclohexyl-2-hydroxybutano-
hydrazide
[0407] The desired product was prepared by substituting
3-chloro-4-fluorophenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0408] MS(APCI) m/e 344 (M+H).sup.+;
[0409] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.06 (t, 1H), 6.91
(q, 1H), 6.78 (m, 1H), 4.31 (d, 1H), 3.62 (m, 1H), 1.88-1.63 (m,
6H), 1.57-1.41 (m, 2H), 1.41-1.12 (m, 2H), 1.12-0.90 (m, 2H).
EXAMPLE 95
(2RS,3R)-3-amino-N'-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxybutanoh-
ydrazide
[0410] The desired product was prepared by substituting
3-chloro-6-hydrazinopyridazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0411] MS(APCI) m/e 328 (M+H).sup.+;
[0412] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.55 (d, 1H), 7.17
(d, 1H), 4.38 (d, 1H), 3.64 (m, 1H), 1.87-1.68 (m, 6H), 1.56-1.49
(m, 1H), 1.49-1.37 (m, 1H), 1.37-1.17 (m, 3H), 1.07-0.95 (m,
2H).
EXAMPLE 96
(2RS,3R)-3-amino-N'-(2-chlorobenzvl)-4-cyclohexyl-2-hydroxybutanohydrazide
[0413] The desired product was prepared by substituting
1-(2-chlorobenzyl)hydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0414] MS(APCI) m/e 340 (M+H).sup.+;
[0415] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.54 (m, 1H), 7.49
(m, 1H), 7.28 (m, 2H), 4.13 (q, 2H), 4.11 (d, 1H), 3.52 (m, 1H),
1.80-1.66 (m, 6H), 1.60-1.50 (m, 1H), 1.45-1.16 (m, 4H), 1.00-0.96
(m, 2H).
EXAMPLE 97
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2R)-2-(methoxymethyl)pyrrolidi-
nyl)butanarmide
[0416] The desired product was prepared by substituting
(2R)-2-(methoxymethyl)-1-pyrrolidinamine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0417] MS(APCI) mle 314 (M+H).sup.+;
[0418] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.11 (d, 1H), 3.58
(m, 1H), 3.45 (q, 1H), 3.35 (t, 1H), 3.32 (s, 3H), 3.21 (m, 1H),
3.07 (m, 1H), 2.80 (q, 2H), 2.08-1.93 (m, 1H), 1.88-1.68 (m, 6H),
1.67-1.53 (ml 1H), 1.53-1.48 (m, 2H), 1.48-1.18 (m, 3H), 1.04-0.98
(m, 2H).
EXAMPLE 98
(2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N-phenoxypentamide
EXAMPLE 98A
3-amino-3,4-dideoxy-5-S-ethyl-5-thio-D-glycero-pentonic acid
[0419] The desired product was prepared by substituting
(2R)-2-((tert-butoxycarbonyl)amino)-4-(ethylsulfanyl)butanoic acid
for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid
in Examples 1A-C.
EXAMPLE 98B
(2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N-phenoxypentamide
[0420] A solution of Example 98A (0.39 g, 1.3 mmol), O-phenyl
hydroxylamine hydrochloride (0.27 g, 1.9 mmol),
1-(3-dimethylaminopropyl)- -3-ethylcarbodiimide hydrochloride (0.29
g, 1.5 mmol), 1-hydroxybenzotriazole hydrate (0.20 g, 1.5 mmol),
and N-methylmorpholine (0.40 mL, 3.6 mmol) in 3:1
dichloromethane/DMF (8 mL) at room temperature was stirred for 16
hours, diluted with dichloromethane, washed sequentially with
aqueous NaHCO.sub.3, brine, 10% KHSO4, and brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with
95:5/dichloromethane:metha- nol, and the purified concentrate was
dissolved in saturated HCl/dioxane (2 mL), stirred for 1 hour,
concentrated, treated with diethyl ether, then concentrated to
provide the desired product.
[0421] MS(ESI) m/e 285 (M+H).sup.+;
[0422] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 12.31 (bs, 1H),
8.08 (bs, 0.4H), 7.94 (bs, 0.6H), 7.34 (m, 2H), 7.03 (m, 3H), 6.73
(d, 0.6H), 6.62 (d, 0.4H), 4.41 (m, 0.4H), 4.28 (t, 0.6H), 3.48 (m,
1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 1.98-1.78 (m, 2H), 1.21 (t,
3H).
EXAMPLE 99
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-phenoxybutanamide
[0423] The desired product was prepared by substituting Example IC
for Example 98A in Example 98B.
[0424] MS(ESI) m/e 293 (M+H).sup.+;
[0425] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.92 (bs, 1H),
7.34 (m, 2H), 7.06 (m, 3H), 6.73 (d, 0.4H), 6.70 (d, 0.6H), 4.21
(m, 1H), 3.36 (m, 1H), ), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H),
1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
EXAMPLE 100
(2RS,3R)-3-amino-N-(benzyloxy)-4-cyclohexyl-2-hydroxybutanamide
[0426] A solution of Example 1C (0.20 g, 0.66 mmol), O-benzyl
hydroxylamine hydrochloride (0.22 g, 1.4 mmol),
1-(3-dimethylaminopropyl)- -3-ethylcarbodiimide hydrochloride (0.17
g, 0.89 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 mmol), and
N-methylmorpholine (0.40 mL, 3.6 mmol) in 5:1 dichloromethane/DMF
(6 mL) at room temperature was stirred for 16 hours, diluted with
dichloromethane, washed sequentially with aqueous NaHCO.sub.3,
brine, 10% KHSO4, and brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with 98:2/dichloromethane:metha- nol,
and the purified concentrate was dissolved in saturated HCl/dioxane
(8 mL), stirred for 1 hour, concentrated, treated with diethyl
ether, then concentrated to provide the desired product.
[0427] MS(ESI) m/e 307 (M+H).sup.+;
[0428] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.78 (br s, 1H),
7.40 (m, 5H), 6.42 (d, 1H), 4.84 (s, 2H), 3.95 (m, 1H), 1.74-1.60
(m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.96-0.80 (m,
2H).
EXAMPLE 101
(2RS 3R)-3-amino-N-(methoxy)-4-cyclohexyl-2-hvdroxybutanamide
[0429] The desired product was prepared by substituting 0-methyl
hydroxylamine hydrochloride for O-benzyl hydroxylamine
hydrochloride in Example 100.
[0430] MS(APCI) m/e 231 (M+H).sup.+;
[0431] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.74 (br s, 1H),
6.42 (d, 1H) 3.95 (m, 1H), 3.63 (s, 3H), 1.74-1.60 (m, 6H),
1.50-1.40 (m, 1H), 1.33-1.15 (mn, 4H), 0.96-0.80 (m, 2H).
EXAMPLE 102
(2RS,3R)-3-amino-N-(tert-butoxy)-4-cyclohexyl-2-hydroxvbutanamide
[0432] The desired product was prepared by substituting
0-tert-butyl hydroxylamine hydrochloride for O-benzyl hydroxylamine
hydrochloride in Example 100.
[0433] MS(APCI) m/e 273 (M+H).sup.+;
[0434] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.74 (br s, 1H),
6.44 (d, 1H) 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H),
1.33-1.15 (m, 4H), 1.19 (s, 9H), 0.96-0.80 (m, 2H).
EXAMPLE 103
(2RS,3R)-3-amino-4-cyclohexyl-N-ethoxy-2-hydroxybutanamide
[0435] The desired product was prepared by substituting O-ethyl
hydroxylamine hydrochloride for O-benzyl hydroxylamine
hydrochloride in Example 100.
[0436] MS(APCI) m/e 245 (M+H).sup.+;
[0437] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.73 (br s, 1H),
6.41 (d, 1H), 3.92 (m, 1H), 3.84 (q, 2H), 1.74-1.60 (m, 6H),
1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 1.14 (t, 3H), 0.96-0.80 (m,
2H).
EXAMPLE 104
(2RS,3R)-N-(allyloxy)-3-amino-4-cvclohexyl-2-hydroxybutanamide
[0438] The desired product was prepared by substituting O-allyl
hydroxylamine hydrochloride for O-benzyl hydroxylamine
hydrochloride in Example 100.
[0439] MS(APCI) m/e 257 (M+H).sup.+;
[0440] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.74 (br s, 1H),
6.43 (d, 1H), 5.95 (m, 1H), 5.32 (dd, 1H), 5.27 (m, 1H), 4.32 (d,
2H), 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15
(m, 4H), 0.96-0.80 (m, 2H).
EXAMPLE 105
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-isobutoxybutanamide
[0441] The desired product was prepared by substituting O-isobutyl
hydroxylamine hydrochloride for O-benzyl hydroxylamine
hydrochloride in Example 100.
[0442] MS(APCI) m/e 273 (M+H).sup.+;
[0443] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.73 (br s, 1H),
6.39 (d, 1H), 3.92 (m, 1H), 3.58 (d, 2H), 1.88 (sept, 1H),
1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.91 (d,
6H), 0.90-0.75 (m, 2H).
EXAMPLE 106
(2RS,3R)-3-amino-4-cyclohexyl-N,2-dihydroxybutanamide
EXAMPLE 106A
(2RS,3R)-3-(tert-butoxycarbonyl)amino-N-(benzyloxy)-4-cyclohexyl-2-hydroxy-
butanamide
[0444] A solution of Example 1C (0.20 g, 0.66 mmol), O-benzyl
hydroxylamine hydrochloride (0.22 g, 1.4 mmol),
1-(3-dimethylaminopropyl)- -3-ethylcarbodiimide hydrochloride (0.17
g, 0.89 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 mmol), and
N-methylmorpholine (0.40 mL, 3.6 mmol) in 5:1 dichloromethane/DMF
(6 mL) at room temperature was stirred for 16 hours, diluted with
dichloromethane, washed sequentially with aqueous NaHCO.sub.3,
brine, 10% KHSO4, and brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with 98:2/dichloromethane:metha- nol
to provide the desired product.
[0445] MS(APCI) m/e 407 (M+H).sup.+.
EXAMPLE 106B
(2RS,3R)-3-amino-4-cyclohexyl-N,2-dihydroxybutanamide
[0446] A solution of Example 106A (0.33 g, 0.82 mmol), and 10%
palladium on charcoal (0.13 g) in THF (8 mL) at room temperature
was stirred for 16 hours under an atmosphere of hydrogen gas,
filtered, and concentrated. The concentrate was dissolved in
saturated HCl/dioxane (5 mL), stirred for 1 hour, concentrated,
treated with diethyl ether, then concentrated to provide the
desired product.
[0447] MS(APCI) m/e 217 (M+H).sup.+;
[0448] H .sup.1NMR (300 MHz, DMSO-d.sub.6) .delta. 10.89 (br s,
1H), 8.89 (br s, 1H), 7.80 (br s, 2H), 6.31 (d, 1H), 3.92 (m, 1H),
1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.90-0.75
(m, 2H).
EXAMPLE 107
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N-phenoxybutanamide
[0449] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine in Example
193.
[0450] MS(ESI) m/e 271 (M+H).sup.+;
[0451] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.32 (t, 2H), 7.10
(d, 2H), 7.06 (m, 1H), 4.56 (d, 0.65H), 4.54 (d, 0.35H), 3.66 (m,
1H), 2.95 (dd, 1H), 2.78 (dd, 1H), 2.64 (dd, 1.3H), 2.59 (dd,
0.7H), 1.29 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 108
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N-phenoxypropanamide
[0452] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 122A
for Example 97A in Example 193.
[0453] MS(ESI) m/e 279 (M+H).sup.+;
[0454] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (t, 2H), 7.08
(m, 3H), 4.51 (d, 0.65H), 4.48 (d, 0.35H), 3.37 (dd, 1H), 1.87-1.72
(m, 6H), 1.35-1.11 (m, 5H).
EXAMPLE 109
(2RS,3S)-3-amino-2-hydroxy-N-phenoxy-4-(propylsulfanyl)butanamide
[0455] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 195B
for Example 97A in Example 193.
[0456] MS(ESI) m/e 285 (M+H).sup.+;
[0457] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (t, 2H), 7.08
(m, 3H), 4.58 (d, 0.65H), 4.56 (d, 0.35H), 3.68 (m, 1H), 2.94 (dd,
0.65H), 2.87 (dd, 0.35H), 2.78 (m, 1H), 2.60 (dd, 1H), 2.54 (m,
1H), 1.65 (dd, 1H), 1.60 (dd, 1H), 1.02 (t, 1.95 H), 0.99 (t,
1.05H).
EXAMPLE 110
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-phenoxypentanamide
[0458] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 124B
for Example 97A in Example 193.
[0459] MS(ESI) m/e 299 (M+H).sup.+;
[0460] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (dd, 2H),
7.08 (m, 3H), 4.48 (d, 0.35H), 4.31 (d, 0.65H), 3.75 (m, 1H), 2.97
(dd, 0.65H), 2.93 (dd, 0.35H), 2.71 (m, 1.65H), 2.67 (m, 0.35H),
2.10 (dd, 0.65H), 1.99 (dd, 0.35H), 1.92 (dd, 1H), 1.28 (d, 3 H),
1.27 (d, 3H).
EXAMPLE 111
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-phenoxybutanamide
[0461] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 124B
for Example 97A in Example 193.
[0462] MS(ESI) m/e 299 (M+H).sup.+;
[0463] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (t, 2H), 7.08
(m, 3H), 4.60 (d, 1H), 3.69 (ddd, 1H), 2.93 (dd, 1H), 2.78 (dd,
1H), 2.50 (m, 2H), 1.83 (ddd, 1H), 1.03 (d, 6H).
EXAMPLE 112
(2RS,3R)-3-amino-5-phenyl-2-hydroxy-N-phenoxypentanamide
[0464] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 125A
for Example 97A in Example 193.
[0465] MS(ESI) m/e 301 (M+H).sup.+;
[0466] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.30 (m, 3H),
7.26-7.20 (m, 4H), 7.06 (m, 3H), 4.48 (d, 0.5H), 4.45 (d, 0.5H),
3.59 (m, 1H), 2.79 (m, 1.5H), 2.71 (m, 0.5H), 2.15 (m, 0.5H), 2.02
(m, 1H), 1.94 (m, 0.5H).
EXAMPLE 113
(2RS,3R)-3-amino-3-cyclooctyl-2-hydroxy-N-phenoxypropanamide
[0467] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 199A
for Example 97A in Example 193.
[0468] MS(ESI) mle 307 (M+H).sup.+;
[0469] .sup.1H NMR (500 MHz, CD30D) .delta.7.33 (m, 2H), 7.10 (m,
3H), 3.86 (m, 1H), 3.79 (m, 1H), 1.80-1.52 (m, 15H).
EXAMPLE 114
(2RS .3R)-3-amino-5-cyclohexyl-2-hvdroxy-N-phenoxypentanamide
[0470] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 238A
for Example 97A in Example 193.
[0471] MS(ESI) m/e 307 (M+H).sup.+;
[0472] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (m, 2H), 7.10
(m, 311), 3.89 (m, 1H), 3.71 (d, 1H), 1.74 (m, 3H), 1.65 (m, 2H),
1.53 (m, 2H), 1.29 (m, 4H), 1.20 (m, 2H), 0.95 (m, 2H).
EXAMPLE 115
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-phenoxybutanam-
ide
[0473] The desired product was prepared by substituting
O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 200B
for Example 97A in Example 193.
[0474] MS(ESI) m/e 339 (M+H).sup.+;
[0475] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.32 (dd, 2H),
7.08 (dd, 3H), 4.60 (d, 0.65H), 4.56 (d, 0.35H), 3.70 (m, 1H), 2.91
(dd, 1H), 2.82 (dd, 0.35H), 2.77 (dd, 0.65H), 2.51 (m, 1.5H), 2.43
(m, 0.5H), 1.88 (m, 2H), 1.75-1.66 (m, 3H), 1.32-1.16 (m, 4H), 0.98
(m, 2H).
EXAMPLE 116
ethyl
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate
[0476] The desired product was prepared by substituting
O-(carboethoxy)methyl hydroxylamine hydrochloride for O-benzyl
hydroxylamine hydrochloride in Example 100.
[0477] MS(APCI) m/e 303 (M+H).sup.+;
[0478] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.7.95 (br s, 1H),
6.39 (d, 1H), 4.50 (d, 2H), 4.18 (m, 2H), 3.92 (m, 1H), 1.74-1.60
(m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 1.23 (t, 3H),
0.90-0.75 (m, 2H).
EXAMPLE 117
benzyl
((((2RS,3R)-3-amino-4-cyclohexYl-2-hydroxybutanoyl)amino)oxy)acetat-
e
EXAMPLE 117A
benzyl
((((2RS,3R)-3-(tert-butoxycarbonyl)amino-4-cyclohexyl-2-hydroxybuta-
noyl)amino)oxy)acetate
[0479] The desired product was prepared by substituting
O-(carbobenzyloxy)methyl hydroxylamine for O-(carboethoxy)methyl
hydroxylamine hydrochloride in Example 106A.
[0480] MS(APCI) m/e 465 (M+H).sup.+.
EXAMPLE 117B
benzyl
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetat-
e
[0481] Example 117A was dissolved in saturated HCl/dioxane (3 mL),
stirred for 1 hour, concentrated, treated with diethyl ether, then
concentrated to provide the desired product.
[0482] MS(APCI) m/e 365 (M+H).sup.+;
[0483] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.7.96 (br s, 1H),
7.39 (m, 5H), 6.39 (d, IH), 5.20 (s, 2H), 4.49 (s, 2H), 3.92 (m,
1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H),
0.90-0.75 (m, 2H).
EXAMPLE 118
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetic
acid
EXAMPLE 118A
((((2RS,3R)-3-(tert-butoxycarbonvl)amino-4-cyclohexyl-2-hydroxvbutanoyl)am-
ino)oxy)acetic acid
[0484] A solution of Example 117A (0.99 g, 2.1 mmol), and 10%
Palladium on charcoal (0.21 g) in THF (10 mIL) at room temperature
was stirred for 4 hours under an atmosphere of hydrogen gas,
filtered, and concentrated to provide the desired product.
[0485] MS(APCI) m/e 375 (M+H).sup.+;
EXAMPLE 118B
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetic
acid
[0486] Example 118A (0.17 g, 0.45 mmol) was dissolved in saturated
HCl/dioxane (4 mL), stirred for 1 hour, concentrated, treated with
diethyl ether, then concentrated to provide the desired
product.
[0487] MS(APCI) m/e 275 (M+H).sup.+;
[0488] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.96 (br s, 1H),
6.39 (d, 1H), 5.20 (s, 2H), 3.92 (m, 1H), 1.74-1.60 (m, 6H),
1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.90-0.75 (m, 2H).
EXAMPLE 119
ethyl
(2S)-2-((((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)ox-
y)acetyl)amino)propanoate
[0489] A solution of Example 118A (0.17 g, 0.45 mmol), L-alanine
ethyl ester hydrochloride (0.098 g, 0.64 mmol),
1-(3-dimethylaminopropyl)-3-eth- ylcarbodiimide hydrochloride
(0.098 g, 0.51 mmol), 1-hydroxybenzotriazole (0.091 g, 0.67 mmol),
and N-methylmorpholine (0.11 mL, 1.0 mmol) in dichloromethane (5
mL) at room temperature was stirred for 16 hours, diluted with
dichloromethane, washed sequentially with 1 M HCl, aqueous
NaHCO.sub.3, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was dissolved in saturated HCl/dioxane (4 mL), stirred
for 1 hour, concentrated, then purified by HPLC to provide the
desired product.
[0490] MS(ESI) m/e 374 (M+H).sup.+;
[0491] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.71 (br s,
1H), 8.56 (br s, 1), 7.74 (br s, 2H), 6.55 (d, 1H), 4.35 (d, 2H),
4.29 (m, 1H), 4.09 (m, 2H), 4.03 (m, 1H), 1.74-1.60 (m, 6H),
1.40-1.35 (m, 1H), 1.31 (d, 3H), 1.33-1.15 (m, 4H), 1.19 (t, 3H),
0.96-0.80 (m, 2H).
EXAMPLE 120
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(2-oxo-2-((2-phenylethyl)amino)e-
thoxy)butanamide
[0492] The desired product was prepared by substituting
2-phenylethylamine for L-alanine ethyl ester hydrochloride in
Example 119.
[0493] MS (APCI) m/e 378 (M+H).sup.+;
[0494] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.69 (br s,
1H), 8.29 (br s, 1H), 7.75 (br s, 2H), 7.30 (m, 3H), 7.22 (m, 2H),
6.56 (d, 1H), 4.28 (d, 2H), 4.01 (m, 1H), 2.75 (m, 2H), 1.74-1.60
(m, 6H), 1.50-1.40 (m, 1H), 1.36 (m, 2H), 1.33-1.15 (m, 4H),
0.90-0.75 (m, 2H).
EXAMPLE 121
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-benzyloxypentanamide
[0495] The desired product was prepared by substituting O-benzyl
hydroxylamine hydrochloride for O-phenyl hydroxylamine
hydrochloride in Example 98B.
[0496] MS(ESI) m/e 299 (M+H).sup.+;
[0497] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.51 (br s,
1H), 7.92 (br s, 0.3H), 7.84 (br s, 0.7H), 7.39 (m, 5H), 6.49 (d,
0.7H), 6.40 (d, 0.3H), 4.84 (s, 1.4H), 4.82 (s, 0.6H), 4.17 (m,
0.3H), 4.03 (m, 0.7H), 3.48 (m, 1H), 2.60 (m, 2H), 2.48 (q, 2H),
1.73 (m, 2H), 1.18 (t, 3H).
EXAMPLE 122
(2RS,3R)-3-amino-N-(benzyloxy)-3-cyclohexyl-2-hydroxypropanamide
EXAMPLE 122A
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoic acid
[0498] The desired product was prepared by substituting
(2R)-2-((tert-butoxycarbonyl)amino)-2-(cyclohexyl)ethanoic acid for
(2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in
Examples 1A-C.
[0499] MS(ESI) m/e 288 (M+H).sup.+.
EXAMPLE 122B
(2RS,3R)-3-amino-N-(benzyloxy)-3-cyclohexyl-2-hvdroxypropanamide
[0500] The desired product was prepared by substituting O-benzyl
hydroxylamine hydrochloride for O-phenyl hydroxylamine
hydrochloride and Example 122A for Example 98A in Example 98B.
[0501] MS(ESI) m/e 293 (M+H).sup.+;
[0502] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.52 (s, 1H),
7.73 (br s, 2H), 7.41 (m, 5H), 6.40 (m, 1H), 4.85 (s, 2H), 4.08 (m,
1H), 1.77-1.44 (m, 6H), 1.20-0.94 (m, 5H).
EXAMPLE 123
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)pentanamide
EXAMPLE 123A
(2R)-2-((tert-butoxvcarbonyl)amino)-4-((isopropyl)sulfanvl)butanoic
acid
[0503] A solution of D-homocystine (20 g, 75 mmol) in liquid
ammonia (600 mL) was treated sequentially with sodium (8.9 g, 390
mmol) and 2-bromopropane (20 mL, 210 mmol). The ammonia was allowed
to evaporate under a stream of nitrogen, and the residues take up
in 1:1 2-propanol/water (500 mL), then treated with di-tert-butyl
dicarbonate (50 g, 230 mmol) at room temperature for 6 hours, then
concentrated. The residues were taken up in water and the pH
adjusted to 10 with NaOH. The solution was washed twice with ether,
then adjusted to pH 2 with HCl, then extracted twice with ethyl
acetate. The ethyl acetate extracts were dried (MgSO.sub.4),
filtered, then concentrated to provide the desired product.
[0504] MS(ESI) m/e 279 (M+H).sup.+.
EXAMPLE 123B
(2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoic acid
[0505] The desired product was prepared by substituting Example
123A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic
acid in Examples 1A-C.
[0506] MS(ESI) m/c 308 (M+H).sup.+.
EXAMPLE 123C
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)pentanamide
[0507] The desired product was prepared by substituting O-benzyl
hydroxylamine hydrochloride for O-phenyl hydroxylamine
hydrochloride and Example 123B for Example 98A in Example 98B.
[0508] MS(ESI) m/e 313 (M+H).sup.+;
[0509] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.50 (br s,
1H), 7.92 (br s, 0.6H), 7.84 (br s, 1.4H), 7.40 (m, 5H), 6.48 (d,
0.7H), 6.38 (d, 0.3H), 4.84 (s, 1.4H), 4.82 (s, 0.6H), 4.17 (m,
0.3H), 4.03 (m, 0.7H), 3.48 (m, 1H), 2.91 (m, 1H), 2.73 (m, 2H),
1.74 (m, 2H), 1.20 (d, 6H).
EXAMPLE 124
(2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide
EXAMPLE 124A
(2S)-2-((tert-butoxycarbonyl)amino)-3-(isobutylsulfanyl)propanoic
acid
[0510] The desired product was prepared by substituting D-cystine
for D-homocystine and 1-bromo-2-methylpropane for 2-bromopropane in
Example 123A.
[0511] MS(ESI) m/e 279 (M+H).sup.+.
EXAMPLE 124B
(2RS,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-(isobutylsulfanyl)buta-
noic acid
[0512] The desired product was prepared by substituting Example
124A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic
acid in Examples 1A-C.
[0513] MS(ESI) m/e 308 (M+H).sup.+.
EXAMPLE 124C
(2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide
[0514] The desired product was prepared by substituting O-benzyl
hydroxylamine hydrochloride for O-phenyl hydroxylamine
hydrochloride and Example 124B for Example 98A in Example 98B.
[0515] MS(ESI) m/e 360 (M+H).sup.+;
[0516] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.55 (br s,
1H), 7.93 (br s, 2H), 7.40 (m, 5H), 6.56 (m, 1H), 4.86 (s, 2H),
4.21 (m, 1H), 2.63 (m, 2H), 2.42 (d, 2H), 1.75 (m, 1H), 0.95 (d,
6H).
EXAMPLE 125
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-phenylpentanamide
EXAMPLE 125A
(2RS,3R)-3-amino-2-hydroxy-5-phenylpentanoic acid
[0517] The desired product was prepared by substituting
(2R)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanoic acid for
(2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in
Examples 1A-C.
[0518] MS(ESI) m/e 309 (M+H).sup.+.
EXAMPLE 125B
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-phenvlpentanamide
[0519] The desired product was prepared by substituting O-benzyl
hydroxylamine hydrochloride for O-phenyl hydroxylamine
hydrochloride and Example 125A for Example 98A in Example 98B.
[0520] MS(ESI) m/e 315 (M+H).sup.+;
[0521] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.7.86 (br s, 2H),
7.35 (m, 5H), 7.20 (m, 5H), 6.48 (m, 1H), 4.82 (s, 211), 4.05 (m,
1H), 2.65 (m, 2H), 1.78 (m, 2H).
EXAMPLE 126
(2S,3S)-3-amino-N-(cyclohexylmethoxy)-2-hydroxy-4-(isobutysulfanyl)butanam-
ide
EXAMPLE 126A
O-Cyclohexylmethylhydroxylamine
[0522] The title compound was prepared by substituting
cyclohexylmethyl bromide for Example 128A in Example 128B-128C.
[0523] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 5.85 (s, 2H),
1.70-1.60 (m, 5H), 1.26-1.08 (m, 4H), 0.94-0.80 (m, 2H).
EXAMPLE 126B
(2S,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-(isobutylsulfanyl)butan-
oic acid pentafluorophenyl ester
[0524] A solution of Example 124B (0.921 g, 3.0 mmol),
pentafluorophenol (0.61 g, 3.3 mmol), 1-hydroxybenzotriazole (0.61
g, 4.5 mmol) and 1,3-dicyclohexyl-carbodiimide (0.62 g, 3.0 mmol in
dichloromethane (10 mL) was stirred at 0.degree. C. for 1 h and
room temperature for 18 h. Dicyclohexyl urea was removed by
filtration, and the filtrate was diluted with ether, washed with
NaHCO.sub.3 and then brine, dried (MgSO.sub.4), filtered, and
concentrated. The crude material was purified by silica gel
chromatography (10:90/ethylacetate:hexanes) to give the title
compound.
[0525] MS(ESI) m/e 472 (M-H).sup.+.
[0526] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 6.64 (d, 1H),
6.10 (d, 1H), 4.85 (dd, 1H), 4.14 (m, 1H), 2.74 (m, 1H), 2.56 (m,
1H), 2.47 (d, 2H), 1.77 (m, 1H), 1.37 (s, 9H), 0.95 (d, 6H).
EXAMPLE 126C
(2S,3S)-3-amino-N-(cyclohexylmethoxy)-2-hdroxy-4-(isobutylsulfanyl)butanam-
ide
[0527] A solution of Example 126B (0.24 g, 0.5 mmol) and Example
126A (0.065 g, 0.5 mmol) in DMF (5 mL) was stirred at room
temperature for 18h, diluted with ether, washed with brine, dried
(Na.sub.2SO.sub.4) and concentrated, purified by silica gel
chromatography (10:90/ethylacetate:hexanes),then treated with 4M
HCl in dioxane to give the title compound.
[0528] MS(ESI) m/e 317 (M-H).sup.+.
[0529] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.38 (br s,
1H), 7.9 (br s, 2H), 6.5 (d, 1H), 4.18 (dd, 111), 3.63 (d, 2H), 3.4
(m, 1H), 2.75-2.59 (m, 2H), 2.53 (d, 2H), 1.8-1.6 (m, 7H),
1.24-1.10 (m, 4H), 1.0-0.9 (m, 1H), 0.95 (d, 6H).
EXAMPLE 127
(2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-(mesitylmethoxy)butanamid-
e
Example 127A
O-2,4,6-trimethylbenzylhydroxylamine
[0530] The title compound was prepared by substituting
2,4,6-trimethylbenzyl bromide for Example 128A in Example
128B-128C.
[0531] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 6.80 (s, 2H),
5.96 (s, 2H), 4.57 (s, 2H), 2.30 (s, 6H), 2.20 (s, 3H).
EXAMPLE 127B
(2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-(mesitylmethoxy)butanamid-
e
[0532] The title compound was prepared by substituting Example 127A
for Example 126B in Example 126C.
[0533] MS(ESI) m/e 353 (M-H)+.
[0534] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.55 (br s,
1H), 7.78 (br s, 2H), 6.85 (s, 2H), 6.57 (d, 1H), 4.87 (s, 2H),
4.24 (dd, 1H), 3.44(m, 1H), 2.75-2.59 (m, 2H), 2.44 (d, 2H), 2.38
(s, 6H), 2.21 (s, 3H), 1.8-1.7 (m,1H), 0.95 (d, 6H).
EXAMPLE 128
(2RS,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)-N-((IRS)-1-phenylethoxy)penta-
namide
EXAMPLE 128A
1-bromoethylbenzene
[0535] To a solution of DL-sec-phenethyl alcohol (1.81 ml, 15 mmol)
in chloroform (20 ml) was added phosphorus tribromide (15.75 ml,
15.75 mmol) dropwise at room temperature. The mixture was stirred
at room temperature for 18 hours, poured into wet ice, washed with
brine (4X), dried (MgSO.sub.4), then evaporated to dryness to yield
2.62 g of the title compound.
EXAMPLE 128B
N-(1-phenylethoxy)phthalimide
[0536] N-hydroxyphthalamide (2.31g, 14.2 mmol), Example 128A
(2.62g, 14.2 mmol) and potassium carbonate (4.91g, 35.5 mmol) in
N,N-dimethylformamide (35 mL) were stirred at room temperature for
1 day, and stirred in 50.degree. C. oil bath for 5 hours. The
mixture was poured into ice-water, the precipitate was collected by
filtration, washed with water and dried to yield 2.69g of the title
compound.
EXAMPLE 128C
O-(1-(phenyl)ethyl)hydroxylamine
[0537] Example 128B (2.18g, 8.2 mmol) and hydrazine hydrate (0.306
ml, 9.84mmol) in ethanol (35 mL) was stirred at room temperature
for 1.5 hours. The solvent was removed, the residue triturated with
30 ml of ether, filtered, and the filtrate was concentrated in
vacuo to yield the title compound (1.09g) as an oil.
EXAMPLE 128D
(2RS,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)-N-((lRS)-1-phenylethoxy)penta-
namide
[0538] The desired product was prepared by substituting Example
128C for O-phenyl hydroxylamine hydrochloride in Example 98B.
[0539] MS(ESI) m/e 313(M+H).sup.+;
[0540] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.28 (d, 0.5H),
11.25 (d, 0.5H), 7.89-8.08 (br. 3H), 7.28-7.43 (m, 5H), 6.43 (d,
0.6H), 6.33 (d, 0.4H), 4.92-5.03 (m, 1H), 4.17 (br., 0.4H), 3.98
(br., 0.6H), 2.42-2.67 (m, 4H), 1.60-1.73 (m, 2H), 1.42-1.46 (m,
3H), 1.13-1.21 (m, 3H).
EXAMPLE 129
(2S,3S)-3-amino-N-(benzloxy)-2-hydroxy-4-(isobutylsulfanyl)-N-methylbutana-
mide
EXAMPLE 129A
N-methyl-O-benzylhydroxylamine hydrochloride
[0541] O-Benzylhydroxylamine hydrochloride (1.59 g, 0.01 mol),
di-tert-butyl dicarbonate (2.18 g, 0.01 mol) and N-methyl
morpholine (1.1 mL, 0.01 mol) in dichloromethane (40 mL) were
stirred at room temperature for 16 hours. The reaction mixture was
diluted with ether, washed with 10% NaHSO.sub.4, then brine, dried
over (Na.sub.2SO.sub.4), and concentrated. The residue was treated
with methyl iodide (1.6 mL, 0.025 mmol) in the presence of NaH (0.4
g, 0.01 mol) in THF at 0.degree. C., then stirred at room
temperature for 16 hours. The reaction was quenched with 1N HCl,
diluted with ether, washed with brine, dried (Na.sub.2SO.sub.4),
concentrated, purified by silica gel chromatography (20:80/ethyl
acetate:hexanes) and treated with 4M HCl in dioxane to give the
title compound.
EXAMPLE 129B
(2S,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)-N-methylbutan-
amide
[0542] The title compound was prepared by substituting Example 129A
for Example 126A in Example 126C.
[0543] MS(ESI) m/e 327 (M+H).sup.+.
[0544] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.7.9 (br s, 2H),
7.49 (m, 2H), 7.4 (m, 3H), 6.22 (br s, 1H), 4.98 (m, 2H), 4.79 (br
s, 1H), 3.24(s, 3H), 2.55 (m, 2H), 2.3 (m, 2H),), 1.68 (m,1H), 0.9
(d, 6H).
EXAMPLE 130
(2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)-N-methylpen-
tanamide
[0545] The desired product was prepared by substituting Example
129A for O-phenyl hydroxylamine hydrochloride and Example 123B for
Example 98A in Example 98B.
[0546] MS(ESI) m/e 327 (M+H)+.
[0547] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.08 & 7.88
(br s, 2H), 7.55-7.38 (m, 5H), 6.25 & 5.97 (br s, 1H), 4.98 (br
s, 2H), 4.77 & 4.55 (br s, 1H), 3.7 & 3.48 (m, 1H), 3.2 (br
s, 3H), 2.85 (m, 1H), 1.8-1.6 (m, 2H), 1.15 (m,6H).
EXAMPLE 131
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-((IRS)-1-phenylethoxy)p-
entanamide
[0548] The desired product was prepared by substituting Example
128C for O-phenyl hydroxylamine hydrochloride and Example 123B for
Example 98A in Example 98B.
[0549] MS(ESI) m/e 327(M+H).sup.+;
[0550] .sup.1H NMR (300 MHz, DMSO-d6) .delta.11.26 (d, 0.6H), 11.24
(d, 0.4H), 7.88-8.10 (br., 3H), 7.30-7.44 (m, 5H), 6.45 (d, 0.6H),
6.36 (d, 0.4H), 4.90-5.02 (m, 1H), 3.97 (br.m, 1H) 3.64-3.73 (m,
1H), 2.82-2.94 (m, 2H), 2.53-2.73 (m, 2H), 1.58-1.72 (m, 2H),
1.42-1.47 (m, 3H), 1.16-1.23 (m, 6H).
EXAMPLE 132
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((3RS)-3-(methylsulfanyl)butyl)-
-N'-phenylbutanohydrazide
[0551] The desired product was prepared by substituting
1-(3-(methylsulfanyl)butyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0552] MS(ESI) m/e 394 (M+H).sup.+;
[0553] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.88
(m, 2H), 6.80 (m, 1H), 4.27 (dd, 1H), 3.57 (m, 3H), 2.17 (m, 1H),
2.07 (s, 3H), 1.42-1.91 (m, 6H), 1.11-1.42 (m, 4H), 0.76-1.11 (m,
8H).
EXAMPLE 133
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-(3
phenylpropyl)butanohydrazide
[0554] The desired product was prepared by substituting
1-(3-phenylpropyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0555] MS(ESI) m/e 410 (M+H).sup.+;
[0556] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.05-7.41 (m, 8H),
6.83 (m, 2H), 4.26 (d, 1H), 3.57 (m, 1H), 3.48 (m, 2H), 2.74 (t,
2H), 1.86-2.07 (m, 2H), 1.55-1.86 (m, 7H), 1.47 (m, 2H), 1.07-1.39
(m, 2H), 0.75-1.07 (m, 2H).
EXAMPLE 134
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-isobutyl-N'-phenylbutanohydrazi-
de
[0557] The desired product was prepared by substituting
1-(2-methylpropyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0558] MS(ESI) m/e 348 (M+H).sup.+;
[0559] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 5H), 6.87
(m, 2H), 6.80 (m, 1H), 4.24 (d, 1H), 3.54 (m, 1H), 3.28 (d, 2H),
1.99 (m, 1H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H),
1.02 (s, 3H), 1.00 (s, 3H), 0.91 (m, 2H).
EXAMPLE 135
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-pentyl-N'-phenylbutanohydrazide
[0560] The desired product was prepared by substituting
1-pentyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0561] MS(ESI) m/e 362 (M+H).sup.+;
[0562] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.89
(m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.59 (m, 1H), 3.46 (dd, 2H),
1.58-1.92 (m, 6H), 1.11-1.58 (m, 12H), 0.83-1.11 (m, 4H).
EXAMPLE 136
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-methylbutyl)-N'-phenylbutano-
hydrazide
[0563] The desired product was prepared by substituting
1-(2-methylbutyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0564] MS(ESI) m/e 362 (M+H).sup.+;
[0565] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.88
(m, 2H), 6.80 (m, 1H), 4.24 (dd, 1H), 3.53 (m, 1H), 3.40 (m, 1H),
3.24 (m, 1H), 1.42-1.91 (m, 9H), 1.11-1.42 (m, 4H), 0.76-1.11 (m,
8H).
EXAMPLE 137
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-isopentyl-N'-phenylbutanohydraz-
ide
[0566] The desired product was prepared by substituting
1-(3-methylbutyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0567] MS(ESI) m/e 362 (M+H).sup.+;
[0568] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.89
(m, 2H), 6.83 (m, 1H), 4.28 (d, 1H), 3.58 (m, 1H), 3.49 (m, 2H),
1.61-1.92 (m, 7H), 1.52 (m, 4H), 1.11-1.42 (m, 3H), 0.83-1.11 (m,
8H).
EXAMPLE 138
(2RS,3R)-3-amino-4-cyclohexyl-N'-hexyl-2-hydroxy-N'-phenylbutanohydrazide
[0569] The desired product was prepared by substituting
1-hexyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0570] MS(ESI) m/e 376 (M+H).sup.+;
[0571] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.90
(m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.57 (m, 1H), 3.45 (m, 2H),
1.59-1.91 (m, 7H), 1.11-1.59 (m, 12H), 0.84-1.11 (m, 5H).
EXAMPLE 139
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-methylpentyl)-N'
phenylbutanohydrazide
[0572] The desired product was prepared by substituting
1-(2-methylpentyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0573] MS(ESI) m/e 376 (M+H).sup.+;
[0574] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.87
(m, 2H), 6.80 (m, 1H), 4.19-4.28 (m, 1H), 3.53 (dt, 1H), 3.39 (m,
1H), 3.24 (m, 1H), 1.59-1.99 (m, 7H), 1.50 (m, 4H), 1.04-1.42 (m,
6H), 1.00 (d, 3H), 0.93 (t, 3H), 0.83-1.05 (m, 2H).
EXAMPLE 140
(2RS
3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(3-methylpentyl)-N'-phenylbutan-
ohydrazide
[0575] The desired product was prepared by substituting
1-(3-methylpentyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0576] MS(ESI) m/e 376 (M+H).sup.+;
[0577] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.88
(m, 2H), 6.83 (m, 1H), 4.27 (d, 1H), 3.39-3.65 (m, 3H), 1.59-1.93
(m, 7H), 1.37-1.59 (m, 5H), 1.10-1.37 (m, 4H), 0.83-1.10 (m,
8H).
EXAMPLE 141
(2RS,3R)-3-amino-4-cyclohexyl-N-(3,3-dimethylbutyl)-2-hydroxy-N'
phenylbutanohydrazide
[0578] The desired product was prepared by substituting
1-(3,3-dimethylbutyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0579] MS(ESI) m/e 376 (M+H).sup.+;
[0580] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.88
(m, 2H), 6.83 (m, 1H), 4.29 (d, 1H), 3.52 (m, 4H), 1.42-1.91 (m,
10H), 1.11-1.42 (m, 3H), 0.76-1.11 (m, 11H).
EXAMPLE 142
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-ethylbutyl)-2-hydroxy-N'-phenylbutanoh-
ydrazide
[0581] The desired product was prepared by substituting
1-(2-ethylbutyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0582] MS(ESI) m/e 376 (M+H).sup.+;
[0583] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.88
(m, 2H), 6.81 (m, 1H), 4.23 (d, 1H), 3.52 (dt, 1H), 3.37 (d, 2H),
1.58-1.92 (m, 7H), 1.38-1.58 (m, 6H), 1.10-1.38 (m, 3H), 0.82-1.10
(m, 8H).
EXAMPLE 143
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclopropylmethyl)-2-hydroxy-N'
phenylbutanohydrazide
[0584] The desired product was prepared by substituting
1-(cyclopropylmethyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1
[0585] MS(ESI) m/e 346 (M+H).sup.+;
[0586] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.93
(m, 2H), 6.85 (m, 1H), 4.30 (d, 1H), 3.60 (ddd, 1H), 3.43 (m, 1H),
3.28 (m, 1 H), 1.64-1.94 (m, 6H), 1.42-1.64 (m, 2H), 1.16-1.42 (m,
3H), 0.69-1.16 (m, 3H), 0.41-0.69 (m, 2H), 0.15-0.41 (m, 2H).
EXAMPLE 144
(2RS,3R)-3-amino-4-cyclohexyl-N'-dodecyl-2-hydroxy-N'-phenylbutanohydrazid-
e
[0587] The desired product was prepared by substituting
1-dodecyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0588] MS(ESI) m/e 460 (M+H).sup.+;
[0589] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.88
(m, 2H), 6.83 (m, 1H), 4.26 (d, 1H), 3.56 (dt, 1H), 3.46 (m, 2H),
1.57-1.93 (m, 8H), 1.51 (m, 2H), 1.10-1.45 (m, 21H), 0.82-1.10 (m,
5H).
EXAMPLE 145
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-(3,5,5-trimethylhexyl-
)butanohydrazide
[0590] The desired product was prepared by substituting
1-(3,5,5-trimethylhexyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0591] MS(ESI) r/e 418 (M+H).sup.+;
[0592] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.89
(m, 2H), 6.83 (m, 1H), 4.27 (d, 11H), 3.40-3.63 (m, 3H), 1.59-1.98
(m, 8H), 1.51 (m, 3H), 1.18-1.42 (m, 4H), 1.14 (m, 1H), 1.03 (m,
4H), 0.70-0.97 (m, 10H).
EXAMPLE 146
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-octyl-N'-phenylbutanohydrazide
[0593] The desired product was prepared by substituting
1-octyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0594] MS(ESI) m/e 404 (M+H).sup.+;
[0595] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.88
(m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.56 (dt, 1H), 3.46 (m, 2H),
1.59-1.97 (m, 8H), 1.52 (m, 2H), 1.09-1.45 (m, 13H), 0.76-1.09 (m,
5H).
EXAMPLE 147
(2RS,3R)-3-amino-N'-(2-(benzyloxy)ethyl)-4-cyclohexyl-2-hydroxy-N'-phenylb-
utanohydrazide
[0596] The desired product was prepared by substituting
1-(2-benzyloxymethyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0597] MS(ESI) m/e 426 (M+H).sup.+;
[0598] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.35 (m, 10H),
6.92 (m, 2H), 6.83 (m, 1H), 4.53 (m, 4H), 4.32 (d, 1H), 3.60 (m,
3H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m,
2H).
EXAMPLE 148
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-(2,2,5-trichloropenty-
l)butanohydrazide
[0599] The desired product was prepared by substituting
1-(2,2,5-trichloropentyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0600] MS(ESI) m/e 464 (M+H).sup.+;
[0601] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.85
(m, 3H), 4.38 (d, 1H), 3.79 (m, 11H), 3.68 (m, 2H), 2.46 (m, 2H),
2.17 (m, 2H), 1.58-1.91 (m, 8H), 1.50 (m, 2H), 1.17-1.42 (m, 3H),
0.91 (m, 2H).
EXAMPLE 149
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-propylbutanohydrazide
[0602] The desired product was prepared by substituting
1-propyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0603] MS(ESI) m/e 334 (M+H).sup.+;
[0604] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.90
(m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.59 (m, 1H), 3.45 (m, 2H),
1.59-1.99 (m, 8H), 1.51 (m, 2H), 1.12-1.43 (m, 3H), 0.78-1.12 (m,
5H).
EXAMPLE 150
(2RS,3R)-3-amino-4-cyclohexyl-N'-heptyl-2-hydroxy-N'-phenylbutanohydrazide
[0605] The desired product was prepared by substituting
1-heptyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0606] MS(ESI) m/e 390 (M+H).sup.+;
[0607] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.88
(m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.56 (dt, 1H), 3.45 (m, 2H),
1.59-1.96 (m, 8H), 1.52 (m, 2H), 1.12-1.45 (m, 11H), 0.83-1.12 (m,
5H).
EXAMPLE 151
(2RS,3R)-3-amino-4-cyclohexyl-N'-ethyl-2-hydroxy-N'-phenylbutanohydrazide
[0608] The desired product was prepared by substituting
1-ethyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in
Example 1.
[0609] MS(ESI) m/e 320 (M+H).sup.+;
[0610] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.23 (m, 2H), 6.91
(m, 2H), 6.83 (m, 1H), 4.30 (d, 1H), 3.61 (m, 1H), 3.54 (dd, 2H),
1.59-1.92 (m, 6H), 1.50 (m, 2H), 1.4-1.12 (m, 3H), 1.22 (t, 3H),
0.85-1.18 (m, 2H).
EXAMPLE 152
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(3-(methylsulfanyl)propyl)-N'-p-
henylbutanohydrazide
[0611]
[0612] The desired product was prepared by substituting
1-(3-(methylsulfanyl)propyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0613] MS(ESI) m/e 380 (M+H).sup.+;
[0614] .sup.1H NMR (300 MLz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.92
(m, 2H), 6.83 (m, 1H), 4.28 (d, 1H), 3.47-3.72 (m, 3H), 2.50-2.75
(m, 2H), 2.10 (s, 3H), 1.93 (m, 2H), 1.58-1.87 (m, 6H), 1.51 (m,
2H), 1.13-1.42 (m, 3H), 0.82-1.12 (m, 2H).
EXAMPLE 153
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclopentylmethyl)-2-hydroxy-N'
phenylbutanohydrazide
[0615] The desired product was prepared by substituting
1-(cyclopentylmethyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0616] MS(ESI) m/e 374 (M+H).sup.+;
[0617] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.21 (m, 2H), 6.89
(m, 2H), 6.82 (m, 1H), 4.25 (d, 1H), 3.54 (dt, 1H), 3.41 (d, 2H),
2.26 (m, 1H), 1.42-2.00 (m, 15H), 1.10-1.43 (m, 5H), 0.80-1.10 (m,
2H).
EXAMPLE 154
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(5-hydroxypentyl)-N'
phenylbutanohydrazide
[0618] The desired product was prepared by substituting
1-(5-hydroxypentyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0619] MS(ESI) m/e 378 (M+H).sup.+;
[0620] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.90
(m, 2H), 6.82 (m, 1H), 4.28 (d, 1H), 3.68 (m, 1H), 3.57 (t, 2H),
3.48 (m, 2H), 1.41-2.11 (m, 14H), 1.12-1.41 (m, 4H), 0.80-1.12 (m,
2H).
EXAMPLE 155
(2RS,3R)-3-amino-4-cyclohexyl-N'-((2R)-2,3-dihydroxypropyl)-2-hydroxy-N'-p-
henylbutanohydrazide
[0621] The desired product was prepared by substituting
1-((2R)-2,3-dihydroxypropyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0622] MS(ESI) m/e 366 (M+H).sup.+;
[0623] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.86
(m, 3H), 4.27 (d, 1H), 3.62 (m, 3H), 3.28 (d, 4H), 1.58-1.91 (m,
6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m, 2H).
EXAMPLE 156
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2,2-dichlorohexyl)-2-hydroxy-N'-phenylbu-
tanohydrazide
[0624] The desired product was prepared by substituting
1-(2,2-dichlorohexyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0625] MS(ESI) m/e 444 (M+H).sup.+;
[0626] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.87
(m, 3H), 4.29 (d, 1H), 3.57 (m, 3H), 2.27 (m, 2H), 1.58-1.91 (m,
6H), 1.50 (m, 4H), 1.17-1.42 (m, 5H), 1.05 (m, 2H), 0.92 (t,
3H).
EXAMPLE 157
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-((3RS)-7-methoxy-3,7-dimethyloc-
tyl)-N'-phenylbutanohydrazide
[0627] The desired product was prepared by substituting
1-(7-methoxy-3,7-dimethyloctyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0628] MS(ESI) m/e 462 (M+H).sup.+;
[0629] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.23 (m, 2H), 6.89
(m, 2H), 6.83 (m, 1H), 4.27 (s, 1H), 3.38-3.65 (m, 3H), 3.17 (s,
3H), 1.14 (s, 6H), 0.97 (d, 3H), 0.85-1.12 (m, 2H), 0.85-1.12 (m,
20H).
EXAMPLE 158
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(2-(4-methylphenyl)ethyl)-N'
phenylbutanohydrazide
[0630] The desired product was prepared by substituting
1-(2-(4-methylphenyl)ethyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0631] MS(ESI) m/e 410 (M+H).sup.+;
[0632] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.24 (m, 2H), 7.13
(m, 4H), 6.91 (m, 2H), 6.83 (m, 1H), 4.29 (d, 1H), 3.69 (m, 2H),
3.57 (m, 1H), 2.90 (t, 2H), 2.30 (s, 3H), 1.59-1.95 (m, 5H), 1.50
(m, 2H), 1.12-1.40 (m, 4H), 0.75-1.12 (m, 2H).
EXAMPLE 159
(2RS,3R)-3-amino-4-cyclohexyl-N'-((2RS)-2-ethylhexyl)-2-hydroxy-N'-phenylb-
utanohydrazide
[0633] The desired product was prepared by substituting
1-(2-ethylhexyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0634] MS(ESI) m/e 404 (M+H).sup.+;
[0635] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.21 (m, 2H), 6.88
(m, 2H), 6.81 (m, 1H), 4.23 (m, 1H), 3.52 (dt, 1H), 3.37 (m, 2H),
1.61-1.92 (m, 6H), 1.10-1.61 (m, 14H), 0.75-1.10 (m, 8H).
EXAMPLE 160
(2RS,3R)-3-amino-N'-((2RS)-2-(4-chlorophenyl)-2-cyanoethyl)-4-cyclohexyl-2-
-hydroxy-N'-phenylbutanohydrazide
[0636] The desired product was prepared by substituting
1-(2-(4-chlorophenyl)-2-cyanoethyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0637] MS(ESI) m/e 456 (M+H).sup.+;
[0638] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.50-7.10 (m, 9H),
6.84 (m, 1H), 4.57 (d, 1H), 3.82 (m, 1H), 3.41 (m, 2H), 1.58-1.91
(m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m, 2H).
EXAMPLE 161
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-((2RS)-2-phenylpropyl-
)butanohydrazide
[0639] The desired product was prepared by substituting
1-(2-phenylpropyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0640] MS(ESI) m/e 410 (M+H).sup.+;
[0641] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.32 (m, 5H), 7.18
(m, 2H), 6.87 (m, 2H), 6.80 (m, 1H), 4.18 (d, 1H), 3.65 (m, 2H),
3.52 (m, 1H), 3.13 (m, 1H), 1.58-1.91 (m, 6H), 1.50 (m, 2H),
1.17-1.42 (m, 3H), 1.37 (d, 3H), 0.91 (m, 2H).
EXAMPLE 162
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclooctylmethyl)-2-hydroxy-N'-phenylbut-
anohydrazide
[0642] The desired product was prepared by substituting
1-(cyclooctylmethyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0643] MS(ESI) m/e 416 (M+H).sup.+;
[0644] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.88
(m, 2H), 6.80 (m, 1H), 4.24 (d, 1H), 3.53 (dt, 1H), 3.27 (m, 2H),
1.11-2.08 (m, 26H), 0.82-1.11 (m, 2H).
EXAMPLE 163
(2RS,3R)-3-amino-4-cyclohexyl-N'-((11Z)-11-hexadecenyl)-2-hydroxy-N'-pheny-
lbutanohydrazide
[0645] The desired product was prepared by substituting
1-((11Z)-11-hexadecenyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0646] MS(ESI) m/e 514 (M+H).sup.+;
[0647] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.88
(m, 2H), 6.82 (m, 1H), 5.34 (m, 2H), 4.27 (d, 1H), 3.56 (dt, 1H),
3.46 (m, 2H), 1.92-2.14 (m, 4H), 1.58-1.92 (m, 7H), 1.51 (m, 2H),
1.12-1.44 (m, 22H), 0.94-1.12 (m, 2H), 0.89 (m, 3H).
EXAMPLE 164
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-tridecylbutanohydrazi-
de
[0648] The desired product was prepared by substituting
1-tridecyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride
in Example 1.
[0649] MS(ESI) m/e 474 (M+H).sup.+;
[0650] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.90
(m, 2H), 6.83 (m, 1H), 4.27 (d, 1H), 3.56 (m, 1H), 3.46 (m, 2H),
1.57-1.91 (m, 7H), 1.51 (m, 2H), 1.12-1.44 (m, 21H), 1.01 (m, 2H),
0.90 (t, 3H).
EXAMPLE 165
4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-phenylhydrazino)b-
utanoic acid
[0651] The desired product was prepared by substituting
4-(1-phenylhydrazino)butanoic acid for 1-benzylhydrazine
dihydrochloride in Example 1.
[0652] MS(ESI) m/e 378 (M+H).sup.+;
[0653] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.23 (m, 2H), 6.88
(m, 3H), 4.29 (m, 1H), 3.64 (m, 1H), 3.53 (m, 1H), 3.31 (m, 1H),
2.46 (t, 1H), 1.94 (m, 1H), 1.59-1.88 (m, 7H), 1.50 (m, 3H),
1.12-1.41 (m, 4H), 0.86-1.12 (m, 2H).
EXAMPLE 166
(2RS.3R)-3-amino-4-cvclohexyl-2-hydroxy-N'-((6Z)-6-nonenyl)-N'-phenylbutan-
ohydrazide
[0654] The desired product was prepared by substituting
1-((6Z)-6-nonenyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0655] MS(ESI) m/e 416 (M+H).sup.+;
[0656] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.89
(m, 2H), 6.83 (m, 1H), 5.35 (m, 2H), 4.27 (d, 1H), 3.57 (dt, 1H),
3.46 (m, 2H), 2.06 (m, 4H), 1.58-1.90 (m, 7H), 1.52 (m, 2H), 1.42
(m, 4H), 1.12-1.38 (m, 4H), 0.95 (t, 3H), 0.86-1.09 (m, 2H).
EXAMPLE 167
(2RS,3R)-3-amino-4-cyclohexyl-N'-((4Z)-4-decenvl)-2-hydroxy-N
'-phenylbutanohydrazide
[0657] The desired product was prepared by substituting
1-((4Z)-4-decenyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0658] MS(ESI) m/e 430 (M+H).sup.+;
[0659] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.89
(m, 211), 6.83 (m, 1H), 5.41 (m, 2H), 4.26 (d, 1H), 3.57 (m, 1H),
3.47 (m, 2H), 2.05 (m, 4H), 1.59-1.90 (m, 7H), 1.51 (m, 2H),
1.12-1.42 (m, 10H), 0.82-1.08 (m, 5H).
EXAMPLE 168
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-(4-pentenyl)-N'-phenylbutanohyd-
razide
[0660] The desired product was prepared by substituting
1-(4-pentenyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0661] MS(ESI) m/e 360 (M+H).sup.+;
[0662] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.20 (m, 2H), 6.87
(m, 2H), 6.78 (m, 1H), 5.87 (m, 1H), 5.05 (m, 2H), 4.27 (d, 1H),
3.58 (m, 1H), 3.48 (m, 2H), 2.20 (m, 2H), 1.58-1.91 (m, 8H), 1.50
(m, 2H), 1.17-1.42 (m, 3H), 0.97 (m, 2H).
EXAMPLE 169
(2RS,3R)-3-amino-4-cyclohexyl-N'-((3RS)-3,7-dimethyl-6-octenyl)-2-hydroxy--
N'-phenylbutanohydrazide
[0663] The desired product was prepared by substituting
1-(3,7-dimethyl-6-octenyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0664] MS(ESI) m/e 430 (M+H).sup.+;
[0665] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.87
(m, 2H), 6.80 (m, 1H), 5.12 (m, 1H), 4.28 (d, 1H), 3.55 (m, 3H),
2.04 (m, 2H), 1.58-1.91 (m, 6H), 1.50 (m, 5H), 1.17-1.42 (m, 5H),
1.12 (s, 6H), 0.97 (d, 31H), 0.91 (m, 2H).
EXAMPLE 170
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N'-phenyl-N'-(4,4,4-trifluorobutyl-
)butanohydrazide
[0666] The desired product was prepared by substituting
1-(4,4,4-trifluorobutyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0667] MS(ESI) m/e 402 (M+H).sup.+;
[0668] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.25 (m, 2H), 6.93
(m, 2H), 6.86 (m, 1H), 3.57 (m, 3H), 2.25-2.46 (m, 2H), 1.91 (m,
3H), 1.62-1.84 (m, 6H), 1.42-1.62 (m, 2H), 1.12-1.42 (m, 3H),
0.84-1.12 (m, 2H).
EXAMPLE 171
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((3RS)-3-hydroxybutyl)-N'-phenyl-
butanohydrazide
[0669] The desired product was prepared by substituting
1-(3-hydroxybutyl)-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0670] MS(ESI) m/e 364 (M+H).sup.+;
[0671] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.23 (m, 2H), 6.92
(m, 2H), 6.84 (m, 1H), 4.30 (d, 1H), 3.44-3.71 (m, 4H), 1.63-1.91
(m, 7H), 1.54 (m, 3H), 1.35 (m, 3H), 1.19 (m, 4H), 0.84-1.12 (m,
2H).
EXAMPLE 172
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-(((3RS)-3,7-dimethyl-6-octenyl)oxy)eth-
yl)-2-hydroxy-N'-phenylbutanohydrazide
[0672] The desired product was prepared by substituting
1-(2-((3,7-dimethyl-6-octenyl)oxy)ethyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0673] MS(ESI) m/e 474 (M+H).sup.+;
[0674] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.24 (m, 2H), 6.93
(m, 2H), 6.85 (m, 1H), 5.09 (m, 1H), 4.33 (d, 1H), 3.72 (m, 2H),
3.67 (m, 2H), 3.50 (m, 3H), 2.04 (m, 2H), 1.58-1.91 (m, 6H),
1.50-1.20 (m, 10H), 1.17 (s, 3H), 1.12 (s, 3H), 0.91 (m, 2H), 0.87
(d, 3H).
EXAMPLE 173
(2RS,3R)-3-amino-4-cyclohexyl-N'-(2-((lRS)-3,3-dimethylcyclohexyl)ethyl)-2-
-hydroxy-N'-phenylbutanohydrazide
[0675] The desired product was prepared by substituting
1-(2-(3,3-dimethylcyclohexyl)ethyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0676] MS(ESI) m/e 430 (M+H).sup.+;
[0677] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.22 (m, 2H), 6.89
(m, 2H), 6.82 (m, 1H), 4.26 (d, 1H), 3.53 (m, 3H), 1.65-1.94 (m,
7H), 1.18-1.65 (m, 11H), 0.94-1.18 (m, 4H), 0.92 (s, 3H), 0.91 (s,
3H), 0.65-0.87 (m, 2H).
EXAMPLE 174
(2RS
3R)-3-amino-N'-((4S)-6-bromo-4-methylhexyl)-4-cyclohexyl-2-hydroxy-N'-
-phenylbutanohydrazide
[0678] The desired product was prepared by substituting
1-((4S)-6-bromo-4-methylhexyl)-1-phenylhydrazine for
1-benzylhydrazine dihydrochloride in Example 1.
[0679] MS(ESI) m/e 468, 470 (M+H).sup.+;
[0680] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.23 (m, 2H), 6.89
(m, 2H), 6.83 (m, 1H), 4.27 (d, 1H), 3.55 (m, 3H), 1.65-1.89 (m,
6H), 1.45-1.65 (m, 9H), 1.17-1.42 (m, 5H), 0.97 (d, 3H), 0.95 (m,
2H).
EXAMPLE 175
(2RS,3R)-3-amino-4-cyclohexyl-N'-(cyclohexylmethyl)-2-hydroxy-N'
phenylbutanohydrazide
[0681] The desired product was prepared by substituting
1-cyclohexylmethyl-1-phenylhydrazine for 1-benzylhydrazine
dihydrochloride in Example 1.
[0682] MS(ESI) m/e 388 (M+H).sup.+;
[0683] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.21 (m, 2H), 6.86
(m, 2H), 6.80 (m, 1H), 4.25 (d, 1H), 3.54 (dt, 1H), 3.31 (d, 2H),
1.92 (m, 2H), 1.59-1.84 (m, 10H), 1.51 (m, 2H), 1.13-1.42 (m, 6H),
0.81-1.13 (m, 4H).
EXAMPLE 176
((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-naphthohydrazide
[0684] The desired product was prepared by substituting
2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride in
Example 98B.
[0685] MS(ESI) m/e 362 (M+H).sup.+;
[0686] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.48 (m, 1H),
7.89-8.09 (m, 4H), 7.47-7.75 (m, 2H), 4.54 (d, 0.34H), 4.48 (d,
0.66H), 3.56-3.87 (m, 1H), 2.76 (m, 2H), 2.62 (q, 1.32H), 2.60 (q,
0.68H), 2.10-2.31 (m, 0.68H), 1.84-2.08 (m, 1.32H), 1.28 (t,
1.98H), 1.27 (t, 1.02H).
EXAMPLE 177
(2RS
3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-(1-piperidinyl)pentanamide
[0687] The desired product was prepared by substituting
1-aminopiperidine for O-phenyl hydroxylamine hydrochloride in
Example 98B.
[0688] MS(ESI) m/e 276 (M+H).sup.+;
[0689] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.67 (m, 0.28H),
4.62 (m, 0.72H), 3.37-3.78 (m, 5H), 2.72-3.16 (m, 4H), 2.00-2.30
(m, 2H), 1.70 (m, 4H), 1.57 (m, 2H), 1.35 (t, 2.16H), 1.33 (m,
0.84H).
EXAMPLE 178
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzohydrazide
[0690] The desired product was prepared by substituting
benzoylhydrazine for O-phenyl hydroxylamine hydrochloride in
Example 98B.
[0691] MS(ESI) m/e 312 (M+H).sup.+;
[0692] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.89 (m, 2H), 7.61
(m, 1H), 7.50 (m, 2H), 4.49 (d, 0.24H), 4.44 (d, 0.76H), 3.79 (m,
1H), 2.71 (t, 2H), 2.60 (q, 2H), 2.17 (m, 1H), 1.99 (m, 1H), 1.27
(t, 3H.)
EXAMPLE 179
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hdroxy-N'-(4-iodophenyl)pentanohydraz-
ide
[0693] The desired product was prepared by substituting
1-(4-iodophenyl)hydrazine for 1-benzylhydrazine dihydrochloride and
Example 98A for Example 1C in Example 1D.
[0694] MS(ESI) m/e 410 (M+H).sup.+;
[0695] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.48 (m, 2H), 6.67
(m, 2H), 4.43 (d, 0.38H), 4.36 (d, 0.62H), 3.74 (m, 1H), 2.72 (m,
2H), 2.57 (q, 0.76H), 2.51 (q, 1.24H), 2.11 (m, 0.76H), 1.93 (m,
1.24H), 1.26 (t, 1.86H), 1.22 (t, 1.14H).
EXAMPLE 180
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-cyclopentylpentanohvdrazid-
e
[0696] The desired product was prepared by substituting
1-(cyclopentyl)hydrazine for 1-benzylhydrazine dihydrochloride and
Example 98A for Example 1C in Example 1D.
[0697] MS(ESI) m/e 276 (M+H).sup.+;
[0698] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 4.36 (d, 0.23H),
4.27 (d, 0.77H), 3.67 (td, 1H), 3.53 (m, 1H), 2.68 (m, 2H), 2.57
(q, 1.54H), 2.54 (q, 0.46H), 2.07 (m, 0.46H), 1.91 (m, 1.54H), 1.76
(m, 4H), 1.44-1.67 (m, 4H), 1.26 (t, 2.31H), 1.24 (t, 0.69H).
EXAMPLE 181
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-chlorophenyl)pentanohyd-
razide
[0699] The desired product was prepared by substituting
1-(3-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
and Example 98A for Example 1C in Example 1D.
[0700] MS(ESI) m/e 318 (M+H).sup.+;
[0701] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.15 (m, 1H), 6.85
(m, 1H), 6.77 (m, 2H), 5.98 (d, 0.32H), 5.85 (d, 0.68H), 3.71 (m,
1H), 3.43 (q, 1.36H), 3.36 (q, 0.64H), 2.70 (m, 2H), 2.11 (m,
0.64H), 1.95 (m, 1.36H), 1.67 (t, 2.04H), 1.63 (t, 0.96H).
EXAMPLE 182
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3
methoxyphenyl)pentanohy- drazide
[0702] The desired product was prepared by substituting
1-(3-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride
and Example 98A for Example 1C in Example 1D.
[0703] MS(ESI) m/e 314 (M+H).sup.+;
[0704] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.09 (m, 1H), 6.44
(m, 3H), 4.43 (d, 0.37H), 4.36 (d, 0.63H), 3.75 (s, 3H), 3.69 (m,
1H), 2.71 (m, 2H), 2.57 (q, 1.26H), 2.50 (q, 0.74H), 2.12 (m,
0.74H), 1.82-2.04 (m, 1.26H), 1.25 (t, 1.89H), 1.21 (t, 1.11H).
EXAMPLE 183
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(2-chlorophenyl)pentanohyd-
razide
[0705] The desired product was prepared by substituting
1-(2-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
and Example 98A for Example 1C in Example 1D.
[0706] MS(ESI) m/e 318 (M+H).sup.+;
[0707] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.29 (m, 1H), 7.17
(m, 1H), 6.93 (m, 1H), 6.83 (m, 1H), 4.47 (d, 0.23H), 4.41 (d,
0.77H), 3.76 (m, 1H), 2.71 (m, 2H), 2.58 (q, 1.54H), 2.52 (q,
0.46H), 2.13 (td, 0.46H), 1.95 (m, 1.54H), 1.26 (t, 2.31H), 1.22
(t, 0.69H).
EXAMPLE 184
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-trifluoromethylphenyl)p-
entanohydrazide
[0708] The desired product was prepared by substituting
1-(3-(trifluoromethyl)phenyl)hydrazine for 1-benzylhydrazine
dihydrochloride and Example 98A for Example 1C in Example 1D.
[0709] MS(ESI) m/e 352 (M+H).sup.+;
[0710] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.37 (m, 1H), 7.08
(m, 3H), 4.48 (d, 0.39H), 4.40 (d, 0.61H), 3.69 (m, 1H), 2.71 (m,
2H), 2.57 (q, 1.22H), 2.51 (q, 0.78H), 2.13 (m, 0.78H), 1.84-2.05
(m, 1.22H), 1.25 (t, 1.83H), 1.21 (t, 1.17H).
EXAMPLE 185
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-chlorobenzohy-
drazide
[0711] The desired product was prepared by substituting
3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride
in Example 98B.
[0712] MS(ESI) m/e 346 (M+H).sup.+;
[0713] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.89 (m, 1H), 7.81
(m, 1H), 7.61 (m, 1H), 7.50 (m, 1H), 4.49 (d, 0.14H), 4.44 (d,
0.86H), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 2H), 2.16 (m, 1H),
1.98 (m, 1H), 1.27 (t, 3H).
EXAMPLE 186
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-chlorobenzohy-
drazide
[0714] The desired product was prepared by substituting
2-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride
in Example 98B.
[0715] MS(ESI) mle 346 (M+H).sup.+;
[0716] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.62 (m, 1H), 7.46
(m, 3H), 4.49 (d, 0.26H), 4.43 (d, 0.74H), 3.80 (m, 1H), 2.71 (t,
2H), 2.60 (q, 0.52H), 2.57 (q, 1.48H), 2.16 (m, 0.52H), 1.99 (m,
1.48H), 1.27 (t, 2.22H), 1.24 (t, 0.78H).
EXAMPLE 187
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(4-isopropyl)pentanohydraz-
ide
[0717] The desired product was prepared by substituting
1-(4-(2-methylethyl)phenyl)hydrazine for 1-benzylhydrazine
dihydrochloride and Example 98A for Example 1C in Example 1D.
[0718] MS(ESI) m/e 326 (M+H).sup.+;
[0719] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.02 (d, 2H), 6.77
(d, 2H), 4.42 (d, 0.41H), 4.35 (d, 0.59H), 3.74 (m, 1H), 2.61-2.81
(m, 2H), 2.55 (m, 3H), 2.02-2.24 (m, 0.82H), 1.81-2.02 (m, 1.18H),
1.26 (t, 1.77H), 1.22 (t, 1.23H) 1.17 (d, 6H).
EXAMPLE 188
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-chloro-4-methylphenyl)p-
entanohydrazide
[0720] The desired product was prepared by substituting
1-(3-chloro-4-methylphenyl)hydrazine for 1-benzylhydrazine
dihydrochloride and Example 98A for Example 1C in Example 1D.
[0721] MS(ESI) m/e 332 (M+H).sup.+;
[0722] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.09 (m, 1H), 6.86
(m, 1H), 6.71 (m, 1H), 4.43 (d, 0.33H), 4.36 (d, 0.67H), 3.73 (m,
1H), 2.71 (m, 2H), 2.57 (q, 1.34H), 2.50 (q, 0.66H), 2.25 (m, 3H),
2.12 (m, 0.66H), 1.82-2.04 (m, 1.34H), 1.25 (t, 2.01H), 1.21 (t,
1H).
EXAMPLE 189
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-fluorophenyl)pentanohyd-
razide
[0723] The desired product was prepared by substituting
1-(3-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
and Example 98A for Example 1C in Example 1D.
[0724] MS(ESI) m/e 302 (M+H).sup.+;
[0725] .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.15 (m, 1H), 6.64
(m, 1H), 6.52 (m, 2H), 4.48 (d, 0.37H), 4.38 (d, 0.63H), 3.80 (m,
0.37H), 3.70 (m, 0.63H), 2.70 (m, 2H), 2.57 (q, 1.23H), 2.52 (q,
0.74H), 2.12 (m, 0.74H), 1.95 (m, 1.23H), 1.25 (t, 1.89H), 1.22 (t,
1.11H).
EXAMPLE 190
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'
(2-ethylphenyl)pentanohydr- azide
[0726] The desired product was prepared by substituting
1-(2-ethylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride
and Example 98A for Example 1C in Example 1D.
[0727] MS(ESI) m/e 312 (M+H).sup.+;
[0728] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.07 (m, 111),
6.90 (m, 1H), 6.86 (m, 1H), 6.73 (m, 1H), 4.44 (d, 0.26H), 4.37 (d,
0.74H), 3.80 (m, 1H), 2.45-2.71 (m, 6H), 2.02 (m, 2H), 1.15-1.27
(m, 6H).
EXAMPLE 191
(2RS,3R)-3-amino-5-(ethylsulfanyl)2-hydroxy-N'-(4-fluorophenyl)pentanohydr-
azide
[0729] The desired product was prepared by substituting
1-(4-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride
and Example 98A for Example 1C in Example 1D.
[0730] MS(ESI) mn/e 302 (M+H).sup.+;
[0731] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 6.96 (m, 2H), 6.84
(m, 2H), 4.42 (d, 0.41H), 4.35 (d, 0.59H), 3.74 (m, 1H), 2.61-2.81
(m, 2H), 2.57 (q, 1.18H), 2.51 (q, 0.82H), 2.02-2.24 (m, 0.82H),
1.81-2.02 (m, 1.18H), 1.26 (t, 1.77H), 1.22 (t, 1.23H).
EXAMPLE 192
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxv-N'-(4-trifluoromethoxyphenyl)-
pentanohydrazide
[0732] The desired product was prepared by substituting
1-(4-(trifluoromethoxy)phenyl)hydrazine for 1-benzylhydrazine
dihydrochloride and Example 98A for Example IC in Example ID.
[0733] MS(ESI) m/e 368 (M+H).sup.+;
[0734] .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.00-7.20 (m, 2H),
6.87 (m, 2H), 4.44 (d, 0.42H), 4.37 (d, 0.58H), 3.63-3.83 (m, 1H),
2.71 (m, 2H), 2.57 (q, 1.16H), 2.51 (q, 0.84H), 2.11 (m, 0.84H),
1.82-2.03 (m, 1.16H), 1.25 (t, 1.74H), 1.22 (t, 1.26H).
EXAMPLE 193
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N'-(4-methylphenyl)butanohydr-
azide
[0735] To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of
dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt
(0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL
of a 0.3M solution of Example 97A (0.15 mmol) in dimethylacetamide.
After 5 minutes, 1.0 mL of a 0.225 M solution of
4-methylphenylhydrazine (0.225 mmol) in
dimethylacetamide/dichloromethane (1:1) was added. The mixture was
agitated for 18 hours and quenched with 0.19 g of trisamine resin
(0.75 mmol) followed by 0.13 g of isocyanate resin (0.225 mmol) and
agitated for 4 hours. The mixture was filtered and the resins
washed with lx3 niL of dichloromethane, the solvent was removed in
vacuo, and the crude material purified by reverse phase preparative
BPLC. The resulting material was treated with 1 mL of 50%
trifluoroacetic acid/dichloromethane and agitated at ambient
temperature for 18 hours. The solvent was removed in vacuo to give
the desired product.
[0736] MS(ESI) m/e 284 (M+H).sup.+;
[0737] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.02 (m, 2H), 6.77
(m, 2H), 4.51 (d, 0.65H), 4.39 (d, 0.35H), 3.77 (m, 1H), 2.96 (dd,
1H), 2.76 (dd, 1H), 2.63 (dd, 1.3H), 2.57 (dd, 0.7H), 2.23 (s, 3H),
1.28 (t, 1.95H), 1.23 (t, 1.05H).
EXAMPLE 194
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N'-(4-methylphenyl)propanohydrazid-
e
[0738] The desired product was prepared by substituting Example
122A for Example 97A in Example 193.
[0739] MS(ESI) m/e 292 (M+H).sup.+;
[0740] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.02 (m, 2H), 6.77
(m, 2H), 4.45 (d, 0.65H), 4.43 (d, 0.35H), 3.27 (m, 1H), 2.23 (s,
3H), 1.87-1.72 (m, 6H), 1.36-1.12 (m, 5H).
EXAMPLE 195
(2RS,3S)-3-amino-2-hydroxy-N'-(4-methylphenyl)-4-(propylsulfanyl)butanohyd-
razide
EXAMPLE 195A
(2S)-2-((tert-butoxycarbonyl)amino)-3-(propylsulfanyl)propanoic
acid
[0741] The desired product was prepared by substituting
1-bromopropane for 2-brompropane and D-cystine for D-homocystine in
Example 123A.
EXAMPLE 195B
(2RS,3S)-2-hydroxy-3-((tert-butoxycarbonyl)amino)-3-(propylsulfanyl)propan-
oic acid
[0742] The desired product was prepared by substituting Example
195A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic
acid in Examples 1A-C.
[0743] MS(ESI) m/e 294 (M+H).sup.+.
EXAMPLE 195C
(2RS,3S)-3-amino-2-hydroxy-N'-(4-methylphenyl)-4-(propylsulfanyl)butanohyd-
razide
[0744] The desired product was prepared by substituting Example
195B for Example 97A in Example 193.
[0745] MS(ESI) m/e 298 (M+H).sup.+;
[0746] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.02 (dd, 2H),
6.77 (dd, 2H), 4.50 (d, 0.65H), 4.48 (d, 0.35H), 3.76 (m, 0.65H),
3.67-3.58 (m, 0.35H), 2.93 (dd, 0.65H), 2.84 (dd, 0.35H), 2.75 (m,
1H), 2.58 (dd, 1H), 2.51 (m, 1H), 2.23 (s, 3H), 1.65 (dd, 1H), 1.57
(dd, 1H), 1.02 (t, 1.95 H), 0.98 (t, 1.05H).
EXAMPLE 196
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-(4-methylphenyl)pentan-
ohydrazide
[0747] The desired product was prepared by substituting Example
123B for Example 97A in Example 193.
[0748] MS(ESI) m/e 312 (M+H).sup.+;
[0749] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.01 (dd, 2H),
6.77 (d, 2H), 4.40 (d, 0.35H), 4.33 (d, 0.65H), 3.66 (m, 1H), 2.96
(dd, 0.65H), 2.89 (dd, 0.35H), 2.69 (m, 1.65H), 2.58 (m, 0.35H),
2.23 (s, 3H), 2.09 (dd, 0.65H), 1.96 (dd, 0.35H), 1.89 (dd, 1H),
1.27 (d, 3 H), 1.26 (d, 3H).
EXAMPLE 197
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N'-(4-methylphenyl)butanoh-
ydrazide
[0750] The desired product was prepared by substituting Example
124B for Example 97A in Example 193.
[0751] MS(ESI) m/e 312 (M+H).sup.+;
[0752] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.02 (d, 2H), 6.77
(d, 2H), 4.52 (d,1H), 3.65 (ddd, 1H), 2.94 (dd, 1H), 2.75 (dd, 1H),
2.51 (d, 2H), 2.23 (s, 3H), 1.82 (ddd, 1H), 1.02 (d, 6H).
EXAMPLE 198
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N'-(4-methylphenyl)pentanohydrazide
[0753] The desired product was prepared by substituting Example
125A for Example 97A in Example 193.
[0754] MS(ESI) m/e 314 (M+H).sup.+;
[0755] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.30 (m, 2H),
7.25-7.18 (m, 3H), 6.97 (m, 2H), 6.74 (m, 2H), 4.43 (d, 0.5H), 4.40
(d, 0.5H), 3.57 (m, 1H), 2.78 (m, 1.5H), 2.67 (m, 0.5H), 2.27 (m,
0.5H), 2.23 (s, 1.5H), 2.21 (s, 1.5H), 2.14 (m, 0.5H), 2.00 (m,
0.5H), 1.93 (m, 0.5H).
EXAMPLE 199
(2S
,3R)-3-amino-3-cyclooctyl-2-hvdroxy-N'-(4-methylphenyl)propanohydrazid-
e
EXAMPLE 199A
(2S,3R)-3-(tertbutoxycarbonyl)amino-3-cyclooctyl-2-hydroxy-propanoic
acid
[0756] The desired product was prepared by substituting cyclooctyl
aldehyde for 2-ethylhexanal in Examples 236A-236C.
EXAMPLE 199B
(2S,3R)-3-amino-3-cyclooctyl-2-hydroxy-N'-(4-methylphenyl)propanohydrazide
[0757] The desired product was prepared by substituting Example
199A for Example 97A in Example 193.
[0758] MS(ESI) m/e 320 (M+H).sup.+;
[0759] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.02 (d, 2H), 6.77
(m, 2H), 4.46 (d, 0.35H), 4.38 (d, 0.65H), 3.85 (m, 1H), 3.78 (m,
1H), 2.25 (s, 1.05H), 2.23 (s, 2.95H), 1.80-1.50 (m, 14H).
EXAMPLE 200
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N'-(4-methylphen-
yl)butanohydrazide
EXAMPLE 200A
(.sup.2S)-.sup.2-((tert-butoxycarbonyl)amino)-3-(cyclohexylmethylsulfanyl)-
propanoic acid
[0760] The desired product was prepared by substituting
cyclohexylmethyl bromide for 2-brompropane and D-cystine for
D-homocystine in Example 123A.
EXAMPLE 200B
(2RS,3S)-2-((tert-butoxycarbonyl)amino)-3-(cyclohexylmethylsulfanyl)propan-
oic acid
[0761] The desired product was prepared by substituting Example
200A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic
acid in Examples 1A-C.
EXAMPLE 200C
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-(4
methylphenyl)butanohydrazide
[0762] The desired product was prepared by substituting Example
200B for Example 97A in Example 193.
[0763] MS(ESI) m/e 298 (M+H).sup.+;
[0764] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.02 (dd, 2H),
6.77 (d, 2H), 4.52 (d, 0.65H), 4.50 (d, 0.35H), 3.76 (m, 0.35H),
3.67-3.58 (m, 0.65H), 2.93 (dd, 0.65H), 2.82 (dd, 0.35H), 2.75 (m,
1H), 2.48 (m, 1H), 2.41 (m, 1H), 2.23 (s, 3H), 1.86 (m, 2H),
1.75-1.66 (m, 3H), 1.47 (m, 1H), 1.32-1.15 (m, 3H), 1.00 (m,
2H).
EXAMPLE 201
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N'-(1-naphthyl)butanohydrazid-
e
[0765] The desired product was prepared by substituting
1-napthylhydrazine for 4-methylphenylhydrazine in Example 193.
[0766] MS(ESI) m/e 320 (M+H).sup.+;
[0767] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.07 (m, 1H), 7.81
(ddd, 1H), 7.47 (ddd, 2H), 7.39 (dd, 1H), 7.33 (ddd, 1H), 6.91 (dd,
1H), 4.62 (d, 0.65H), 4.60 (d, 0.3511), 4.51 (m, 0.5H), 3.71 (m,
1H), 3.00 (dd, 0.5H), 2.81 (m, 1H), 2.65 (dd, 1.3H), 2.60 (dd,
0.7H), 1.30 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 202
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N'-(1-naphthyl)propanohydrazide
[0768] The desired product was prepared by substituting
1-napthylhydrazine for 4-methylphenylhydrazine and Example 122A for
Example 97A in Example 193.
[0769] MS(ESI) m/e 328 (M+H).sup.+;
[0770] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.08 (m, 1H), 7.82
(ddd, 1H), 7.47 (ddd, 2H), 7.39 (d, 1H), 7.33 (m, 1H), 6.91 (dd,
1H), 4.56 (d, 0.65H), 4.53 (d, 0.35H), 3.37 (dd, 1H), 1.99-1.72 (m,
6H), 1.39-1.12 (m, 5H).
EXAMPLE 203
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-(1-naphthyl)pentanohyd-
razide
[0771] The desired product was prepared by substituting
1-napthylhydrazine for 4-methylphenylhydrazine and Example 123B for
Example 97A in Example 193.
[0772] MS(ESI) m/e 348 (M+H).sup.+;
[0773] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.07 (m, 1H), 7.81
(ddd, 1H), 7.47 (ddd, 2H), 7.39 (m, 1H), 7.34 (m, 1H), 6.90 (dd,
1H), 4.51 (d, 0.35H), 4.46 (d, 0.65H), 3.76 (m, 1H), 2.99 (dd,
0.65H), 2.93 (dd, 0.35H), 2.74 (m, 1.65H), 2.69 (m, 0.35H), 2.17
(dd, 0.65H), 2.05 (dd, 0.35H), 1.95 (dd, 1H), 1.29 (d, 3 H), 1.27
(d, 3H).
EXAMPLE 204
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N'-(1-naphthyl)butanohydra-
zide
[0774] The desired product was prepared by substituting
1-napthylhydrazine for 4-methylphenylhydrazine and Example 124B for
Example 97A in Example 193.
[0775] MS(ESI) m/e 347 (M+H).sup.+;
[0776] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (m, 1H), 7.82
(ddd, 1H), 7.48 (ddd, 2H), 7.41 (m, 1H), 7.33 (t, 1H), 6.92 (d,
1H), 4.63 (d, 1H), 3.70 (ddd, 1H), 2.99 (dd, 1H), 2.80 (dd, 1H),
2.53 (d, 2H), 1.84 (ddd, 1H), 1.03 (d, 6H).
EXAMPLE 205
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N'-(1-naphthyl)pentanohydrazide
[0777] The desired product was prepared by substituting
1-napthylhydrazine for 4-methylphenylhydrazine and Example 125A for
Example 97A in Example 193.
[0778] MS(ESI) m/e 350 (M+H).sup.+;
[0779] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (m, 1H), 7.80
(m, 1H), 7.46 (rn, 2H), 7.37 (m, 1H), 7.31 (dd, 1H), 7.25 (m, 5H),
6.86 (dd, 1H), 4.53 (d, 0.5H), 4.51 (d, 0.5H), 3.65 (m, 0.5H), 3.60
(m, 0.5H), 2.82 (m, 1.5H), 2.72 (m, 0.5H), 2.20 (m, 0.5H), 2.08 (m,
1H), 1.98 (m, 0.5H).
EXAMPLE 206
(2RS,3R)-3-amino-3-cvclooctyl-2-hydroxy-N'-(1-naphthyl)propanohydrazide
[0780] The desired product was prepared by substituting
1-napthylhydrazine for 4-methylphenylhydrazine and Example 199A for
Example 97A in Example 193.
[0781] MS(ESI) m/e 356 (M+H).sup.+;
[0782] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.08 (m, 1H), 7.84
(m, 1H), 7.49 (m, 2H), 7.41 (m, 1H), 7.32 (t, 1H), 6.97 (ddd, 1H),
4.49 (d, 0.5H), 3.99 (d, 0.5H), 3.85 (m, 1H), 1.80-1.52 (m,
15H).
EXAMPLE 207
N'-((2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxybutanoyl)-3-chlorobenzohyd-
razide
[0783] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine in Example
193.
[0784] MS(ESI) m/e 332 (M+H).sup.+;
[0785] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.91 (m, 1H), 7.81
(m, 1H), 7.62 (m, 1H), 7.51 (m, 1H), 4.63 (d, 0.65H), 4.58 (d,
0.35H), 3.70 (m, 1H), 3.00 (dd, 1H), 2.84 (m, 1H), 2.66 (dd, 1.3H),
2.62 (dd, 0.7H), 1.31 (t, 1.95H), 1.29 (t, 1.05H).
EXAMPLE 208
N'-((2RS,3R)-3-amino-3-cyclohexvl-2-hydroxypropanoyl)-3-chlorobenzohydrazi-
de
[0786] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
122A for Example 97A in Example 193.
[0787] MS(ESI) m/e 340 (M+H).sup.+;
[0788] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.91 (m, 1H), 7.82
(m, 1H), 7.62 (m, 1H), 7.50 (m, 1H), 4.56 (d, 0.65H), 4.52 (d,
0.35H), 3.33 (m, 1H), 1.95 (m, 1H), 1.86 (m, 4H), 1.74 (m, 1H),
1.35 (m, 2H), 1.24 (m, 1H), 1.16 (m, 2H).
EXAMPLE 209
N'-((2RS,3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)-3-chlorobenzohy-
drazide
[0789] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
195B for Example 97A in Example 193.
[0790] MS(ESI) m/e 346 (M+H).sup.+;
[0791] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.91 (ddd, 1H),
7.81 (ddd, 1H), 7.62 (ddd, 1H), 7.50 (m, 1H), 4.63 (d, 0.65H), 4.58
(d, 0.35H), 3.70 (m, 1H), 3.17 (dd, 0.35H), 2.98 (dd, 0.65H), 2.84
(dd, 0.65H), 2.80 (dd, 0.35H), 2.60 (m, 2H), 1.66 (m, 2H), 1.03 (t,
1.95 H), 1.01 (t, 1.05H).
EXAMPLE 210
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chloroben-
zohydrazide
[0792] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
123B for Example 97A in Example 193.
[0793] MS(ESI) m/e 360 (M+H).sup.+;
[0794] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.90 (dt, 1H),
7.81 (m, 1H), 7.62 (m, 1H), 7.50 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 211
N'-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-chlorobenzo-
hydrazide
[0795] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
124B for Example 97A in Example 193.
[0796] MS(ESI) m/e 360 (M+H).sup.+;
[0797] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.91 (dd, 1H),
7.82 (ddd, 1H), 7.63 (ddd, 1H), 7.51 (t, 1H), 4.64 (d, 1H), 3.70
(ddd, 1H), 2.97 (dd, 1H), 2.83 (dd, 1H), 2.53 (d, 2H), 1.85 (ddd,
1H), 1.04 (d, 6H).
EXAMPLE 212
N'-((2RS,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-3-chlorobenzohydrazide
[0798] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
125A for Example 97A in Example 193.
[0799] MS(ESI) m/e 362 (M+H).sup.+;
[0800] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.91 (m, 1H), 7.81
(ddd, 1H), 7.61 (ddd, 1H), 7.50 (m, 1H), 7.29 (m, 4H), 7.20 (m,
1H), 4.50 (m, 1H), 3.62 (m, 1H), 2.80 (m, 2H), 2.20 (m, 1H), 2.02
(m, 1H).
EXAMPLE 213
N'-((2RS,3R)-3-amino-3-cyclooctyl-2-hydroxypropanoyl)-3-chlorobenzohydrazi-
de
[0801] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
199A for Example 97A in Example 193.
[0802] MS(ESI) m/e 368 (M+H).sup.+;
[0803] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.90 (m, 1H), 7.82
(m, 1H), 7.62 (ddd, 1H), 7.50 (t, 1H), 3.95 (d, 1H), 3.82 (t, 1H),
1.81 (m, 4H), 1.68 (m, 4H), 1.55 (m, 7H).
EXAMPLE 214
N'-((2RS,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohydrazi-
de
[0804] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
238A for Example 97A in Example 193.
[0805] MS(ESI) m/e 367 (M+H).sup.+;
[0806] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.89 (dd, 1H),
7.80 (d, 111), 7.62 (ddd, 1H), 7.50 (t, 1H), 3.90 (m, 1H), 3.78 (d,
1H), 1.81-1.72 (m, 5H), 1.68 (m, 1H), 1.54 (m, 2H), 1.29 (m, 4H),
1.21 (m, 1H), 0.96 (m, 2H).
EXAMPLE 215
(2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N'-(4-methylphenyl)pentanohydrazid-
e
[0807] The desired product was prepared by substituting Example
238A for Example 97A in Example 193.
[0808] MS(ESI) m/e 320 (M+H).sup.+;
[0809] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.07 (d, 0.5H),
7.00 (d, 1.5H), 6.77 (m, 2H), 3.81 (m, 1H), 3.62 (d, 1H), 2.22 (s,
3H), 1.77-1.60 (m, 6H), 1.50 (m, 2H), 1.29-1.17 (m, 6H), 0.97-0.91
(m, 1H).
EXAMPLE 216
(2RS,3S)-3-amino-2-hydroxy-N'-(1-naphthyl)-4-(propylsulfanyl)butanohydrazi-
de
[0810] The desired product was prepared by substituting
1-naphthylhydrazine for 4-methylphenylhydrazine and Example 195B
for Example 97A in Example 193.
[0811] MS(ESI) m/e 334 (M+H).sup.+;
[0812] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (m, 1H), 7.81
(ddd, 1H), 7.47 (ddd, 2H), 7.39 (d, 1H), 7.34 (m, 1H), 6.90 (dd,
1H), 4.62 (d, 0.65H), 4.59 (d, 0.35H), 3.71 (m, 1H), 2.99 (dd,
0.65H), 2.92 (dd, 0.35H), 2.81 (m, 1H), 2.60 (dd, 1H), 2.54 (m,
1H), 1.66 (dd, 1H), 1.59 (dd, 1H), 1.02 (t, 1.95 H), 0.98 (t,
1.05H).
EXAMPLE 217
(2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N'-(1-naphthyl)pentanohydrazide
[0813] The desired product was prepared by substituting
1-naphthylhydrazine for 4-methylphenylhydrazine and Example 238A
for Example 97A in Example 193.
[0814] MS(ESI) m/e 356 (M+H).sup.+;
[0815] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (m, 1H), 7.81
(m, 1H), 7.47 (m, 2H), 7.41 (m, 1H), 7.31 (t, 1H), 6.95 (dd, 1H),
3.91 (m, 1H), 3.78 (d, 1H), 1.74 (m, 5H), 1.55 (m, 2H), 1.28 (m,
4H), 1.20 (m, 2H), 0.97 (m, 2H).
EXAMPLE 218
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-(1-naphthyl)bu-
tanohydrazide
[0816] The desired product was prepared by substituting
1-naphthylhydrazine for 4-methylphenylhydrazine and Example 200B
for Example 97A in Example 193.
[0817] MS(ESI) m/e 388 (M+H).sup.+;
[0818] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (m, 1H), 7.81
(ddd, 1H), 7.47 (ddd, 2H), 7.39 (dd, 1H), 7.32 (m, 1H), 6.90 (dd,
1H), 4.62 (d, 0.65H), 4.58 (d, 0.35H), 3.68 (m, 1H), 2.96 (dd, 1H),
2.83 (dd, 0.35H), 2.77 (dd, 0.65H), 2.51 (d, 1.5H), 2.44 (d, 0.5H),
1.88 (m, 2H), 1.75-1.66 (m, 3H), 1.50 (m, 1H), 1.22, (m, 3H), 0.98
(m, 2H).
EXAMPLE 219
N'-((2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)-3-c-
hlorobenzohydrazide
[0819] The desired product was prepared by substituting
3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example
200B for Example 97A in Example 193.
[0820] MS(ESI) m/e 401 (M+H).sup.+;
[0821] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.91 (m, 1H), 7.81
(dd, 1H), 7.61 (ddd, 1H), 7.50 (t, 1H), 4.63 (d, 0.65H), 4.56 (d,
0.35H), 3.68 (m, 1H), 2.95 (dd, 1H), 2.81 (dd, 1H), 2.78 (dd,
0.35H), 2.52 (d, 1H), 2.46 (m, 0.65H), 1.88 (m, 2H), 1.76-1.64 (m,
3H), 1.51 (m, 1H), 1.32-1.16 (m, 3H), 0.99 (m, 2H).
EXAMPLE 220
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N'-(1-naphthyl)pentanohydrazide
[0822] The desired product was prepared by substituting
2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride and
Example 125A for Example 98A in Example 98B.
[0823] MS(ESI) m/e 378 (M+H).sup.+;
[0824] .sup.1H NMR (300 MHz, DMSO-d6) .delta.10.73 (br s, 1H),
10.32 (br s, 1H), 8.52 (s, 1H), 8.04 (m, 6H), 7.65 (m, 2H), 7.30
(m, 5H), 6.69 (m, 1H), 4.32 (m, 1H), 2.74 (m, 2H), 2.06 (m, 1H),
1.89 (m, 1H).
EXAMPLE 221
N'-((2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoyl)-2-naphthohydrazide
[0825] The desired product was prepared by substituting
2-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and
Example 122A for Example 98A in Example 98B.
[0826] MS(ESI) m/e 356 (M+H).sup.+;
[0827] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.60 (s, 1H),
10.29 (s, 1H), 8.51 (s, 1H), 8.07 (m, 4H), 7.80 (br s, 2H), 7.64
(m, 2H), 6.54 (m, 1H), 4.41 (m, 1H), 1.77-1.44 (m, 6H), 1.20-0.94
(m, 5H).
EXAMPLE 222
N'-((2RS,3R)-3-amino-2-hydroxy-5-isopropylsulfanylpentanovl)-2-naphthohydr-
azide
[0828] The desired product was prepared by substituting
2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride and
Example 123B for Example 98A in Example 98B.
[0829] MS(ESI) mle 376 (M+H).sup.+;
[0830] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.56 (br s,
0.7H), 10.47 (br s, 0.3H), 9.90 (br s, 0.3H), 9.83 (br s, 0.7H),
8.75 (s, 0.3H), 8.51 (s, 0.7H), 8.00 (m, 3H), 7.63 (m, 2H), 7.38
(m, 1H), 7.22 (m, 1H), 6.89 (m, 1H), 6.18 (m, 1H), 4.21 (m, 0.7H),
4.13 (m, 0.3H), 2.96 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.91 (m,
111), 1.73 (m, 1H), 1.21 (d, 6H).
EXAMPLE 223
N'-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-2-naphthohydr-
azide
[0831] The desired product was prepared by substituting
2-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and
Example 124B for Example 98A in Example 98B.
[0832] MS(ESI) m/e 376 (M+H).sup.+;
[0833] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.52 (s, 1H),
8.04 (m, 6H), 7.65 (m, 2H), 6.74 (m, 1H), 4.40 (m, 1H), 2.94 (dd.
1H), 2.72 (dd, 1H), 2.48 (d, 2H), 1.80 (m, 1H), 0.98 (d, 6H).
EXAMPLE 224
N'-((2S,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenz-
ohydrazide
EXAMPLE 224A
N'-((2S,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-5-(isopropylsulfanyl)pe-
ntanoyl)-3-chlorobenzohydrazide
[0834] A solution of Example 123B (0.20 g, 0.65 mmol),
3-chlorobenzoyl hydrazine (0.17 g, 1.0 mmol),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimi- de hydrochloride (0.13
g, 0.68 mmol), 1-hydroxybenzotriazole (0.11 g, 0.81 mmol), and
N-methylmorpholine (0.070 mL, 0.64 mmol) in dichloromethane (6 mL)
at room temperature was stirred for 16 hours, diluted with
dichloromethane, washed sequentially with aqueous NaHCO.sub.3,
brine, 10% KHSO4, and brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate was purified by HPLC on silica gel
with 4:1/hexanes:acetone to provide the desired product.
[0835] MS(ESI) m/e 460 (M+H)+.
EXAMPLE 224B
N'-((2S
,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chloroben-
zohydrazide
[0836] The desired product was prepared by substituting Example
224A for Example 118A in Example 118B.
[0837] MS(ESI) m/e 360 (M+H).sup.+;
[0838] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.60 (br s,
1H), 10.30 (br s, 1H), 8.01 (br s, 2H), 7.92 (m, 1H), 7.85 (d, 1H),
7.69 (m, 1H), 7.57 (t, 1H), 6.67 (d, 1H), 4.26 (m, 1H), 2.97 (m,
1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.97 (m, 1H), 1.85 (m, 1H), 1.21
(d, 6H).
EXAMPLE 225
N'-((2S
,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzohy-
drazide
EXAMPLE 225A
N'-((2S,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-5-(isopropylsulfanyl)pe-
ntanoyl)-3-chlorobenzohydrazide
[0839] The desired product was prepared by substituting Example 98A
for Example 123B in Example 224A.
[0840] MS(ESI) m/e 446 (M+H).sup.+.
EXAMPLE 225B
N'-((2S
,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzohy-
drazide
[0841] The desired product was prepared by substituting Example
225A for Example 118A in Example 118B.
[0842] MS(ESI) m/e 346 (M+H).sup.+;
[0843] .sup.1H NMR (300 MHz, DMSO-d6) .delta.10.68 (br s, 1H),
10.29 (br s, 1H), 7.99 (br s, 2H), 7.91 (m, 1H), 7.84 (m, 1H), 7.69
(m, 1H), 7.57 (t, 1H), 6.67 (d, 1H), 4.25 (m, 1H), 3.40 (m, 1H),
2.67 (m, 2H), 2.50 (m, 2H), 1.99 (m, 1H), 1.85 (m, 1H), 1.19 (t,
3H).
EXAMPLE 226
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide
[0844] The desired product was prepared by substituting
1-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and
Example 1C for Example 98A in Example 98B.
[0845] MS(ESI) m/e 370 (M+H).sup.+;
[0846] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.53 (br s,
1H), 10.34 (br s, 1H), 8.34 (dd, 1H), 8.08 (d, 1H), 8.01 (m, 1H),
7.85 (br s, 2H), 7.66 (m, 1H), 7.59 (m, 3H), 6.61 (d, 1H), 4.20 (m,
1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H),
0.96-0.80 (m, 2H).
EXAMPLE 227
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hydroxy-2-naphthohy-
drazide
[0847] The desired product was prepared by substituting
3-hydroxy-2-naphthoylhydrazine for O-phenyl hydroxylamine
hydrochloride and Example iC for Example 98A in Example 98B.
[0848] MS(ESI) m/e 386 (M+H).sup.+;
[0849] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.44 (br s,
1H), 10.70 (br s, 1H), 10.58 (br s, 1H), 8.52 (s, 1H), 7.93 (d,
1H), 7.79 (m, 3H), 7.53 (t, 1H), 7.38 (d, 1H), 7.43 (s, 1H), 6.61
(d, 1H), 4.22 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H),
1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
EXAMPLE 228
N'-((2RS
3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthohydraz-
ide
[0850] The desired product was prepared by substituting
1-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride in
Example 98B.
[0851] MS(ESI) m/e 362 (M+H).sup.+;
[0852] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.54 (br s,
1H), 10.37 (br s, 1H), 8.34 (br s, 1H), 8.01 (m, 3H), 7.59 (m, 4H),
6.68 (d, 0.7H), 6.60 (d, 0.3H), 4.40 (m, 0.3H), 4.26 (m, 0.7H),
3.39 (m, 1H), 2.70 (m, 2H), 2.54 (m, 2H), 2.06 (m, 1H), 1.87 (m,
1H), 1.19 (t, 3H).
EXAMPLE 229
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-hydroxy-2-nap-
hthohydrazide
[0853] The desired product was prepared by substituting
3-hydroxy-2-naphthoylhydrazine for O-phenyl hydroxylamine
hydrochloride in Example 98B.
[0854] MS(ESI) m/e 378 (M+H).sup.+;
[0855] .sup.1H NMR (300 MHz, DMSO-d6) .delta.11.45 (br s, 1H),
10.69 (br s, 1H), 10.58 (br s, 1H), 8.52 (br s, 1H), 8.03 (br s,
2H), 7.90 (m, 2H), 7.77 (m, 1H), 7.53 (t, 1H), 7.38 (d, 1H), 7.33
(m, 1H), 6.68 (d, 0.6H), 6.62 (d, 0.4H), 4.40 (m, 0.4H), 4.29 (m,
0.6H), 3.39 (m, 1H), 2.66 (m, 2H), 2.54 (m, 2H), 1.97 (m, 1H), 1.87
(m, 1H), 1.20 (t, 3H).
EXAMPLE 230
N'-((2S,3R)-3-amino-2-hydroxv-5-phenylpentanoyl)-1-naphthohydrazide
[0856] The desired product was prepared by substituting
1-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and
Example 125A for Example 98A in Example 98B.
[0857] MS(ESI) m/e 378 (M+H).sup.+;
[0858] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.54 (br s,
1H), 10.38 (br s, 1H), 8.35 (m, 1H), 8.08 (m, 1H), 8.00 (br s, 2H),
7.59 (m, 4H), 7.29 (m, 5H), 7.18 (m, 1H), 6.68 (m, 1H), 4.31 (m,
1H), 2.74 (m, 2H), 2.06 (m, 1H), 1.89 (m, 1H).
EXAMPLE 231
N'-((2S
,3R)-3-amino-2-hvdroxv-5-phenylpentanoyl)-3-hydroxv-2-naphthohydra-
zide
[0859] The desired product was prepared by substituting
3-hydroxy-2-naphthoylhydrazine for O-phenyl hydroxylamine
hydrochloride and Example 125A for Example 98A in Example 98B.
[0860] MS(ESI) m/e 394 (M+H).sup.+;
[0861] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.43 (br s,
1H), 10.70 (br s, 1H), 10.58 (br s, 1H), 8.52 (s, 1H), 7.94 (m,
3H), 7.77 (d, 1H), 7.53 (t, 1H), 7.30 (m, 7H), 6.69 (d, 1H), 4.35
(m, 1H), 2.72 (m, 2H), 1.99 (m, 1H), 1.91 (m, 1H).
EXAMPLE 232
(2S ,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide
EXAMPLE 232A
(2S,3R)-3-((tert-butoxycarbonyl)amino)-4-cyclohexyl-2-hydroxybutanoic
acid pentafluorophenyl ester
[0862] The title compound was prepared by substituting Example 1C
for Example 124A in Example 126B.
[0863] MS(ESI) m/e 466 (M-H)+.
EXAMPLE 232B
(2S ,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide
[0864] The title compound was prepared by substituting Example 232A
for Example 126B and anhydrous hydrazine for Example 126A in
Example 126C.
[0865] MS(ESI) m/e 216 (M+H).sup.+.
[0866] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.05 (br s,
1H), 7.97 (br s, 2H), 6.75 (br s, 1H), 4.22 (d, 2H), 1.74-1.60 (m
6H), 1.42 (d, 2H), 1.28-1.10 (m, 3H), 0.92-0.74 (m, 2H).
EXAMPLE 233
N'-((2R,3R)-3-amino-2-hydroxv-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzoyl
hydrazide
EXAMPLE 233A
N-((2R,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-5-(ethylsulfanyl)pentano-
yl)-3-chlorobenzoyl hydrazide
[0867] The desired product was prepared by substituting Example 98A
for Example 123B in Example 224A.
[0868] MS(ESI) m/e 446 (M+H)+.
EXAMPLE 233B
N'-((2R,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzoyl
hydrazide
[0869] The desired product was prepared by substituting Example
233A for Example 118A in Example 118B.
[0870] MS(ESI) m/e 346 (M+H).sup.+;
[0871] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.52 (br s,
1H), 10.20 (br s, 1H), 8.07 (br s, 2H), 7.90 (m, 1H), 7.83 (m, 1H),
7.67 (m, 1H), 7.56 (t, 1H), 6.60 (d, 1H), 4.39 (m, 1H), 3.57 (m,
1H), 2.69 (m, 2H), 2.53 (m, 2H), 1.95 (m, 1H), 1.86 (m, 1H), 1.18
(t, 3H).
EXAMPLE 234
N'-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenz-
oyl hydrazide
EXAMPLE 234A
N'-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenz-
oyl hydrazide
[0872] The desired product was prepared as described in Example
224A.
[0873] MS(ESI) m/e 460 (M+H).sup.+.
EXAMPLE 234B
N'-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenz-
oyl hydrazide
[0874] The desired product was prepared by substituting Example
234A for Example 118A in Example 118B.
[0875] MS(ESI) m/e 360 (M+H).sup.+;
[0876] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.10.52 (br s, 1H),
10.18 (br s, 1H), 8.11 (br s, 2H), 7.90 (m, 1H), 7.84 (d, 1H), 7.64
(m, 1H), 7.56 (t, 1H), 6.59 (d, 1H), 4.42 (m, 1H), 2.97 (m, 1H),
2.69 (m, 1H), 2.62 (m, 1H), 1.89 (m, 2H), 1.20 (d, 6H).
EXAMPLE 235
3-(2-aminoethyl)-N'-((2S,3S)-3-amino-2-hydroxy-4-(isobutvlsulfanyl)butanoy-
l)benzohvdrazide
EXAMPLE 235A
methyl 3-(cyanomethyl)benzoate
[0877] A solution of methyl 3-(bromomethyl)benzoate (2.29 g, 0.01
mol) and potassium cyanide (3.26 g, 0.05 mol) in DMSO (20 mL) was
heated to 100.degree. C. for 1 h. The reaction mixture was cooled,
partitioned between ether and water, washed with brine, dried
(Na.sub.2SO.sub.4) and concentrated to give the title compound.
[0878] MS(ESI) m/e 193 (M+NH4)+.
EXAMPLE 235B
3-(2-(tertbutoxvcarbonylamino)ethyl)benzoyl hydrazide
[0879] A solution of Example 235A (1.23 g, 7 mmol) in methanol (15
mL) was hydrogenated in the presence of RaNi (2.5 g) for 18h. After
filtration and evaporation of the solvent, the resulting oil (0.1
g, 0.6 mmol) was dissolved in dichloromethane (5 mL), treated with
di-tert-butyl dicarbonate (0.13 g, 0.6 mmol) for 16 h at room
temperature. The solvent was evaporated and the residue treated
with hydrazine hydrate (0.2 mL, 6.0 mmol) in ethanol at reflux for
48h. After the solvent was evaporated, and the residue purified by
silica gel chromatography (10:90/methanol:dichloromethane) to give
the title compound.
[0880] MS(ESI) m/e 280 (M+H).sup.+.
EXAMPLE 235C
3-(2-aminoethyl)-N'-((2S,3S)-3-amino-2-hydroxy4-(isobutylsulfanyl)butanoyl-
)benzohydrazide
[0881] The title compound was prepared by substituting Example 235B
for Example 126A in Example 126C.
[0882] MS(ESI) m/e 367 (M-H).sup.+.
[0883] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.62 (s, 1H),
10.27 (s, 1H), 8.12 (br s, 2H), 8.0 (br s, 2H), 7.78 (m, 2H), 7.5
(m, 2H), 6.74 (d, 1H), 4.4 (t, 1H), 3.7 (m, 2H), 2.92 (m, 3H), 2.75
(m, 1H), 2.48 (d, 2H), 1.84-1.7 (m, 1H), 0.97 (d, 6H).
EXAMPLE 236
N'-((2S,3R,4RS)-3-amino-4-ethvl-2-hydroxyoctanoyl)-3-chlorobenzohydrazide
EXAMPLE 236A
Ethyl 4-ethyl-oct-2-enoate
[0884] A solution of 2-ethyl-hexanal (5.0 g, 39 mmol), triethyl
phosphonoacetate (8.0 mL, 40 mmol), lithium bromide (3.65 g, 42
mmol), and triethylamine (5.6 mL, 40 mmol) in tetrahydrofuran (160
niL) at room temperature was stirred for 16 hours, quenched with
water, stirred for 15 minutes, diluted with ethyl acetate, washed
sequentially with pH 7 buffer and brine, dried (MgSO.sub.4),
filtered, and concentrated. The concentrate was purified by flash
column chromatography on silica gel with
1:1/dichloromethane:hexanes to provide the desired product.
[0885] MS(ESI) rn/e 199 (M+H)+.
EXAMPLE 236B
ethyl (2S
,3R,4RS)-3-(tert-butoxycarbonyl)amino-4-ethyl-2-hydroxyoctanoate
[0886] A solution of tert-butylcarbamate (2.85 g, 24 mmol),
tert-butylhypochlorite (2.7 mL, 24 mmol), and 0.5 M NaOH (50 mL, 25
mmol) in 1-propanol (75 mL) at room temperature was stirred for 15
minutes. Example 236A (1.70 g, 8.6 mmol), potassium osmate
dihydrate (0.27 g, 0.73 mmol) and hydroquinidine
1,4-phthalazinediyl diether (0.62 g, 0.80 mmol) were added, and the
mixture stirred in an ice bath for 2 hours, diluted with ethyl
acetate, washed sequentially with water, 1 M HCl, aqueous
NaHCO.sub.3, and brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with 1:4/ethyl acetate:hexanes to
provide the desired product.
[0887] MS(ESI) m/e 331 (M+H).sup.+.
EXAMPLE 236C
(2S,3R,4RS)-3-(tert-butoxycarbonvl)amino-4-ethyl-2-hydroxyoctanoic
acid
[0888] A solution of Example 236B (0.168 g, 0.51 mmol), 30%
hydrogen peroxide (0.25 mL, 2.2 mmol), and lithium hydroxide
monohydrate (0.042 g, 1.0 mmol) in 3:1 tetrahydrofuran/water (7 mL)
was stirred in an ice bath for 3 hours, then concentrated. The
residues were taken up in water and the pH adjusted to 10 with
NaOH. The solution was washed twice with ether, adjusted to pH 2
with HCl, then extracted twice with ethyl acetate. The ethyl
acetate extracts were dried (MgSO.sub.4), filtered, then
concentrated to provide the desired product.
[0889] MS(ESI) m/e 304 (M+H).sup.+.
EXAMPLE 236D
N'-((2S,3R,4RS)-3-amino-4-ethyl-2-hydroxyoctanoyl)-3-chlorobenzohydrazide
[0890] The desired product was prepared by substituting
3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride
and Example 236C for Example 98A in Example 98B.
[0891] MS(ESI) m/e 356 (M+H).sup.+;
[0892] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.17 (br s, 2H),
7.96 (m, 1H), 7.87 (d, 1H), 7.58 (m, 1H), 7.52 (t, 1H), 5.79 (m,
1H), 3.70 (m, 1H), 1.58 (m, 2H), 1.40-0.80 (m, 5H), 0.70 (t, 3H),
0.64 (m, 2H), 0.42 (t, 3H).
EXAMPLE 237
N'-((2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-propoxybenzo-
hydrazide
EXAMPLE 237A methyl 3-propoxybenzoate
[0893] The title compound was prepared by substituting
1-bromopropane for Example 364A in Example 364B.
[0894] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.54 (m, 1H),
7.43 (m, 2H), 7.23 (m, 1H), 3.98 (t, 2H), 3.84 (s, 3H), 1.8-1.66
(m, 2H), 0.99 (t, 3H).
EXAMPLE 237B
N'-((2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-propoxybenzo-
hydrazide
[0895] The title compound was prepared by substituting Example 237B
for Example 126A in Example 126C.
[0896] MS(ESI) m/e 382 (M-H)+.
[0897] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.58 (s, 1H),
10.24 (s, 1H), 8.07 (br s, 2H), 7.44 (m, 3H), 7.16 (m, 1H), 6.24
(d, 1H), 4.4 (t, 1H), 3.98 (t, 2H), 3.4 (m, 1H), 2.92 (dd, 1H),
2.73 (dd, 1H), 2.46 (d, 2H), 1.84-1.7 (m, 3H), 1.0 (t, 3H), 0.97
(d, 6H).
EXAMPLE 238
N'-((2S,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohydrazid-
e
EXAMPLE 238A
(2S
3R)-3-(tert-butoxycarbonyl)amino-5-cyclohexyl-2-hydroxypentanoic
acid
[0898] The desired product was prepared by substituting
3-cyclohexylpropanal for 2-ethylhexanal in Examples 236A-236C.
[0899] MS(ESI) m/e 316 (M+H).sup.+.
EXAMPLE 238B
N'-((2S,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohYdrazid-
e
[0900] The desired product was prepared by substituting
3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride
and Example 238A for Example 98A in Example 98B.
[0901] MS(ESI) m/e 368 (M+H).sup.+;
[0902] .sup.1H NMR (300 MHz, DMSO-d6) .delta.10.67 (br s, 1H),
10.27 (br s, 1H), 7.91 (m, 1H), 7.85 (m, 3H), 7.69 (d, 1H), 7.57
(t, 1H), 6.58 (m, 1H), 4.18 (m, 1H), 1.80-1.50 (m, 7H), 1.35-1.10
(m, 6H), 0.89 (m, 2H).
EXAMPLE 239
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-trifluorometh-
ylsulfanylbenzohydrazide
EXAMPLE 239A
N'-((2RS,3R)-3-(tert-butoxycarbonyl)amino-5-(ethylsulfanYl)-2-hydroxypenta-
noyl)hydrazide
[0903] To a solution of Example 97A (2.00 g, 6.5 mmol) in
acetonitrile (120 niL) was added HOAt (0.443 g, 3.3 mmol) and the
mixture stirred for 5 min until homogeneous. To this solution was
added DCC (2.00 g, 9.75 mmol) in acetonitrile (20 mL) and the
mixture was stirred for 2 minutes. Hydrazine monohydrate (0.306 mL,
9.76 mmol) was added and the reaction stirred fo 16 hours. The
solvent was removed in vacuo and the crude material filtered, the
solid washed with dichloromethane, and the resulting oil was
purified by column chromatography using ethyl acetate to give the
desired product 1.2 g (60%).
EXAMPLE 239B
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hvdroxypentanoyl)-3-trifluorometh-
ylsulfanylbenzohydrazide
[0904] To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of
dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt
(0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL
of a 0.3M solution of 3-(ethylsulfanyl)benzoic acid (0.15 mmol) in
dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of
Example 239A (0.225 mmol) in dimethylacetamide/dichloromethane
(1:1) was added. The mixture was agitated for 18 hours and quenched
with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of
isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture
was filtered and the resins washed with 1.times.3 mL of
dichloromethane, the solvent was removed in vacuo, and the crude
material purified by reverse phase preparative HPLC. The resulting
material was treated with 1 mL of 50% trifluoroacetic
acid/dichloromethane and agitated at ambient temperature for 18
hours. The solvent was removed in vacuo to give the desired
product.
[0905] MS(ESI) m/e 412 (M+H).sup.+;
[0906] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.22 (d, 1H), 8.07
(dd, 1H), 7.93 (t, 1H), 7.65 (m, 1H), 4.49 (d, 0.35), 4.45 (d,
0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H),
1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 240
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-methylbenzohy-
drazide
[0907] The desired product was prepared by substituting
2-methylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0908] MS(ESI) m/e 326 (M+H).sup.+;
[0909] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.7.49 (m, 1H), 7.40
(dd, 1H), 7.28 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.80 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.47 (s, 1.95H), 2.46 (s, 1.05H),
2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.245 (t,
1.05H).
EXAMPLE 241
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methylbenzohy-
drazide
[0910] The desired product was prepared by substituting
3-methylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0911] MS(ESI) m/e 326 (M+H).sup.+;
[0912] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.72 (d, 1H), 7.67
(dd, 1H), 7.42 (t, 1H), 7.38 (m, 1H), 4.48 (d, 0.35), 4.43 (d,
0.65), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.41 (s, 3H),
2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 242
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzohy-
drazide
[0913] The desired product was prepared by substituting
4-methylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0914] MS(ESI) m/e 326 (M+H).sup.+;
[0915] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.79 (m, 211),
7.32 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71
(t, 2H), 2.61 (dd, 2H), 2.41 (s, 3H), 2.16 (dd, 1H), 2.00 (dt, 1H),
1.27 (t, 1.95H), 1.26 (t, 1.05H).
EXAMPLE 243
N'-((2RS,3R)-3-amino-5-(ethvlsulfanyl)-2-hvdroxypentanoyl)-2-aminobenzohyd-
razide
[0916] The desired product was prepared by substituting
2-aminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0917] MS(ESI) m/e 327 (M+H).sup.+;
[0918] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.56 (dd, 1H),
7.24 (m, 1H), 6.78 (d, 1H), 6.65 (ddd, 1H), 4.48 (d, 0.35), 4.44
(d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd,
1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 244
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-aminobenzohyd-
razide
[0919] The desired product was prepared by substituting
3-aminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0920] MS(ESI) m/e 327 (M+H).sup.+;
[0921] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.26 (m, 3H), 6.99
(m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.78 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H),
1.25 (t, 1.05H).
EXAMPLE 245
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-aminobenzohyd-
razide
[0922] The desired product was prepared by substituting
4-aminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0923] MS(ESI) m/e 327 (M+H).sup.+;
[0924] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.66 (dd, 2H),
6.67 (dd, 2H), 4.46 (d, 0.35), 4.42 (d, 0.65), 3.76 (m, 1H), 2.70
(t, 2H), 2.61 (dd, 2H), 2.15 (dd, 1H), 1.99 (dt, 1H), 1.27 (t,
1.95H), 1.25 (t, 1.05H).
EXAMPLE 246
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxvpentanoyl)-2-hydroxybenzoh-
ydrazide
[0925] The desired product was prepared by substituting
2-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0926] MS(ESI) m/e 328 (M+H).sup.+;
[0927] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.86 (ddd, 1H),
7.44 (m, 1H), 6.96 (m, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78
(m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 111), 1.99 (dt,
1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 247
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hvdroxypentanoyl)-3-hydroxybenzoh-
ydrazide
[0928] The desired product was prepared by substituting
3-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0929] MS(ESI) m/e 328 (M+H).sup.+;
[0930] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.30 (m, 3H), 7.00
(ddd, 1H), 4.46 (d, 0.35), 4.42 (d, 0.65), 3.75 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.15 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H),
1.25 (t, 1.05H).
EXAMPLE 248
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-hydroxybenzoh-
ydrazide
[0931] The desired product was prepared by substituting
4-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0932] MS(ESI) m/e 328 (M+H).sup.+;
[0933] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.77 (m, 2H), 6.85
(m, 2H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H),
1.25 (t, 1.05H).
EXAMPLE 249
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methoxybenzoh-
ydrazide
[0934] The desired product was prepared by substituting
3-methoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0935] MS(ESI) m/e 342 (M+H).sup.+;
[0936] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.44 (m, 3H), 7.16
(ddd, 1H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.85 (s, 3H), 3.78 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H),
1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 250
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxygentanoyl)-4-methoxybenzoh-
ydrazide
[0937] The desired product was prepared by substituting
4-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0938] MS(ESI) m/e 342 (M+H).sup.+;
[0939] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 2H), 7.02
(m, 2H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.87 (s, 3H), 3.76 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.15 (dd, 1H), 1.99 (dt, 1H),
1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 251
N-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-fluorobenzohyd-
razide
[0940] The desired product was prepared by substituting
2-fluorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0941] MS(ESI) m/e 330 (M+H).sup.+;
[0942] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.7.82 (m, 1H), 7.60
(m, 1H), 7.73 (t, 1H), 7.26 (m, 1B), 4.48 (d, 0.35), 4.44 (d,
0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1B),
1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 252
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-fluorobenzohy-
drazide
[0943] The desired product was prepared by substituting
3-fluorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0944] MS(ESI) m/e 330 (M+H).sup.+;
[0945] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.71 (dd, 1H),
7.62 (m, 1H), 7.53 (t, 1H), 7.36 (m, 1B), 4.49 (d, 0.35), 4.45 (d,
0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1B),
2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 253
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-fluorobenzohy-
drazide
[0946] The desired product was prepared by substituting
4-fluorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0947] MS(ESI) m/e 330 (M+H).sup.+;
[0948] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.95 (m, 2H), 7.24
(m, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H),
1.26 (t, 1.05H).
EXAMPLE 254
(2RS,3R)-N'-acetyl-3-amino-5-(ethylsulfanyl)-2-hydroxypentanohydrazide
[0949] The desired product was prepared by substituting acetic acid
for 3-(ethylsulfanyl)benzoic acid in Example 239B.
[0950] MS(ESI) m/e 250 (M+H).sup.+;
[0951] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.35),
4.37 (d, 0.65), 3.72 (m, 1H), 2.68 (ddd, 2H), 2.58 (dd, 1.3H), 2.55
(dd, 0.7H), 2.10 (m, 1H), 2.03 (s, 1.95H), 2.01 (s, 1.05H),1.95 (m,
1H), 1.23-1.28 (m, 3H).
EXAMPLE 255
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-isobutylpentanohydrazide
[0952] The desired product was prepared by substituting
2-methylpropionic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0953] MS(ESI) m/e 278 (M+H).sup.+;
[0954] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.35),
4.37 (d, 0.65), 3.73 (m, 1H), 2.73-2.51 (m, 5H), 2.10 (m, 1H), 1.95
(dt, 1H), 1.26 (t, 1.95H), 1.24 (t, 1.05H), 1.17 (m, 6H).
EXAMPLE 256
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(3-methylbutanoyl)pentanoh-
ydrazide
[0955] The desired product was prepared by substituting
3-methylbutyric acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0956] MS(ESI) m/e 292 (M+H).sup.+;
[0957] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.35),
4.37 (d, 0.65), 3.73 (m, 1H), 2.67 (dd, 2H), 2.59 (dd, 1.3H), 2.55
(dd, 0.7H), 2.07-2.16 (m, 4H), 1.95 (dt, 1H), 1.26 (t, 1.95H), 1.24
(t, 1.05H), 1.10 (t, 6H).
EXAMPLE 257
(2RS,3R)-3-amino-5-(ethylsulfanyl)-N'-heptanoyl-2-hydroxypentanohydrazide
[0958] The desired product was prepared by substituting heptanoic
acid for 3-(ethylsulfanyl)benzoic acid in Example 239B.
[0959] MS(ESI) m/e 320 (M+H).sup.+;
[0960] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.35),
4.37 (d, 0.65), 3.73 (m, 1H), 2.67 (dd, 211), 2.59 (dd, 1.3H), 2.55
(dd, 0.7H), 2.28 (dd, 2H), 2.12 (ddd, 1H), (1.95 (dt, 1H), 1.64
(dd, 211), 1.31-1.40 (m, 6H), 1.26 (t, 1.95H), 1.24 (t, 1.05H),
0.91 (t, 3H).
EXAMPLE 258
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(tetrahydro-2-furanylcarbo-
nyl)pentanohydrazide
[0961] The desired product was prepared by substituting
2-tetrahydrofuroic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0962] MS(ESI) m/e 306 (M+H).sup.+;
[0963] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.48-4.41 (m,
1.35), 4.37 (d, 0.65), 4.01 (m, 1H), 3.88 (m, 1H), 3.73 (m, 1H),
2.67 (dd, 2H), 2.59 (dd, 1.3H), 2.55 (dd, 0.7H), 2.29 (m. 1H), 2.08
(m, 2H), 1.96 (m, 3H), 1.26 (t, 1.95H), 1.24 (t, 1.05H).
EXAMPLE 259
(2RS,3R)-3-amino-N'-(cyclohexylacetyl)-5-(ethylsulfanyl)-2-hydroxyheptanoh-
ydrazide
[0964] The desired product was prepared by substituting
cyclohexylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0965] MS(ESI) m/e 332 (M+H).sup.+;
[0966] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.35),
4.36 (d, 0.65), 3.73 (m, 1H), 2.67 (dd, 2H), 2.59 (dd, 1.3H), 2.55
(dd, 0.7H), 2.16-2.07 (m, 31H), 1.95 (dt, 1H), 1.65-1.81 (m, 9H),
1.26 (t, 1.95H), 1.24 (t, 1.05H) 1.02 (dd, 2H).
EXAMPLE 261
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-bromobenzohyd-
razide
[0967] The desired product was prepared by substituting
4-bromobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0968] MS(ESI) m/e 391 (M+H).sup.+;
[0969] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.68
(m, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H),
1.25 (t, 1.05H).
EXAMPLE 262
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-(phenylacetyl)pentanohydra-
zide
[0970] The desired product was prepared by substituting
phenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0971] MS(ESI) m/e 326 (M+H).sup.+;
[0972] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.35-7.23 (m, 5H),
4.41 (d, 0.35), 4.37 (d, 0.65), 3.72 (m, 1H), 3.61 (d, 2H), 2.67
(t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt,
1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 263
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hvdroxy-N'-((2-methoxyphenyl)acetyl)p-
entanohydrazide
[0973] The desired product was prepared by substituting
2-methoxyphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0974] MS(ESI) m/e 356 (M+H).sup.+;
[0975] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.21 (dt, 1H),
6.94 (d, 1H), 6.90 (d, 1H), 6.81 (m, 1H), 4.41 (d, 0.35), 4.37 (d,
0.65), 3.78 (s, 3H), 3.72 (m, 11H), 3.58 (d, 2H), 2.67 (t, 2H),
2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H),
1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 264
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-((3-methoxyphenyl)acetyl)p-
entanohydrazide
[0976] The desired product was prepared by substituting
3-methoxyphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0977] MS(ESI) m/e 356 (M+H).sup.+;
[0978] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.25 (m, 2H), 6.95
(d, 1H), 6.90 (d, 1H), 4.41 (d, 0.35), 4.37 (d, 0.65), 3.83 (s,
3H), 3.72 (m, 1H), 3.61 (dd, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H),
2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H),
1.21 (t, 1.05H).
EXAMPLE 265
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-((4-methoxyphenyl)acetyl)p-
entanohydrazide
[0979] The desired product was prepared by substituting
4-methoxyphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0980] MS(ESI) m/e 356 (M+H).sup.+;
[0981] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.25 (d, 2H), 6.87
(dd, 2H), 4.41 (d, 0.35), 4.37 (d, 0.65), 3.77 (s, 3H), 3.72 (m,
1H), 3.53 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H),
2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 266
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxv-N'-((2-chlorophenyl)acetyl)pe-
ntanohydrazide
[0982] The desired product was prepared by substituting
2-chlorophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0983] MS(ESI) m/e 360 (M+H).sup.+;
[0984] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.43 (m, 2H), 7.27
(m, 2H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.80 (d, 1H), 3.78 (s,
1H), 3.73 (m, 1H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H),
2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 267
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-((3-chlorophenyl)acetyl)pe-
ntanohydrazide
[0985] The desired product was prepared by substituting
3-chlorophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0986] MS(ESI) m/e 360 (M+H).sup.+;
[0987] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.39 (m, 1H),
7.25-7.31 (m, 3H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.72 (m, 1H),
3.61 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11
(dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 268
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N'-((4-chlorophenyl)acetyl)pe-
ntanohydrazide
[0988] The desired product was prepared by substituting
4-chlorophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0989] MS(ESI) m/e 360 (M+H).sup.+;
[0990] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.32 (m, 4H), 4.42
(d, 0.35), 4.37 (d, 0.65), 3.72 (m, 1H), 3.61 (d, 2H), 2.67 (t,
2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt,
1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 269
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1,1
'-biphenyl)-4-ylacetohydrazide
[0991] The desired product was prepared by substituting
4-phenylphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[0992] MS(ESI) m/e 402 (M+H).sup.+;
[0993] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.58 (m, 4H), 7.42
(m, 4H), 7.32 (m, 1H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.72 (m,
1H), 3.65 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H),
2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
EXAMPLE 270
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(4-dimethylam-
inophenyl)acetohydrazide
[0994] The desired product was prepared by substituting
4-dimethylaminophenylacetic acid for 3-(ethylsulfanyl)benzoic acid
in
[0995] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.36 (m, 2H), 7.13
(m, 2H), 4.42 (d, 0.35), 4.37 (d, 0.65), 3.72 (m, 11H), 3.59 (d,
2H), 3.09 (s, 3H), 3.07 (s, 3H), 2.67 (t, 2H), 2.58 (dd, 1.3H),
2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H),
1.21 (t, 1.05H).
EXAMPLE 271
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1-naphthyl)a-
cetohydrazide
[0996] The desired product was prepared by substituting
1-naphthylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[0997] MS(ESI) m/e 369 (M+H).sup.+;
[0998] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.10 (d, 1H), 7.88
(d, 1H), 7.81 (d, 1H), 7.51 (m, 3H) 7.45 (t, 1H), 4.42 (d, 0.35),
4.37 (d, 0.65), 4.10 (d, 2H), 3.70 (m, 1H), 2.65 (t, 2H), 2.56 (dd,
1.3H), 2.47 (dd, 0.7H), 2.09 (dd, 1H), 1.92 (dt, 1H), 1.24 (t,
1.95H), 1.15 (t, 1.05H).
EXAMPLE 272
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(2-naphthyl)a-
cetohydrazide
[0999] The desired product was prepared by substituting
2-naphthylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1000] MS(ESI) m/e 376 (M+H).sup.+;
[1001] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.82 (m, 4H), 7.46
(m, 3H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.78 (d, 2H), 3.73 (m,
1H), 2.66 (t, 2H), 2.57 (dd, 1.3H), 2.52 (dd, 0.7H), 2.09 (dd, 1H),
1.94 (dt, 1H), 1.25 (t, 1.95H), 1.19 (t, 1.05H).
EXAMPLE 273
N'-((2RS,3R)-3-amino-5-(ethyl
sulfanyl)-2-hydroxypentanoyl)-2-furohydrazid- e
[1002] The desired product was prepared by substituting 2-furoic
acid for 3-(ethylsulfanyl)benzoic acid in Example 239B.
[1003] MS(ESI) m/e 302 (M+H).sup.+;
[1004] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.73 (dd, 0.65H),
7.72 (dd, 0.35H), 7.24 (dd, 0.65H), 7.22 (dd, 0.35H), 6.64 (dd,
0.65H), 6.63 (dd, 0.35H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m,
1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H),
1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 274
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-furohydrazide
[1005] The desired product was prepared by substituting 3-furoic
acid for 3-(ethylsulfanyl)benzoic acid in Example 239B.
[1006] MS(ESI) m/e 302 (M+H).sup.+;
[1007] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.16 (m, 0.65H),
8.14 (m, 0.35H), 7.62 (dd, 0.65H), 7.61 (dd, 0.35H), 6.83 (m, 1H),
4.47 (d, 0.35), 4.42 (d, 0.65), 3.76 (m, 1H), 2.70 (t, 2H), 2.60
(dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.98 (dt, 1H), 1.27 (t,
1.95H), 1.25 (t, 1.05H).
EXAMPLE 275
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-thiophenecarb-
ohydrazide
[1008] The desired product was prepared by substituting 2-thiophene
carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1009] MS(ESI) m/e 318 (M+H).sup.+;
[1010] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.79 (dd, 0.65H),
7.78 (dd, 0.35H), 7.77 (dd, 0.65H), 7.75 (dd, 0.35H), 7.17 (m, 1H),
4.47 (d, 0.35), 4.43 (d, 0.65), 3.76 (m, 1H), 2.70 (t, 2H), 2.60
(dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t,
1.95H), 1.25 (t, 1.05H).
EXAMPLE 276
N'-((2RS,3R)-3-amino-5-(ethvlsulfanyl)-2-hydroxypentanoyl)-3-thiophenecarb-
ohydrazide
[1011] The desired product was prepared by substituting 3-thiophene
carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1012] MS(ESI) m/e 318 (M+H).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. 8.18 (dd, 0.65H), 8.16 (dd, 0.35H), 7.53 (m,
2H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.71 (t, 2H),
2.60 (dd, 1.3H), 2.58 (dd, 0.71H), 2.16 (dd, 1H), 1.99 (dt, 1H),
1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 277
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrrole-2-ca-
rbohydrazide
[1013] The desired product was prepared by substituting 2-pyrrole
carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1014] MS(ESI) m/e 301 (M+H).sup.+;
[1015] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 6.99 (dd, 0.65H),
6.98 (dd, 0.35H), 6.91 (dd, 0.65H, 6.89 (dd, 0.35H), 6.21 (m, 1H),
4.46 (d, 0.35), 4.42 (d, 0.65), 3.77 (m, 1H), 2.71 (m, 2H), 2.60
(dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.99 (dt, 1H), 1.27 (t,
1.95H), 1.25 (t, 1.05H).
EXAMPLE 278
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-2--
carbohydrazide
[1016] The desired product was prepared by substituting 2-thiazole
carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1017] MS(ESI) m/e 319 (M+H).sup.+;
[1018] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.02 (d, 0.65H),
8.00 (d, 0.35H), 7.94 (d, 0.65H, 7.91 (d, 0.35H), 4.49 (d, 0.35),
4.44 (d, 0.65), 3.79 (m, 1H), 2.71 (m, 2H), 2.60 (dd, 1.3H), 2.58
(dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t,
1.05H).
EXAMPLE 279
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-4--
carbohydrazide
[1019] The desired product was prepared by substituting 4-thiazole
carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1020] MS(ESI) m/e 319 (M+H).sup.+;
[1021] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.9.06 (d, 0.65H),
9.04 (d, 0.35H), 8.40 (d, 0.65H, 8.37 (d, 0.35H), 4.48 (d, 0.35),
4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 1.3H), 2.58
(dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t,
1.05H).
EXAMPLE 280
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-5--
carbohydrazide
[1022] The desired product was prepared by substituting 5-thiazole
carboxyl acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1023] MS(ESI) m/e 319 (M+H).sup.+;
[1024] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.9.21 (s, 0.65H),
9.19 (s, 0.35H), 8.49 (s, 0.65H, 8.47 (s, 0.35H), 4.49 (d, 0.35),
4.44 (d, 0.65), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58
(dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t,
1.05H).
EXAMPLE 281
N'-((2RS,3R)-3-arnino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrazole-5--
carbohydrazide
[1025] The desired product was prepared by substituting
1H-pyrazole-5-carboxylic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1026] MS(ESI) m/e 302 (M+H).sup.+;
[1027] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.74 (d, 0.65H),
7.73 (d, 0.35H), 8.83 (m, 1H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.78
(m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd,
1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 282
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrazole-4-c-
arbohydrazide
[1028] The desired product was prepared by substituting
1-H-pyrazole-4-carboxylic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1029] MS(ESI) m/e 302 (M+H).sup.+;
[1030] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.11 (s, 1H), 8.10
(s, 1H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.76 (m, 1H), 2.70 (t,
2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.99 (dt,
1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 283
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-5-isoxazolecarb-
ohydrazide
[1031] The desired product was prepared by substituting 5-isoxazole
caboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1032] MS(ESI) m/e 303 (M+H).sup.+;
[1033] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.58 (d, 0.65H),
8.56 (d, 0.35H), 7.09 (d, 0.65H), 7.06 (d, 0.35H), 4.49 (d, 0.35),
4.44 (d, 0.65), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58
(dd, 0.7H), 2.16 (dd, 1H), 1.97 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t,
1.05H).
EXAMPLE 284
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyridinecarbo-
hydrazide
[1034] The desired product was prepared by substituting 2-pyridine
caboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1035] MS(ESI) m/e 313 (M+H).sup.+;
[1036] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.67 (t, 1H), 8.11
(t, 1H), 7.99 (m, 1H), 7.60 (m, 1H), 4.49 (d, 0.35), 4.45 (d,
0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 1.3H), 2.58 (dd,
0.7H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t,
1.05H).
EXAMPLE 285
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(2-pyridnyl)a-
cetohydrazide
[1037] The desired product was prepared by substituting
2-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1038] MS(ESI) m/e 327 (M+H).sup.+;
[1039] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.63 (d, 0.35H),
8.59 (d, 0.65H), 8.11 (dt, 0.35H), 8.04 (dt, 0.65H), 7.71 (d,
0.35H), 7.66 (d, 0.65H), 7.59 (ddd, 0.35H), 7.53 (ddd, 0.65H), 4.44
(d, 0.35), 4.38 (d, 0.65), 3.73 (m, 1H), 2.67 (t, 2H), 2.58 (dd,
1.3H), 2.52 (dd, 0.7H), 2.10 (dd, 1H), 1.93 (dt, 1H), 1.25 (t,
1.95H), 1.20 (t, 1.05H).
EXAMPLE 286
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-pyrndinecarbo-
hydrazide
[1040] The desired product was prepared by substituting
3-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1041] MS(ESI) m/e 313 (M+H).sup.+;
[1042] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.9.04 (m, 1H), 8.77
(d, 1H), 8.32 (dd, 0.35H), 8.30 (dd, 0.65H), 7.61 (d, 0.35H), 7.60
(d, 0.65H), 4.51 (d, 0.35), 4.46 (d, 0.65), 3.79 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 1.3H), 2.58 (dd, 0.7H), 2.17 (dd, 1H), 2.00 (dt,
1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 287
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(3-pyridinyl)-
acetohydrazide
[1043] The desired product was prepared by substituting
3-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1044] MS(ESI) m/e 327 (M+H).sup.+;
[1045] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.69 (d, 1H), 8.61
(m, 1H), 8.24 (d, 0.35H), 8.19 (dd, 0.65H), 7.75 (dd, 0.35H), 7.71
(dd, 0.65H), 4.44 (d, 0.35), 4.38 (d, 0.65), 3.81 (m, 2H), 3.73 (m,
1H), 2.67 (t, 2H), 2.57 (dd, 1.3H), 2.52 (dd, 0.7H), 2.10 (dd, 1H),
1.93 (dt, 1H), 1.25 (t, 1.95H), 1.20 (t, 1.05H).
EXAMPLE 288
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pyridinecarbo-
hydrazide
[1046] The desired product was prepared by substituting 4-pyridine
caboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1047] MS(ESI) m/e 313 (M+H).sup.+;
[1048] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.76 (m, 2H), 7.86
(m, 2H), 4.51 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t,
2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.17 (dd, 1H), 2.00 (dt,
1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 289
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(4-pyridinyl)-
acetohydrazide
[1049] The desired product was prepared by substituting
4-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1050] MS(ESI) m/e 327 (M+H).sup.+;
[1051] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.68 (t, 2H), 7.87
(d, 0.711), 7.83 (d, 1.3H), 4.45 (d, 0.35), 4.38 (d, 0.65), 3.73
(m, 1H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.52 (dd, 0.7H), 2.10 (dd,
1H), 1.93 (dt, 1H), 1.25 (t, 1.95H), 1.20 (t, 1.05H).
EXAMPLE 290
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-pyridazinecar-
bohydrazide
[1052] The desired product was prepared by substituting
3-pyridazine carboxylic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1053] MS(ESI) m/e 314 (M+H1)+;
[1054] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 9.37 (ddd, 1H),
8.31 (ddd, 1H), 7.92 (dd, 1H), 4.51 (d, 0.35), 4.47 (d, 0.65), 3.81
(m, 1H), 2.72 (t, 2H), 2.61 (dd, 2H), 2.18 (dd, 1H), 2.00 (dt, 1H),
1.28 (t, 1.95H), 1.26 (t, 1.05H).
EXAMPLE 291
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pynmidinecarb-
ohydrazide
[1055] The desired product was prepared by substituting
4-pyrimidine carboxylic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1056] MS(ESI) m/e 314 (M+H).sup.+;
[1057] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.9.31 (d, 0.65H),
9.30 (d, 0.35H), 9.07 (d, 0.65H), 9.06 (0.35H), 8.11 (dd, 0.65H),
8.09 (dd, 0.35H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H),
2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t,
1.95H), 1.26 (t, 1.05H).
EXAMPLE 292
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyrazinecarbo-
hydrazide
[1058] The desired product was prepared by substituting 2-pyrazine
carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1059] MS(ESI) m/e 314 (M+H).sup.+;
[1060] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.9.25 (d, 0.65H),
9.24 (d, 0.35H), 8.85 (d, 0.65H), 8.83 (0.35H), 8.72 (dd, 0.65H),
8.71 (dd, 0.35H), 4.50 (d, 0.35), 4.46 (d, 0.65), 3.80 (m, 1H),
2.71 (t, 2H), 2.60 (t, 2H), 2.18 (dd, 1H), 1.99 (dt, 1H), 1.28 (t,
1.95H), 1.26 (t, 1.05H).
EXAMPLE 293
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropylbenz-
ohydrazide
[1061] The desired product was prepared by substituting
4-(2-methylethyl)phenylbenzoic acid for 3-(ethylsulfanyl)benzoic
acid in Example 239B.
[1062] MS(ESI) m/e 355 (M+H).sup.+;
[1063] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.82 (m, 2H), 7.37
(m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t,
2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.24-1.29 (m,
10H)
EXAMPLE 294
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-propoxybenzoh-
ydrazide
[1064] The desired product was prepared by substituting
4-propoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1065] MS(ESI) m/e 370 (M+H).sup.+;
[1066] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.86 (m, 2H), 7.01
(m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 4.01 (dt, 2H), 3.77 (m,
1H), 2.71 (t, 2H), 2.60 (dd, 211), 2.16 (dd, 1H), 1.99 (dt, 1H),
1.82 (ddd, 2H), 1.28 (t, 1.95H), 1.25 (t, 1.05H) 1.05 (t, 3H).
EXAMPLE 295
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(methylsulfan-
yl)benzohydrazide
[1067] The desired product was prepared by substituting
4-methylsulfanylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1068] MS(ESI) m/e 358 (M+H).sup.+;
[1069] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 2H),
7.35(m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.53 (s, 3H), 2.16 (dd, 1H), 1.99 (dt, 1H),
1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 296
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropoxyben-
zohydrazide
[1070] The desired product was prepared by substituting
4-(2-methylethoxy)benzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1071] MS(ESI) m/e 370 (M+H).sup.+;
[1072] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.84 (m, 2H), 6.99
(m, 2H), 4.71 (ddd, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, o 1H),
1.34 (d, 6H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 297
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(diethylamino-
)benzohydrazide
[1073] The desired product was prepared by substituting
4-(diethylamino)benzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1074] MS(ESI) m/e 383 (M+H).sup.+;
[1075] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.76 (dd, 2H),
6.73 (m, 2H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 3.46
(q, 4H), 2.70 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H),
1.28 (t, 1.95H), 1.26 (t, 1.05H), 1.19 (t, 6H).
EXAMPLE 298
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-butoxybenzohy-
drazide
[1076] The desired product was prepared by substituting
4-butoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1077] MS(ESI) m/e 384 (M+H).sup.+;
[1078] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.85 (m, 2H), 6.99
(m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 4.06 (dt, 2H), 3.77 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H),
1.78 (ddd, 2H), 1.53 (ddd, 2H), 1.28 (t, 1.95H), 1.26 (t, 1.05H),
0.99 (t, 3H).
EXAMPLE 299
N'-((2RS,3R)-3-arnino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-diethoxybe-
nzohydrazide
[1079] The desired product was prepared by substituting
2,3-diethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1080] MS(ESI) rn/e 400 (M+H).sup.+;
[1081] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.52 (dd, 1H),
7.48 (d, 1H), 7.03 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 4.13
(m, 4H), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H),
2.00 (dt, 1H), 1.43 (m, 6H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 300
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-chlorobenzohy-
drazide
[1082] The desired product was prepared by substituting
4-chlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1083] MS(ESI) m/e 346 (M+H).sup.+;
[1084] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (dd, 2H),
7.52 (dd, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71
(t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t,
1.95H), 1.25 (t, 1.05H).
EXAMPLE 301
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-bromobenzohyd-
razide
[1085] The desired product was prepared by substituting
2-bromobenzoic acid for 3(ethylsulfanyl)benzoic acid in Example
239B.
[1086] MS(ESI) m/e 391 (M+H).sup.+;
[1087] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.69 (dd, 1H),
7.59 (ddd, 1H), 7.47 (m, 1H), 7.41 (m, 1H), 4.48 (d, 0.35), 4.43
(d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd,
1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
EXAMPLE 302
(2RS,3R)-3-amino-N'-((2RS,3S)-3-amino-2-hvdroxy-5-(isopropylsulfanYl)penta-
noyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide
[1088] The title compound is obtained by substituting hydrazine
hydrate for O-phenylhydroxylamine hydrochloride and Example 123B
for Example 98A in Example 98B.
[1089] MS(ESI) m/e 409 (M-H)+.
[1090] .sup.1H NMR (300 MHz, DMSO-d6) .delta.10.94 (br s, 1H),
10.11 & 9.93 (s, 1H), 8.2 & 8.02 (m, 4H), 6.8 & 6.65(br
s, 2H), 4.44 & 4.28 (m, 1H), 4.2 (m, 1H), 3.0-2.9 (m, 2H),
2.75-2.55 (m, 4H), 1.95-1.75 (m, 4H), 1.2 (d, 12H).
EXAMPLE 304
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(dimethylamin-
o)benzohydrazide
[1091] The desired product was prepared by substituting
3-dimethylaminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1092] MS(ESI) m/e 355 (M+H).sup.+;
[1093] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.32 (dd, 1H),
7.28 (m, 1H), 7.21 (d, 1H), 7.01 (dd, 1H), 4.48 (d, 0.35), 4.44 (d,
0.65), 3.79 (m, 1H), 3.00 (s, 6H), 2.71 (t, 2H), 2.61 (dd, 2H),
2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
EXAMPLE 305
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(dimethylamin-
o)benzohydrazide
[1094] The desired product was prepared by substituting
4-dimethylaminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1095] MS(ESI) m/e 355 (M+H).sup.+;
[1096] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.78 (dd, 2H),
6.75 (d, 2H), 4.46 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 3.04
(s, 6H), 2.70 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H),
1.28 (t, 1.95H), 1.26 (t, 1.05H).
EXAMPLE 306
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluoromet-
hyl)benzohydrazide
[1097] The desired product was prepared by substituting
3-(trifluoromethyl)benzoic acid for 3-(ethylsulfanyl)benzoic acid
in Example 239B.
[1098] MS(ESI) m/e 380 (M+H).sup.+;
[1099] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.21 (d, 1H), 8.14
(t, 1H), 7.92 (t, 1H), 7.73 (dd, 1H), 4.50 (d, 0.35), 4.46 (d,
0.65), 3.79 (m, 1H), 2.72 (t, 2H), 2.61 (dd, 2H), 2.18 (dd, 1H),
2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
EXAMPLE 307
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(trifluoromet-
hyl)benzohydrazide
[1100] The desired product was prepared by substituting
4-(trifluoromethyl)benzoic acid for 3-(ethylsulfanyl)benzoic acid
in Example 239B.
[1101] MS(ESI) mle 380 (M+H).sup.+;
[1102] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.05 (dd, 2H),
7.82 (dd, 2H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71
(t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t,
1.95H), 1.25 (t, 1.05H)
EXAMPLE 308
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluoromet-
hoxy)benzohydrazide
[1103] The desired product was prepared by substituting
3-(trifluoromethoxy)benzoic acid for 3-(ethylsulfanyl)benzoic acid
in Example 239B.
[1104] MS(ESI) m/e 396 (M+H).sup.+;
[1105] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.89 (dd, 1H),
7.80 (d, 1H), 7.62 (dd, 1H), 7.53 (dd, 1H), 4.50 (d, 0.35), 4.45
(d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd,
1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 309
N'-((2RS.3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-phenoxybenzoh-
ydrazide
[1106] The desired product was prepared by substituting
4-phenoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1107] MS(ESI) m/e 404 (M+H).sup.+;
[1108] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.89 (m, 2H), 7.42
(m, 2H), 7.22 (m, 1H), 7.08 (m, 2H), 7.04 (m, 2H), 4.48 (d, 0.35),
4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16
(dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.26 (t, 1.05H).
EXAMPLE 310
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(phenoxymethy-
l)benzohydrazide
[1109] The desired product was prepared by substituting
4-(phenoxymethyl)benzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1110] MS(ESI) m/e 418 (M+H).sup.+;
[1111] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 2H), 7.44
(d, 2H), 7.38 (t, 2H), 7.32 (t, 1H), 7.11 (m, 2H), 5.17 (s, 2H),
4.48 (d, 0.35), 4.44 (d, 0.65), 3.77 (m, 1H), 2.71 (t, 2H), 2.61
(dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t,
1.05H).
EXAMPLE 311
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dimethylben-
zohydrazide
[1112] The desired product was prepared by substituting
2,3-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1113] MS(ESI) m/e 340 (M+H).sup.+;
[1114] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.29 (m, 2H), 7.16
(m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65),3.80 (m, 1H), 2.71 (t, 2H),
2.61 (dd, 2H), 2.36 (s, 3H), 2.32 (s, 3H), 2.17 (dd, 1H), 1.99 (dt,
1H), 1.28 (t, 1.95H), 1.24 (t, 1.05H).
EXAMPLE 312
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dimethylben-
zohydrazide
[1115] The desired product was prepared by substituting
2,4-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1116] MS(ESI) m/e 340 (M+H).sup.+;
[1117] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.40 (m, 1H), 7.12
(d, 1H), 7.08 (dd, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.43 (s, 3H), 2.34 (s, 3H), 2.16
(dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
EXAMPLE 313
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2.5-dimethylben-
zohydrazide
[1118] The desired product was prepared by substituting
2,5-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1119] MS(ESI) m/e 340 (M+H).sup.+;
[1120] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (m, 1H), 7.21
(dd, 1H), 7.17 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 2.16
(dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
EXAMPLE 314
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4,5-dimethylben-
zohydrazide
[1121] The desired product was prepared by substituting
3,4-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1122] MS(ESI) m/e 340 (M+H).sup.+;
[1123] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.68 (d, 1H), 7.61
(dd, 1H), 7.25 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.33 (s, 6H), 2.16 (dd, 1H), 2.00
(dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 315
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dimethylben-
zohydrazide
[1124] The desired product was prepared by substituting
3,5-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1125] MS(ESI) m/e 340 (M+H).sup.+;
[1126] .sup.1H NMR (500 MHz, CD30D) .delta.7.50 (d, 2H), 7.25 (d,
1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H),
2.61 (dd, 2H), 2.37 (s, 6H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.28 (t,
1.95H), 1.26 (t, 1.05H).
EXAMPLE 316
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dimethoxybe-
nzohydrazide
[1127] The desired product was prepared by substituting
2,3-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1128] MS(ESI) m/e 372 (M+H).sup.+;
[1129] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.42 (dd, 0.65H),
7.40 (dd, 0.35H), 7.24 (ddd, 1H), 7.19 (m, 1H), 4.48 (d, 0.35),
4.44 (d, 0.65), 3.95 (s, 1.95H), 3.94 (s, 1.05H), 3.91 (s, 1.95H),
3.90 (s, 1.05H), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16
(dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 317
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dimethoxybe-
nzohydrazide
[1130] The desired product was prepared by substituting
2,4-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1131] MS(ESI) m/e 372 (M+H).sup.+;
[1132] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.98 (m, 1H), 6.68
(m, 2H), 4.47 (d, 0.35), 4.44 (d, 0.65), 4.00 (s, 1.95H), 3.99 (s,
1.05H), 3.88 (s, 3H), 3.78 (m, 1H), 2.70 (t, 2H), 2.61 (dd, 2H),
2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 318
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dimethoxybe-
nzohydrazide
[1133] The desired product was prepared by substituting
2,5-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1134] MS(ESI) m/e 372 (M+H).sup.+;
[1135] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.54 (dd, 0.65H),
7.53 (dd, 0.35H), 7.14 (m, 2H), 4.48 (d, 0.35), 4.45 (d, 0.65),
3.96 (s, 1.95H), 3.95 (s, 1.05H), 3.79 (s, 3H), 3.78 (m, 1H), 2.71
(t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t,
1.95H), 1.25 (t, 1.05H).
EXAMPLE 319
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-dimethoxybe-
nzohydrazide
[1136] The desired product was prepared by substituting
3,4-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1137] MS(ESI) m/e 372 (M+H).sup.+;
[1138] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.55 (ddd, 1H),
7.49 (dd, 1H), 7.05 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.90
(s, 1.95H), 3.89 (s, 1.05H), 3.88 (s, 3H), 3.78 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H),
1.26 (t, 1.05H).
EXAMPLE 320
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dimethoxybe-
nzohydrazide
[1139] The desired product was prepared by substituting
3,5-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1140] MS(ESI) m/e 372 (M+H).sup.+;
[1141] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.04 (m, 2H), 6.71
(dd, 0.65H), 6.99 (dd, 0.35H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.83
(s, 6H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H),
1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 321
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-benzodioxol-
e-5-carbohydrazide
[1142] The desired product was prepared by substituting
1,3-benzodioxole carboxylic acid for 3-(ethylsulfanyl)benzoic acid
in Example 239B.
[1143] MS(ESI) mle 356 (M+H).sup.+;
[1144] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.49 (m, 1H), 7.35
(d, 0.65H), 7.34 (d, 0.35H), 6.92 (m, 1H), 6.06 (s, 1.3H), 6.05 (s,
0.7H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.70 (t, 2H),
2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25
(t, 1.05H).
EXAMPLE 322
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4,5-trimethox-
ybenzohydrazide
[1145] The desired product was prepared by substituting
3,4,5-trimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1146] MS(ESI) m/e 402 (M+H).sup.+;
[1147] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.25 (s, 1.3H),
7.24 (s, 0.7H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.89 (s, 6H), 3.83
(s, 1.95H), 3.82 (s, 1.05H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd,
2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t,
1.05H).
EXAMPLE 323
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dichloroben-
zohydrazide
[1148] The desired product was prepared by substituting
2,3-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1149] MS(ESI) m/e 381 (M+H).sup.+;
[1150] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.68 (ddd, 1H),
7.54 (m, 1H), 7.41 m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.80 (m,
1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H),
1.27 (t, 1.95H), 1.24 (t, 1.05H).
EXAMPLE 324
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dichloroben-
zohydrazide
[1151] The desired product was prepared by substituting
2,4-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1152] MS(ESI) m/e 381 (M+H).sup.+;
[1153] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.60 (m, 2H), 7.46
(m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t,
2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H),
1.24 (t, 1.05H).
EXAMPLE 325
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dichloroben-
zohydrazide
[1154] The desired product was prepared by substituting
2,5-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1155] MS(ESI) m/e 381 (M+H).sup.+;
[1156] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.65 (m, 1H), 7.52
(m, 2H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t,
2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H),
1.24 (t, 1.05H).
EXAMPLE 326
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-dichloroben-
zohydrazide
[1157] The desired product was prepared by substituting
3,4-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1158] MS(ESI) m/e 381 (M+H).sup.+;
[1159] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.05 (d, 0.65H),
8.04 (d, 0.35H), 7.80 (m, 1H), 7.68 (m, 1H), 4.49 (d, 0.35), 4.44
(d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd,
1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 327
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dichloroben-
zohydrazide
[1160] The desired product was prepared by substituting
3,5-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in
Example 239B.
[1161] MS(ESI) m/e 381 (M+H).sup.+;
[1162] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.85 (d, 1.3H),
7.83 (d, 0.7H), 7.72 (t, 0.65H), 7.70 (t, 0.35H), 4.49 (d, 0.35),
4.44 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16
(dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 328
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanovl)-2-hydroxybenzohydrazi-
de
[1163] The desired compound was prepared by substituting salicylic
acid for o-toluic acid in Example 329B.
[1164] MS(ESI) mle 336 (M+H).sup.+;
[1165] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 1H), 7.44
(m, 1H), 6.95 (m, 2H), 4.45 (d, 0.3H), 4.38 (d, 0.7H), 3.69 (m,
1H), 1.76 (m, 6H), 1.58 (m, 1H), 1.47 (m, 1H), 1.32 (m, 1H), 1.24
(m, 1H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
EXAMPLE 329
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methylbenzohydrazid-
e
EXAMPLE 329A
N'-((2RS,3R)-3-(tert-butoxycarbonyl)amino-4-cyclohexyl-2-hydroxybutanoyl)h-
ydrazide
[1166] The desired compound was prepared by substituting Example 1C
for Example 97A acid in Example 239A.
EXAMPLE 329B
N'-
((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methylbenzohydrazi-
de
[1167] To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of
dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt
(0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL
of a 0.3M solution of o-toluic acid (0.15 mmol) in
dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of
Example 329A (0.225 mmol) in dimethylacetamide/dichloromethane
(1:1) was added. The mixture was agitated for 18 hours and quenched
with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of
isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture
was filtered and the resins washed with 1.times.3 mL of
dichloromethane, the solvent was removed in vacuo, and the crude
material purified by reverse phase preparative HPLC. The resulting
material was treated with 1 mL of 50% trifluoroacetic
acid/dichloromethane and agitated at ambient temperature for 18
hours. The solvent was removed in vacuo to give the desired
product.
[1168] MS(ESI) m/e 334 (M+H).sup.+;
[1169] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.50 (m, 1H), 7.39
(ddd, 1H), 7.28 (m, 2H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.71 (mn,
0.7H), 3.67 (m 0.3H), 2.46 (s, 3H), 1.73 (m, 6H), 1.56 (m, 1H),
1.47 (m, 1H), 1.28 (m, 3H), 1.02 (m, 1.4H), 0.93 (m, 0.6H).
EXAMPLE 330
2-amino-N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide
[1170] The desired compound was prepared by substituting
o-aminobenzoic acid for o-toluic acid in Example 329B.
[1171] MS(ESI) m/e 335 (M+H).sup.+;
[1172] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.57 (m, 1H), 7.25
(m, 1H), 6.80 (m, 1H), 6.67 (m, 1H), 4.44 (d, 0.3H), 4.36 (d,
0.7H), 3.69 (m, 0.7H), 3.65 (m 0.3H), 1.76 (m, 6H), 1.57 (m, 1H),
1.47 (m, 1H), 1.37-1.20 (m, 3H), 1.03 (m, 1.4H), 0.93 (m,
0.6H).
EXAMPLE 331
4-amino-N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide
[1173] The desired compound was prepared by substituting
p-aminobenzoic acid for o-toluic acid in Example 329B.
[1174] MS(ESI) m/e 335 (M+H).sup.+;
[1175] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.67 (m, 2H), 6.69
(m, 2H), 4.42 (d, 0.4H), 4.35 (d, 0.6H), 3.69-3.62 (m, 1H),
1.85-1.61 (m, 6H), 1.56 (m, 1H), 1.46 (m, 1H), 1.37-1.20 (m, 3H),
1.03 (m, 1.2H), 0.91 (m, 0.8H).
EXAMPLE 332
3-amino-N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide
[1176] The desired compound was prepared by substituting
m-amninobenzoic acid for o-toluic acid in Example 329B.
[1177] MS(ESI) m/e 335 (M+H).sup.+;
[1178] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.36 (m, 3H), 7.09
(m, 1H), 4.45 (d, 0.25H), 4.36 (d, 0.75H), 3.69 (m, 1H), 1.85-1.64
(m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.22 (m, 1H),
1.02 (m, 1.5 H), 0.92 (m, 0.5H).
EXAMPLE 333
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hydroxybenzohydrazi-
de
[1179] The desired compound was prepared by substituting
3-hydroxybenzoic acid for o-toluic acid in Example 329B.
[1180] MS(ESI) m/e 336 (M+H).sup.+;
[1181] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.31 (m, 3H), 7.01
(m, 1H), 6.80 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.69 (m,
0.7H), 3.65 (m 0.3H), 1.85-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m,
1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.4H), 0.93 (m,
0.6H).
EXAMPLE 334
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-hydroxybenzohydrazi-
de
[1182] The desired compound was prepared by substituting
4-hydroxybenzoic acid for o-toluic acid in Example 329B.
[1183] MS(ESI) m/e 336 (M+H).sup.+;
[1184] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.78 (m, 2H), 6.85
(m, 2H), 4.43 (d, 0.3H), 4.36 (d, 0.7H), 3.71-3.62 (m, 1H), 1.75
(m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.38-1.20 (m, 3H), 1.03 (m,
1.4H), 0.92 (m, 0.6H).
EXAMPLE 335
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methoxybenzohydrazi-
de
[1185] The desired compound was prepared by substituting p-anisic
acid for o-toluic acid in Example 329B.
[1186] MS(ESI) m/e 350 (M+H).sup.+;
[1187] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 2H), 7.02
(m, 2H), 6.80 (m, 1H), 6.67 (m, 1H), 4.44 (d, 0.3H), 4.36 (d,
0.7H), 3.70-3.64 (m, 1H), 1.84-1.62 (m, 6H), 1.57 (m, 1H), 1.47 (m,
1H), 1.39-1.20 (m, 3H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
EXAMPLE 336
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-fluorobenzohydrazid-
e
[1188] The desired compound was prepared by substituting
2-fluorobenzoic acid for o-toluic acid in Example 329B.
[1189] MS(ESI) m/e 338 (M+H).sup.+;
[1190] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 1H), 7.61
(m, 1H), 7.34-7.23 (m, 2H), 4.44 (d, 0.3H), 4.37 (d, 0.7H), 3.69
(m, 1H), 1.75 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.38-1.20 (m,
3H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
EXAMPLE 337
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-fluorobenzohydrazid-
e
[1191] The desired compound was prepared by substituting
3-fluorobenzoic acid for o-toluic acid in Example 329B.
[1192] MS(ESI) m/e 338 (M+H).sup.+;
[1193] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.72 (m, 1H), 7.63
(m, 1H), 6.53 (m, 1H), 7.35 (m, 1H), 4.45 (d, 0.25H), 4.37 (d,
0.75H), 3.68 (m, 1H), 1.83-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m,
1H), 1.33 (m, 2H), 1.24 (m, IH), 1.02 (m, 1.5H), 0.92 (m,
0.5H).
EXAMPLE 338
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-fluorobenzohydrazid-
e
[1194] The desired compound was prepared by substituting
4-fluorobenzoic acid for o-toluic acid in Example 329B.
[1195] MS(ESI) m/e 338 (M+H).sup.+;
[1196] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.95 (m, 2H), 7.24
(m, 2H), 6.53 (m, 1H), 7.35 (m, 1H), 4.45 (d, 0.3H), 4.37 (d,
0.7H), 3.68 (m, 1H), 1.85-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H),
1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 339
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-bromobenzohydrazide
[1197] The desired compound was prepared by substituting
2-bromobenzoic acid for o-toluic acid in Example 329B.
[1198] MS(ESI) m/e 399 (M+H).sup.+;
[1199] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.72 (m, 1H), 7.69
(m, 1H), 7.46 (m, 1H), 7.41 (m, 1H), 4.44 (d, 0.3H), 4.36 (d,
0.7H), 3.68 (m, 1H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H),
1.38-1.18 (m, 3H), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 340
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-cyanobenzohydrazide
[1200] The desired compound was prepared by substituting
3-cyanobenzoic acid for o-toluic acid in Example 329B.
[1201] MS(ESI) m/e 345 (M+H).sup.+;
[1202] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.23 (m, 1H), 8.17
(m, 1H), 7.96 (m, 1H), 7.71 (m, 1H), 4.46 (d, 0.3H), 4.38 (d,
0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.58 (m, 1H), 1.47 (m, 1H),
1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.5H), 0.92 (m, 0.5H).
EXAMPLE 341
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-cyanobenzohydrazide
[1203] The desired compound was prepared by substituting
4-cyanobenzoic acid for o-toluic acid in Example 329B.
[1204] MS(ESI) m/e 345 (M+H).sup.+;
[1205] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.02 (m, 2H), 7.88
(m, 2H), 4.46 (d, 0.3H), 4.37 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65
(m, 6H), 1.56 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.24 (m, 111),
1.03 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 342
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(dimethylamino)benz-
ohydrazide
[1206] The desired compound was prepared by substituting
3-dimethylaminobenzoic acid for o-toluic acid in Example 329B.
[1207] MS(ESI) m/e 363 (M+H).sup.+;
[1208] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.32 (t, 1H), 7.28
(m, 1H), 7.21 (m, 1H), 7.01 (dd, 1H), 4.44 (d, 0.3H), 4.37 (d,
0.7H), 3.68 (m, 1H), 3.01-3.00 (2S, 6H), 1.85-1.65 (m, 6H), 1.57
(m, 1H), 1.47 (m, 1H), 1.32 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.4H),
0.92 (m, 0.6H).
EXAMPLE 343
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(dimethylamino)benz-
ohydrazide
[1209] The desired compound was prepared by substituting
4-dimethylaminobenzoic acid for o-toluic acid in Example 329B.
[1210] MS(ESI) m/e 363 (M+H).sup.+; 1H NMR (500 MHz, CD.sub.3OD)
.delta. 7.78 (d, 2H), 7.65 (d, 2H), 6.53 (m, 1H), 4.42 (d, 0.3H),
4.35 (d, 0.7H), 3.68 (m, 1H), 3.04 (2S, 6H), 1.85-1.63 (m, 6H),
1.57 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m,
1.4H), 0.92 (m, 0.6H).
EXAMPLE 344
N'-((2RS,3R)-3-amino-4-cyclohexvl-2-hydroxybutanoyl)-3-(trifluoromethyl)be-
nzohydrazide
[1211] The desired compound was prepared by substituting
3-(trifluoromethyl)benzoic acid for o-toluic acid in Example
329B.
[1212] MS(ESI) m/e 388 (M+H).sup.+;
[1213] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.21 (s, 1H), 8.14
(m, 1H), 7.93 (m, 1H), 7.73 (m, 1H), 4.45 (d, 0.3H), 4.38 (d,
0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H),
1.33 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 345
N'-((2RS.3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(trifluoromethyl)be-
nzohydrazide
[1214] The desired compound was prepared by substituting
4-(trifluoromethyl)benzoic acid for o-toluic acid in Example
329B.
[1215] MS(ESI) m/e 388 (M+H).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. 8.06 (m, 2H), 7.82 (m, 2H), 4.46 (d, 0.3H),
4.38 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47
(m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m,
0.6H).
EXAMPLE 346
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(trifluoromethoxy)b-
enzohydrazide
[1216] The desired compound was prepared by substituting
3-(trifluoromethoxy)benzoic acid for o-toluic acid in Example
329B.
[1217] MS(ESI) m/e 404 (M+H).sup.+;
[1218] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.89 (m, 1H), 7.80
(s, 1H), 7,62 (m, 1H), 7.53 (m, 1H), 4.46 (d, 0.3H), 4.38 (d,
0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H),
1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 347
N'-((2RS
3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-phenoxybenzohydrazi-
de
[1219] The desired compound was prepared by substituting
4-phenoxybenzoic acid for o-toluic acid in Example 329B.
[1220] MS(ESI) m/e 412 (M+H).sup.+;
[1221] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.89 (m, 2H), 7.42
(m, 2H), 7.21 (m, 1H), 7.07 (m, 2H), 7.03 (m, 2H), 4.44 (d, 0.3H),
4.37 (d, 0.7H), 3.69 (m, 1H), 1.85-1.64 (m, 6H), 1.56 (m, 1H), 1.46
(m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m,
0.6H).
EXAMPLE 348
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dimethylbenzohydr-
azide
[1222] The desired compound was prepared by substituting 2,
4-dimethylbenzoic acid for o-toluic acid in Example 329B.
[1223] MS(ESI) m/e 348 (M+H).sup.+;
[1224] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.41 (dd, 1H),
7.12 (s, 1H), 7.09 (m, 1H), 4.43 (d, 0.25H), 4.36 (d, 0.75H), 3.70
(m, 0.75H), 3.66 (m, 0.25H), 2.43 (s, 3H), 2.34 (s, 3H), 1.85-1.65
(m, 6H), 1.57 (m, 1H), 1.46 (m, 1H), 1.32 (m, 2H), 1.24 (m, 1H),
1.02 (m, 1.5H), 0.92 (m, 0.5H).
EXAMPLE 349
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dimethylbenzohydr-
azide
[1225] The desired compound was prepared by substituting 2,
5-dimethylbenzoic acid for o-toluic acid in Example 329B.
[1226] MS(ESI) m/e 348 (M+H).sup.+;
[1227] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.33 (s, 1H), 7.21
(m, 1H), 7.17 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.70 (m,
0.7H), 3.66 (m, 0.3H), 2.41 (s, 3H), 2.34 (s, 3H), 1.85-1.65 (m,
6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02
(m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 350
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3
,4-dimethylbenzohydrazide
[1228] The desired compound was prepared by substituting
3,4-dimethylbenzoic acid for o-toluic acid in Example 329B.
[1229] MS(ESI) m/e 348 (M+H).sup.+;
[1230] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.66 (s, 1H), 7.62
(dd, 1H), 7.26 (dd, 1H), 4.44 (d, 0.3B), 4.36 (d, 0.7H), 3.68 (m,
1H), 2.07 (s, 6H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H),
1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 351
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethylbenzohydr-
azide
[1231] The desired compound was prepared by substituting
3,5-dimethylbenzoic acid for o-toluic acid in Example 329B.
[1232] MS(ESI) m/e 348 (M+H).sup.+;
[1233] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.50 (s, 2H), 7.26
(s, 0.75H), 7.24 (s, 0.25H), 4.44 (d, 0.25H), 4.36 (d, 0.75H), 3.68
(m, 1H), 2.37 (s, 6H), 1.85-1.65 (m, 6H), 1.55 (m, 1H), 1.47 (m,
1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.5H), 0.92 (m,
0.5H).
EXAMPLE 352
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethoxybenzohyd-
razide
[1234] The desired compound was prepared by substituting 2,
3-dimethoxybenzoic acid for o-toluic acid in Example 329B.
[1235] MS(ESI) m/e 380 (M+H).sup.+;
[1236] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.41 (m, 1H), 7.24
(td, 2H), 7.19 (td, 1H), 4.43 (d, 0.3H), 4.37 (d, 0.7H), 3.95 (s,
2.1H), 3.95 (s, 0.9H), 3.91 (s, 2.1H), 3.90 (s, 0.9H), 3.69 (m,
1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H),
1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 353
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4-dimethoxybenzohyd-
razide
[1237] The desired compound was prepared by substituting
3,4-dimethoxybenzoic acid for o-toluic acid in Example 329B.
[1238] MS(ESI) m/e 380 (M+H).sup.+;
[1239] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.55 (m, 1H), 7.50
(d, 1H), 7.05 (dd, 1H), 4.44 (d, 0.3H), 4.37 (d, 0.7H), 3.90 (s,
3H), 3.88 (s, 3H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H),
1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m,
0.6H).
EXAMPLE 354
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4,5-trimethoxybenzo-
hydrazide
[1240] The desired compound was prepared by substituting
3,4,5-trimethoxybenzoic acid for o-toluic acid in Example 329B.
[1241] MS(ESI) m/e 410 (M+H).sup.+;
[1242] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.25 (s, 2H), 4.46
(d, 0.3H), 4.37 (d, 0.7H), 3.89 (s, 6H), 3.83 (s, 3H), 3.69 (m,
1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H),
1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 355
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dichlorobenzohydr-
azide
[1243] The desired compound was prepared by substituting 2,
3-dichlorobenzoic acid for o-toluic acid in Example 329B.
[1244] MS(ESI) m/e 389 (M+H).sup.+;
[1245] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.68 (td, 1H),
7.54 (dt, 1H), 6.42 (td, 111), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.69
(m, 1H), 1.85-1.65 (m, 6H), 1.55 (m, 1H), 1.47 (m, 1H), 1.33 (m,
2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 356
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dichlorobenzohydr-
azide
[1246] The desired compound was prepared by substituting 2,
4-dichlorobenzoic acid for o-toluic acid in Example 329B.
[1247] MS(ESI) m/e 389 (M+H).sup.+;
[1248] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.60 (m, 2H), 7.46
(m, 1H), 4.44 (d, 0.311), 4.35 (d, 0.7H), 3.68 (m, 1H), 1.85-1.65
(m, 6H), 1.55 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.23 (m, 1H),
1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 357
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4-dichlorobenzohydr-
azide
[1249] The desired compound was prepared by substituting
3,4-dichlorobenzoic acid for o-toluic acid in Example 329B.
[1250] MS(ESI) m/e 389 (M+H).sup.+;
[1251] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.05 (m, 1H), 7.80
(m, 1H), 7.68 (m, 1H), 4.45 (d, 0.3H), 4.37 (d, 0.7H), 3.67 (m,
1H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H),
1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 358
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dichlorobenzohydr-
azide
[1252] The desired compound was prepared by substituting
3,5-dichlorobenzoic acid for o-toluic acid in Example 329B.
[1253] MS(ESI) m/e 389 (M+H).sup.+;
[1254] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.97-7.69 (m, 3H),
4.45 (d, 0.3H), 4.37 (d, 0.7H), 3.68 (m, 1H), 1.85-1.65 (m, 6H),
1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m,
1.4H), 0.92 (m, 0.6H).
EXAMPLE 359
N'-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethylbenzohydr-
azide
[1255] The desired compound was prepared by substituting 2,
3-dimethylbenzoic acid for o-toluic acid in Example 329B.
[1256] MS(ESI) m/e 348 (M+H).sup.+;
[1257] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.29 (m, 2H), 7.16
(m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.68 (m, 1H), 1.85-1.64
(m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H),
1.02 (m, 1.4H), 0.92 (m, 0.6H).
EXAMPLE 360
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzenesulfonohy-
drazide
[1258] The desired product was prepared by substituting
benzenesulfonylhydrazine for O-phenyl hydroxylamine hydrochloride
in Example 98B.
[1259] MS(ESI) m/e 348 (M+H).sup.+;
[1260] .sup.1H NMR (300 M1z, DMSO-d.sub.6) .delta. 7.38 (m, 5H),
6.68 (d, 0.6H), 6.62 (d, 0.4H), 4.30 (m, 0.4H), 4.14 (m, 0.6H),
3.87 (m, 1H), 2.60 (m, 2H), 2.45 (m, 2H), 1.64 (m, 1H), 1.36 (m,
1H), 1.16 (t, 3H).
EXAMPLE 361
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxvpentanoyl)-3-chlorobenzene-
sulfonohydrazide
[1261] The desired product was prepared by substituting
3-chlorophenylsulfonylhydrazine for O-phenyl hydroxylamine
hydrochloride in
EXAMPLE 362
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthalenesu-
lfonohydrazide
[1262] The desired product was prepared by substituting
1-naphthylsulfonylhydrazine for O-phenyl hydroxylamine
hydrochloride in Example 98B.
[1263] MS(ESI) m/e 398 (M+H).sup.+;
[1264] .sup.1H NMR (300 MHz, DMSO-d6) .delta.10.25 (m, 1H), 10.14
(m, 1H), 8.70 (br s, 2H), 8.27 (m, 1H), 8.17 (m, 1H), 8.13 (m, 1H),
7.68 (m, 4H), 6.68 (d, 0.6H), 6.62 (d, 0.4H), 4.30 (m, 0.4H), 4.14
(m, 0.6H), 3.87 (m, 1H), 2.60 (m, 2H), 2.45 (m, 2H), 1.64 (m, 1H),
1.36 (m, 1H), 1.16 (t, 3H).
EXAMPLE 363
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzene-
sulfonohydrazide
[1265] The desired product was prepared by substituting
4-methylphenylsulfonylhydrazine for O-phenyl hydroxylamine
hydrochloride in
EXAMPLE 364
(2RS,3R)-3-amino-N'-(3-(2-aminoethoxy)phenyl)-2-hydroxy-5-(isopropylsulfan-
vl)pentanohydrazide
EXAMPLE 364A
N-(tert-butoxycarbonyl)-2-bromoethylamine
[1266] A solution of 2-bromoethylamine hydrobromide (1.0 g, 4.9
mmol), di-tert-butyl dicarbonate (1.06 g, 4.9 mmol) and
triethylamine (0.7 mL, 4.9 mmol) in dichloromethane (40 mL) was
stirred at room temperature for 18h. The reaction mixture was
diluted with ether, washed with brine, dried (Na.sub.2SO.sub.4),
and concentrated to give the title compound.
EXAMPLE 364B
3-(2-(tertbutoxycarbonylamino)ethoxy)benzoyl hydrazide
[1267] Example 364A, methyl-3-hydroxy-benzoate (1.09 g, 4.9 mmol)
and potassium tert-butoxide (6.5 g, 5.8 mmol) in DMSO were stirred
at room temperature for 16 hours. The reaction was poured into ice
water and extracted with ether, washed with brine, dried over
Na2SO4, evaporated, and treated with hydrazine hydrate in ethanol
at reflux for 48h. The reaction mixture was evaporated to dryness
to give the title compound.
EXAMPLE 364C
(2RS,3R)-3-amino-N'-(3-(2-aminoethoxy)phenyl)-2-hydroxy-5-(isopropylsulfan-
yl)pentanohydrazide
[1268] The desired product was prepared by substituting Example
364A for O-phenyl hydroxylamine hydrochloride and Example 123B for
Example 98A in Example 98B.
[1269] MS(ESI) m/e 383 (M-H)+.
[1270] .sup.1H NMR (300 MHz, DMSO-d6) .delta.10.6 & 10.42 (s,
1H), 10.25 & 10.12 (s, 1H), 8.15 & 8.04 (br s, 2H),
7.56-7.33 (m, 3H), 7.2 (m, 1H), 6.67 & 6.59 (br s, 1H), 4.45
& 4.24 (m, 3H), 3.25 (m, 2H), 3.0-2.9 (m, 1H), 2.75-2.55 (m,
2H), 2.0-1.80 (m, 2H), 1.2 (m,6H).
EXAMPLE 365
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-bromobenzohyd-
razide
[1271] The desired product was prepared by substituting
3-bromobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1272] MS(ESI) m/e 391 (M+H).sup.+;
[1273] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (ddd, 1H),
7.85 (ddd, 1H), 7.77 (ddd, 1H), 7.44 (m, 1H), 4.49 (d, 0.35), 4.44
(d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd,
1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 366
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-cyanobenzohyd-
razide
[1274] The desired product was prepared by substituting
2-cyanobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1275] MS(ESI) m/e 337 (M+H).sup.+;
[1276] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.23 (ddd, 1H),
8.16 (ddd, 1H), 7.96 (ddd, 1H), 7.71 (m, 1H), 4.50 (d, 0.35), 4.45
(d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd,
1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
EXAMPLE 367
N'-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-cyanobenzohyd-
razide
[1277] The desired product was prepared by substituting
4-cyanobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example
239B.
[1278] MS(ESI) m/e 337 (M+H);
[1279] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.02 (m, 2H), 7.88
(m, 2H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t,
2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H),
1.25 (t, 1.05H).
EXAMPLE 368
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropvlsulfanvl)pentanoyl)-3-hydroxybe-
nzohydrazide
[1280] The title compound is obtained by substituting
3-hydroxybenzoyl hydrazide for O-phenylhydroxylamine hydrochloride
and Example 123B for Example 98A in Example 98B.
[1281] MS(ESI) m/e 340 (M-H)+.
[1282] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.10.44 & 10.26
(s, 1H), 10.17 & 10.06 (s, 1H), 9.78 & 9.74 (s, 1H), 8.05
& 8.7.97 (br s, 2H), 7.26 (m, 3H), 6.97 (m, 1H), 6.63 &
6.595(bd, 1H), 4.38 & 4.22 (m, 1H), 3.7 & 3.6 (m, 1H),
3.0-2.9 (m, 1H), 2.75-2.55 (m, 2H), 2.05-1.77 (m, 2H), 1.2 (m,
6H).
EXAMPLE 369
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methylben-
zohydrazide
EXAMPLE 369A
N'-((2RS,3R)-3-(tert-butoxycarbonyl)amino-5-(isopropylsulfanyl)-2-hydroxyp-
entanoyl)hydrazide
[1283] The desired compound was prepared by substituting Example
123B for Example 97A acid in Example 239A.
EXAMPLE 369B
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methylben-
zohydrazide
[1284] To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of
dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt
(0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL
of a 0.3M solution of o-toluic acid (0.15 mmol) in
dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of
Example 369A (0.225 mmol) in dimethylacetamide/dichloromethane
(1:1) was added. The mixture was agitated for 18 hours and quenched
with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of
isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture
was filtered and the resins washed with lx3 niL of dichioromethane,
the solvent was removed in vacuo, and the crude material purified
by reverse phase preparative HPLC. The resulting material was
treated with 1 mL of 50% trifluoroacetic acid/dichloromethane and
agitated at ambient temperature for 18 hours. The solvent was
removed in vacuo to give the desired product.
[1285] MS(ESI) m/e 340 (M+H).sup.+;
[1286] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.50 (m, 1H), 7.40
(ddd, 1H), 7.28 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.79 (m,
1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.47 (2s, 3H), 2.16 (m, 1H), 1.98
(m, 1H), 1.29-1.25 (m, 6H).
EXAMPLE 370
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methylben-
zohydrazide
[1287] The desired compound was prepared by substituting m-toluic
acid for o-toluic acid in Example 369.
[1288] MS(ESI) m/e 340 (M+H).sup.+;
[1289] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.69 (m, 2H), 7.40
(m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.41 (s, 3H), 2.16 (m, 1H), 1.98 (m, 1H),
1.29-1.25 (m, 6H).
EXAMPLE 371
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanovl)-4-methylben-
zohydrazide
[1290] The desired compound was prepared by substituting p-toluic
acid for o-toluic acid in Example 369.
[1291] MS(ESI) m/e 340 (M+H).sup.+;
[1292] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.78 (m, 2H), 7.31
(m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.41 (s, 3H), 2.15 (m, 1H), 1.99 (m, 1H),
1.29-1.24 (m, 6H).
EXAMPLE 372
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methoxybe-
nzohydrazide
[1293] The desired compound was prepared by substituting o-anisic
acid for o-toluic acid in Example 369.
[1294] MS(ESI) m/e 356 (M+H).sup.+;
[1295] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.99 (dd, 1H),
7.57 (m, 1H), 7.19 (m, 1H), 7.09 (m, 1H), 4.48 (d, 0.3H), 4.45 (d,
0.7H), 4.00 (s, 2.1H), 3.99 (s, 0.9H), 3.78 (m, 1H), 3.00 (m, 1H),
2.72 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 373
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methoxybe-
nzohydrazide
[1296] The desired compound was prepared by substituting m-anisic
acid for o-toluic acid in Example 369.
[1297] MS(ESI) m/e 356 (M+H).sup.+;
[1298] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.43 (m, 3H), 7.16
(m, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.85 (s, 3H), 3.78 (m,
1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.16 (m, 1H), 1.98 (m, 1H),
1.29-1.24 (m, 6H).
EXAMPLE 374
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-methoxybe-
nzohvdrazide
[1299] The desired compound was prepared by substituting p-anisic
acid for o-toluic acid in Example 369.
[1300] MS(ESI) m/e 356 (M+H).sup.+;
[1301] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 2H), 7.02
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.87 (s, 2,1H), 3.86 (s,
0.9H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98
(m, 1H), 1.29-1.25 (m, 6H).
EXAMPLE 375
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-fluoroben-
zohydrazide
[1302] The desired compound was prepared by substituting
o-fluorobenzoic acid for o-toluic acid in Example 369.
[1303] MS(ESI) mle 344 (M+H).sup.+;
[1304] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 1H), 7.60
(m, 1H), 7.33 (m, 1H), 7.27 (m, 1H), 4.48 (d, 0.3H), 4.44 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 376
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-fluoroben-
zohydrazide
[1305] The desired compound was prepared by substituting
m-fluorobenzoic acid for o-toluic acid in Example 369.
[1306] MS(ESI) m/e 344 (M+H).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. 7.72 (t, 1H), 7.62 (m, 1H), 7.53 (ddd, 1H),
7.36 (ddd, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00
(m, 1H), 2.72 (t, 2H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m,
6H).
EXAMPLE 377
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-fluoroben-
zohydrazide
[1307] The desired compound was prepared by substituting
p-fluorobenzoic acid for o-toluic acid in Example 369.
[1308] MS(ESI) m/e 344 (M+H).sup.+;
[1309] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.95 (m, 2H), 7.24
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m,
6H).
EXAMPLE 378
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chloroben-
zohydrazide
[1310] The desired compound was prepared by substituting
o-chlorobenzoic acid for o-toluic acid in Example 369.
[1311] MS(ESI) m/e 360 (M+H).sup.+;
[1312] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.61 (m, 1H), 7.50
(m, 2H), 7.42 (m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m,
1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H),
1.29-1.24 (m, 6H).
(399005) EXAMPLE 379
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-chloroben-
zohydrazide
[1313] The desired compound was prepared by substituting
p-chlorobenzoic acid for o-toluic acid in Example 369.
[1314] MS(ESI) m/e 360 (M+H).sup.+;
[1315] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 2H), 7.52
(m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m,
6H).
EXAMPLE 380
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropvlsulfanyl)pentanoyl)-2-bromobenz-
ohydrazide
[1316] The desired compound was prepared by substituting
o-bromobenzoic acid for o-toluic acid in Example 369.
[1317] MS(ESI) m/e 405 (M+H).sup.+;
[1318] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.69 (m, 1H), 7.59
(m, 1H), 7.46 (m, 1H), 7.42 (m, 1H), 4.48 (d, 0.3H), 4.43 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 381
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-bromobenz-
ohydrazide
[1319] The desired compound was prepared by substituting
3-bromobenzoic acid for o-toluic acid in Example 369.
[1320] MS(ESI) m/e 405 (M+H).sup.+;
[1321] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.06 (dt, 1H),
7.85 (m, 1H), 7.77 (m, 1H), 7.44 (m, 1H), 4.49 (d, 0.3H), 4.44 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 382
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-bromobenz-
ohydrazide
[1322] The desired compound was prepared by substituting
4-bromobenzoic acid for o-toluic acid in Example 369.
[1323] MS(ESI) m/e 405 (M+H).sup.+;
[1324] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.68
(m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m,
6H).
EXAMPLE 383
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-dichlor-
obenzohydrazide
[1325] The desired compound was prepared by substituting 2,
3-dichlorobenzoic acid for o-toluic acid in Example 369.
[1326] MS(ESI) m/e 395 (M+H).sup.+;
[1327] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.69 (td, 1H),
7.53 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.43 (d, 0.7H), 3.78
(m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H),
1.29-1.24 (m, 6H).
EXAMPLE 384
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-(tetrahydro-2-furanylc-
arbonyl)pentanohvdrazide
[1328] The desired compound was prepared by substituting
tetrahydrofuran-2-carboxylic acid for o-toluic acid in Example
369.
[1329] MS(ESI) m/e 320 (M+H).sup.+;
[1330] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.45 (m, 1.3H),
4.38 (d, 0.7H), 4.02 (m, 1H), 3.87 (m, 1H), 3.73 (m, 1H), 2.98 (m,
1H), 2.69 (t, 2H), 2.29 (m, 1H), 2.10 (m, 2H), 1.94 (m, 3H),
1.28-1.23 (m, 6H).
EXAMPLE 385
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-(tetrahydro-3-furanylc-
arbonyl)pentanohydrazide
[1331] The desired compound was prepared by substituting
tetrahydro-3-furic acid for o-toluic acid in Example 369.
[1332] MS(ESI) m/e 320 (M+H).sup.+;
[1333] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.42 (d, 0.3H),
4.38 (d, 0.7H), 3.96 (m, 1H), 3.88 (m, 2H), 3.79 (m, 1H), 3.72 (m,
1H), 3.10 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.13 (m, 3H), 1.94
(m, 1H), 1.28-1.23 (m, 6H).
EXAMPLE 386
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-cyclopentylpentanohydr-
azide
[1334] The desired compound was prepared by substituting
cyclopentanecarboxylic acid for o-toluic acid in Example 369.
[1335] MS(ESI) m/e 318 (M+H).sup.+;
[1336] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.3H),
4.37 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.70 (m, 2H), 2.11(m,
1H), 2.10 (m, 1H), 1.91 (m, 3H), 1.77 (m, 5H), 1.62 (m, 1H),
1.28-1.23 (m, 6H).
EXAMPLE 387
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-cyclopent-
ylacetohydrazide
[1337] The desired compound was prepared by substituting
cyclopentylacetic acid for o-toluic acid in Example 369.
[1338] MS(ESI) m/e 332 (M+H).sup.+;
[1339] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.3H),
4.37 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.27 (m,
3H), 2.10 (m, 1H), 1.94 (m, 1H), 1.85 (m, 2H), 1.67 (m, 2H), 1.58
(m, 2H), 1.28-1.23 (m, 8H).
EXAMPLE 388
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N'-cyclohexylpentanohydra-
zide
[1340] The desired compound was prepared by substituting
cyclohexanecarboxylic acid for o-toluic acid in Example 369.
[1341] MS(ESI) m/e 332 (M+H).sup.+;
[1342] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.3H),
4.37 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.30 (m,
1H), 2.10 (m, 1H), 1.94 (m, 1H), 1.82 (m, 4H), 1.71 (m, 1H), 1.48
(m, 2H), 1.37-1.23 (m, 9H).
EXAMPLE 389
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-cyclohexy-
lacetohydrazide
[1343] The desired compound was prepared by substituting
cyclohexylacetic acid for o-toluic acid in Example 369.
[1344] MS(ESI) m/e 346 (M+H).sup.+;
[1345] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.41 (d, 0.3H),
4.36 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.12 (m,
3H), 1.94 (m, 1H), 1.74 (m, 6H), 1.26 (m, 9H), 1.02 (m, 2H).
EXAMPLE 390
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-2-furohydra-
zide
[1346] The desired compound was prepared by substituting
furan-2-carboxylic acid for o-toluic acid in Example 369.
[1347] MS(ESI) m/e 316(M+H).sup.+;
[1348] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.74 (d, 0.7H),
7.72 (d, 0.3H), 7.24 (d, 0.7H), 7.21 (d, 0.3H), 6.64 (m, 1H), 4.47
(d, 0.3H), 4.43 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t,
2H), 2.14 (m, 1H), 1.97 (m, 1H), 1.28-1.23 (m, 6H).
EXAMPLE 391
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-furohydra-
zide
[1349] The desired compound was prepared by substituting
furan-3-carboxylic acid for o-toluic acid in Example 369.
[1350] MS(ESI) m/e 316 (M+H).sup.+;
[1351] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.17 (d, 0.7H),
8.14 (d, 0.3H), 7.62 (m, 1H), 6.83 (m, 1H), 4.47 (d, 0.3H), 4.43
(d, 0.7H), 3.75 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H),
1.97 (m, 1H), 1.28-1.23 (m, 6H).
EXAMPLE 392
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,5-dimethy-
l-3-furohydrazide
[1352] The desired compound was prepared by substituting
2,5-dimethyl-3-furoic acid for o-toluic acid in Example 369.
[1353] MS(ESI) m/e 344 (M+H).sup.+;
[1354] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 6.32 (s, 0.7H),
6.31 (d, 0.3H), 4.46 (d, 0.3H), 4.41 (d, 0.7H), 3.75 (m, 1H), 3.00
(m, 1H), 2.70 (t, 2H), 2.50 (s, 3H), 2.25 (s, 3H), 2.14 (m, 1H),
1.97 (m, 1H), 1.28-1.23 (m, 6H).
EXAMPLE 393
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-2-thiophene-
carbohydrazide
[1355] The desired compound was prepared by substituting
thiophene-2-carboxylic acid for o-toluic acid in Example 369.
[1356] MS(ESI) m/e 332 (M+H).sup.+;
[1357] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.77 (m, 2H), 7.17
(m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.97 (m, 1H), 1.29-1.25 (m,
6H).
EXAMPLE 394
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-thiophene-
carbohydrazide
[1358] The desired compound was prepared by substituting
thiophene-3-carboxylic acid for o-toluic acid in Example 369.
[1359] MS(ESI) m/e 332 (M+H).sup.+;
[1360] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.19 (m, 0.7H),
8.16 (m, 0.3H), 7.54 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77
(m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H),
1.29-1.24 (m, 6H).
EXAMPLE 395
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methyl-2--
thiophenecarbohydrazide
[1361] The desired compound was prepared by substituting
3-methylthiophene-2-carboxylic acid for o-toluic acid in Example
369.
[1362] MS(ESI) m/e 346 (M+H).sup.+;
[1363] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.56 (d, 0.7H),
7.53 (d, 0.3H), 6.99 (m, 1H), 4.47 (d, 0.3H), 4.43 (d, 0.7H), 3.77
(m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.51 (s, 2.1H), 2.50 (s,
0.9H), 2.14 (m, 1H), 1.97 (m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 396
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-5-methyl-2--
thiophenecarbohydrazide
[1364] The desired compound was prepared by substituting
5-methylthiophene-2-carboxylic acid for o-toluic acid in Example
369.
[1365] MS(ESI) m/e 346 (M+H).sup.+;
[1366] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.61 (d, 0.7H),
7.58 (d, 0.3H), 6.86 (m, 1H), 4.46 (d, 0.3H), 4.42 (d, 0.7H), 3.76
(m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.53(s, 3H), 2.14 (m, 1H),
1.97 (m, 1H), 1.28-1.24 (m, 6H).
EXAMPLE 397
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-IH-pyrrole--
2-carbohydrazide
[1367] The desired compound was prepared by substituting
pyrrole-2-carboxylic acid for o-toluic acid in Example 369.
[1368] MS(ES1) m/e 315 (M+H).sup.+;
[1369] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 6.99 (m, 1H), 6.90
(m, 1H), 6.21 (m, 1H), 4.45 (d, 0.3H), 4.42 (d, 0.7H), 3.76 (m,
1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.13 (m, 1H), 1.97 (m, 1H),
1.29-1.25 (m, 6H).
EXAMPLE 398
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanYl)pentanoyl)-1-methyl-1H-
-pyrrole-2-carbohydrazide
[1370] The desired compound was prepared by substituting
1-methylpyrrole-2-carboxylic acid for o-toluic acid in Example
369.
[1371] MS(ESI) m/e 329 (M+H).sup.+;
[1372] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 6.90 (m, 2H), 6.10
(m, 1H), 4.45 (d, 0.3H), 4.42(d, 0.7H), 3.89 (s, 3H), 3.76 (m, 1H),
3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24
(m, 6H).
EXAMPLE 399
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1,3-thiazol-
e-2-carbohydrazide
[1373] The desired compound was prepared by substituting
thiazole-2-carboxylic acid for o-toluic acid in Example 369.
[1374] MS(ESI) m/e 333 (M+H).sup.+;
[1375] .sup.1 H NMR (500 MHz, CD.sub.3OD) .delta. 8.02 (d, 0.6H),
8.00 (d, 0.4H), 7.94 (d, 0.6H), 7.92 (d, 0.4H), 4.49 (d, 0.4H),
4.44 (d, 0.6H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m,
1H), 1.97 (m, 1H), 1.29-1.26 (m, 6H).
EXAMPLE 400
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1,3-thiazol-
e-4-carbohydrazide
[1376] The desired compound was prepared by substituting
thiazole-4-carboxylic acid for o-toluic acid in Example 369.
[1377] MS(ESI) m/e 333 (M+H).sup.+;
[1378] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 90.6 (d, 0.7H),
9.04 (d, 0.3H), 8.41 (d, 0.7H), 8.37 (d, 0.3H), 4.48 (d, 0.3H),
4.45 (d, 0.7H), 3.78 (m, 111), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m,
1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 401
N'-((2RS,3R)-3-amino-2-hydroxy-5-isopropylpentanoyl)-2-pyridinecarbohydraz-
ide
[1379] The desired compound was prepared by substituting
pyridine-2-carboxylic acid for o-toluic acid in Example 369.
[1380] MS(ESI) m/e 327 (M+H).sup.+;
[1381] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.67 (t, 1H), 8.11
(t, 1H), 7.99 (m, 1H), 7.61 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.79 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 402
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-6-chloro-2H-
-chromene-3-carbohydrazide
[1382] The desired compound was prepared by substituting
6-chloro(2H)-1-benzopyran-3-carboxylic acid for o-toluic acid in
Example 369.
[1383] MS(ESI) m/e 414 (M+H).sup.+;
[1384] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.28 (s, 1H), 7.23
(m, 2H), 6.84 (m, 1H), 4.97 (s, 2H), 4.47 (d, 0.3H), 4.42 (d,
0.7H), 3.75 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.13 (m, 1H), 1.96
(m, 1H), 1.28-1.24 (m, 6H).
EXAMPLE 403
N'-((2RS,3R)-3-amino-2-hydroxy-7-(isopropylsulfanyl)pentanoyl)-2-(4-morpho-
linyl)acetohydrazide
[1385] The desired compound was prepared by substituting
1-morpholineacetic acid for o-toluic acid in Example 369.
[1386] MS(ESI) m/e 349 (M+H).sup.+;
[1387] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.48 (d, 0.3H),
4.39 (d, 0.7H), 3.91 (m, 6H), 3.73 (m, 1H), 3.27 (m, 4H), 2.98 (m,
1H), 2.70 (t, 2H), 2.11 (m, 1H), 1.94 (m, 1H), 1.27-1.23 (m,
6H).
EXAMPLE 404
N'-((2RS,3R)-3-amino-2-hydroxy-7-(isopropylsulfanyl)pentanoyl)-2-(4-methyl-
-1-piperazinyl)acetohydrazide
[1388] The desired compound was prepared by substituting
4-N-methylpiperazine-1-acetic acid for o-toluic acid in Example
369.
[1389] MS(ESI) m/e 362 (M+H).sup.+;
[1390] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.47-4.30 (m, 1H),
3.73 (m, 2H), 3.48 (m, 2H), 3.31 (m, 3H), 3.16 (m, 2H), 3.00 (m,
1H), 2.90 (s, 2H), 2.69 (m, 4H), 2.09 (m, 1H), 1.93 (m, 2H),
1.28-1.22 (m, 6H).
EXAMPLE 405
1-acetyl-N'-((2RS,3R)-3-amino-2-hydroxy-7-(isopropylsulfanyl)pentanoyl)-4--
piperidinecarbohydrazide
[1391] The desired compound was prepared by substituting
1-acetylpiperidine-4-carboxylic acid for o-toluic acid in Example
369.
[1392] MS(ESI) m/e 375 (M+H).sup.+;
[1393] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 4.49 (m, 1H),
4.42(d, 0.3H), 4.37 (d, 0.7H), 3.96 (m, 1H), 3.72 (m, 1H), 3.19 (m,
1H), 2.98 (m, 1H), 2.70 (m, 2H), 2.59 (m, 1H), 2.10 (m, 4H), 1.91
(m, 3H), 1.66 (m, 2H), 1.28-1.23 (m, 6H).
EXAMPLE 406
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-ethylbenz-
ohydrazide
[1394] The desired compound was prepared by substituting
4-ethylbenzoic acid for o-toluic acid in Example 369.
[1395] MS(ESI) m/e 354 (M+H).sup.+;
[1396] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.82 (m, 2H), 7.34
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 4H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m,
9H).
EXAMPLE 407
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanvl)pentanovl)-3-fluoro-2--
methylbenzohydrazide
[1397] The desired compound was prepared by substituting
3-fluoro-2-methyl-benzoic acid for o-toluic acid in Example
369.
[1398] MS(ESI) m/e 358 (M+H).sup.+;
[1399] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.32 (m, 2H), 7.21
(m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.79 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.36 (m, 3H), 2.16 (m, 1H), 1.98 (m, 1H),
1.29-1.24 (m, 6H).
EXAMPLE 408
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-difluor-
obenzohydrazide
[1400] The desired compound was prepared by substituting 2,
3-difluorobenzoic acid for o-toluic acid in Example 369.
[1401] MS(ESI) m/e 362 (M+H).sup.+;
[1402] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.55 (m, 1H), 7.49
(m, 1H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m,
1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m, 1H),
1.29-1.24 (m, 6H).
EXAMPLE 409
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propylben-
zohydrazide
[1403] The desired compound was prepared by substituting
4-N-propylbenzoic acid for o-toluic acid in Example 369.
[1404] MS(ESI) m/e 368 (M+H).sup.+;
[1405] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 1H), 7.32
(m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
1H), 2.70 (t, 4H), 2.15 (m, 1H), 1.98 (m, 1H), 1.68 (m, 2H),
1.29-1.24 (m, 6H), 0.95 (t, 1H).
EXAMPLE 410
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-isopropyl-
benzohydrazide
[1406] The desired compound was prepared by substituting
4-isopropylbenzoic acid for o-toluic acid in Example 369.
[1407] MS(ESI) m/e 368 (M+H).sup.+;
[1408] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.82 (m, 2H), 7.38
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m,
12H).
EXAMPLE 411
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanovl)-2-ethoxyben-
zohydrazide
[1409] The desired compound was prepared by substituting
2-ethoxybenzoic acid for o-toluic acid in Example 369.
[1410] MS(ESI) m/e 370 (M+H).sup.+;
[1411] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.97 (m, 1H), 7.54
(m, 1H), 7.18 (m, 1H), 7.09 (t, 1H), 4.49 (d, 0.3H), 4.44 (d,
0.7H), 4.29 (q, 2H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15
(m, 1H), 1.97 (m, 1H), 1.51 (t, 3H), 1.29-1.24 (m, 6H).
EXAMPLE 412
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-ethoxyben-
zohydrazide
[1412] The desired compound was prepared by substituting
4-ethoxybenzoic acid for o-toluic acid in Example 369.
[1413] MS(ESI) m/e 370 (M+H).sup.+;
[1414] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.85 (m, 1H), 6.99
(m, 1H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 4.12 (q,
2H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.41 (t, 3H), 1.29-1.24 (m, 6H).
EXAMPLE 413
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanovl)-1-naphthohy-
drazide
[1415] The desired compound was prepared by substituting
1-naphthoic acid for o-toluic acid in Example 369.
[1416] MS(ESI) m/e 376 (M+H).sup.+;
[1417] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.38 (m, 1H), 8.04
(t, 1H), 7.95 (m, 1H), 7.77 (t, 1H), 7.56 (m, 3H), 4.53 (d, 0.3H),
4.49 (d, 0.7H), 3.84 (m, 1H), 3.02 (m, 1H), 2.74 (t, 2H), 2.19 (m,
1H), 2.01 (m, 1H), 1.31-1.24 (m, 6H).
EXAMPLE 414
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-tert-buty-
lbenzohydrazide
[1418] The desired compound was prepared by substituting
4-tert-butylbenzoic acid for o-toluic acid in Example 369.
[1419] MS(ESI) m/e 382 (M+H).sup.+;
[1420] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.83 (m, 2H), 7.55
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.99 (m, 1H), 1.35 (s, 9H),
1.29-1.24 (m, 6H).
EXAMPLE 415
N-(4-((2-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)hydraz-
ino)carbonyl)phenyl)acetamide
[1421] The desired compound was prepared by substituting
4-acetamidobenzoic acid for o-toluic acid in Example 369.
[1422] MS(ESI) m/e 383 (M+H).sup.+;
[1423] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.86 (m, 2H), 7.71
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.15 (m, 4H), 1.97 (m, 1H), 1.29-1.24 (m,
6H).
EXAMPLE 416
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propoxybe-
nzohydrazide
[1424] The desired compound was prepared by substituting
p-propoxybenzoic acid for o-toluic acid in Example 369.
[1425] MS(ESI) m/e 384 (M+H).sup.+;
[1426] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.85 (m, 2H), 7.00
(m, 2H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 4.01 (m,2H),
3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m,
1H), 1.82 (m, 2H), 1.29-1.24 (m, 6H), 1.05 (t, 3H).
EXAMPLE 417
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-isopropox-
ybenzohydrazide
[1427] The desired compound was prepared by substituting
4-isopropoxybenzoic acid for o-toluic acid in Example 369.
[1428] MS(ESI) m/e 384 (M+H).sup.+;
[1429] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.84 (m, 2H), 6.98
(m, 2H), 4.71 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m,
1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.34
(d, 6H), 1.29-1.24 (m, 6H).
EXAMPLE 418
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-5-chloro-2--
methoxybenzohydrazide
[1430] The desired compound was prepared by substituting
5-chloro-2-methoxybenzoic acid for o-toluic acid in Example
369.
[1431] MS(ESI) m/e 390 (M+H).sup.+;
[1432] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.92 (d, 0.7H),
7.89 (d, 0.3H), 7.55 (td, 1H), 7.20 (m, 1H), 4.47 (d, 0.3H), 4.44
(d, 0.7H), 4.00 (s, 2.1H), 3.98 (s, 0.9H), 3.78 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m,
6H).
EXAMPLE 419
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4
(methylsulfonyl)benzohydrazide
[1433] The desired compound was prepared by substituting
4-(methylsulfonyl)benzoic acid for o-toluic acid in Example
369.
[1434] MS(ESI) m/e 404 (M+H).sup.+;
[1435] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.10 (s, 2.8H),
8.09 (s, 1.2H), 4.51 (d, 0.3H), 4.46 (d, 0.7H), 3.78 (m, 1H), 3.17
(s, 2.8H), 3.17 (s, 1.2H), 3.01 (m, 1H), 2.72 (t, 2H), 2.16 (m,
1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 420
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chloro-5--
(methylsulfanyl)benzohydrazide
[1436] The desired compound was prepared by substituting
2-chloro-5-(methylthio)benzoic acid for o-toluic acid in Example
369.
[1437] MS(ESI) m/e 406 (M+H).sup.+;
[1438] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.49 (d, 1H),
7.43-7.35 (m, 2H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H),
3.00 (m, 1H), 2.72 (t, 2H), 2.52 (s, 1H), 2.15 (m, 1H), 1.97 (m,
1H), 1.29-1.24 (m, 6H).
EXAMPLE 421
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3,4-diethox-
ybenzohydrazide
[1439] The desired compound was prepared by substituting
3,4-diethoxybenzoic acid for o-toluic acid in Example 369.
[1440] MS(ESI) m/e 414 (M+H).sup.+;
[1441] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.51 (m, 1H), 7.48
(m, 1H), 7.02 (m, 1H), 4.47 (d, 0.3H), 4.44 (d, 0.7H), 4.12 (m,
4H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.43 (m, 6H), 1.29-1.24 (m, 6H).
EXAMPLE 422
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-benzylben-
zohydrazide
[1442] The desired compound was prepared by substituting
alpha-phenyl-o-toluic acid for o-toluic acid in Example 369.
[1443] MS(ESI) m/e 416 (M+H).sup.+;
[1444] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.54 (t, 1H), 7.40
(m, 1H), 7.29 (t, 1H), 7.23 (m, 5H), 7.16 (m, 1H), 4.49 (d, 0.3H),
4.43 (d, 0.7H), 4.19 (m, 1H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t,
2H), 2.15 (m, 1H), 1.97 (m, 1H), 1.29-1.19 (m, 6H).
EXAMPLE 423
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-anilinobe-
nzohydrazide
[1445] The desired compound was prepared by substituting
N-phenylanthranilic acid for o-toluic acid in Example 369.
[1446] MS(ESI) m/e 417 (M+H).sup.+;
[1447] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.68 (m, 1H), 7.32
(m, 4H), 7.16 (d, 2H), 7.02 (m, 1H), 6.83 (m, 1H), 4.49 (d, 0.3H),
4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.16 (m,
1H), 1.98 (m, 1H), 1.28-1.19 (m, 6H).
EXAMPLE 424
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-(2-phenyl-
ethyl)benzohydrazide
[1448] The desired compound was prepared by substituting
2-bibenzylcarboxylic acid for o-toluic acid in Example 369.
[1449] MS(ESI) m/e 430 (M+H).sup.+;
[1450] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.53 (m, 1H), 7.40
(m, 1H), 7.28 (m, 2H), 7.23 (d, 4H), 7.15 (m, 1H), 4.50 (d, 0.3H),
4.45 (d, 0.7H), 3.81 (m, 1H), 3.10 (m, 2H), 3.01 (m, 1H), 2.93 (m,
2H), 2.72 (t, 2H), 2.17 (m, 1H), 1.99 (m, 1H), 1.29-1.20 (m,
6H).
EXAMPLE 425
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(methylsu-
lfanyl)benzohydrazide
[1451] The desired compound was prepared by substituting
3-(methylthio)benzoic acid for o-toluic acid in Example 369.
[1452] MS(ESI) m/e 372 (M+H).sup.+;
[1453] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.77 (m, 1H), 7.63
(m, 1H), 7.48 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.53 (s, 3H), 2.15
(m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 426
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(ethylsul-
fanyl)benzohydrazide
[1454] The desired compound was prepared by substituting
3-(ethylthio)benzoic acid for o-toluic acid in Example 369.
[1455] MS(ESI) m/e 386 (M+H).sup.+;
[1456] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.83 (m, 1H), 7.67
(m, 1H), 7.54 (m, 1H), 7.43 (m, 1H), 4.49 (d, 0.311), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.33-1.25 (m, 9H).
EXAMPLE 427
N'-((2RS,3R)-3-amino-2-hvdroxv-5-(isopropylsulfanyl)pentanoyl)-3-(propylsu-
lfanyl)benzohydrazide
[1457] The desired compound was prepared by substituting
3-(propylthio)benzoic acid for o-toluic acid in Example 369.
[1458] MS(ES1) m/e 400 (M+H).sup.+;
[1459] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.83 (m, 1H), 7.66
(t, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.68 (m, 2H), 1.29-1.24 (m, 6H), 1.04 (t, 3H).
EXAMPLE 428
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(butylsul-
fanyl)benzohydrazide
[1460] The desired compound was prepared by substituting
3-(butylthio)benzoic acid for o-toluic acid in Example 369.
[1461] MS(ESI) m/e 414 (M+H).sup.+;
[1462] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.83 (m, 1H), 7.66
(t, 1H), 7.54 (t, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.64 (m, 2H), 1.49 (m, 2H), 1.29-1.24 (m, 6H), 0.94 (t,
3H).
EXAMPLE 429
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(hexylsul-
fanyl)benzohydrazide
[1463] The desired compound was prepared by substituting
3-(hexylthio)benzoic acid for o-toluic acid in Example 369.
[1464] MS(ESI) m/e 442 (M+H).sup.+;
[1465] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.83 (m, 1H), 7.66
(t, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.48 (d, 0.3H), 4.44 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.65 (m, 2H), 1.46 (m, 2H), 1.32-1.24 (m, lOH), 0.90 (t,
3H).
EXAMPLE 430
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isopropy-
lsulfanyl)benzohydrazide
[1466] The desired compound was prepared by substituting
3-(isopropylthio)benzoic acid for o-toluic acid in Example 369.
[1467] MS(ESI) m/e 400 (M+H).sup.+;
[1468] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.90 (m, 1H), 7.73
(m, 1H), 7.61 (m, 1H), 7.45 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.51 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15
(m, 1H), 1.98 (m, 1H), 1.30-1.24 (m, 12H).
EXAMPLE 431
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isobutvl-
sulfanyl)benzohydrazide
[1469] The desired compound was prepared by substituting
3-(2-methylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1470] MS(ESI) m/e 414 (M+H).sup.+;
[1471] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.84 (m, 1H), 7.65
(m, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.90 (d, 2H), 2.72 (t, 2H), 2.15
(m, 1H), 1.98 (m, 1H), 1.86 (m, 1H), 1.29-1.24 (m, 6H), 1.05 (d,
6H).
EXAMPLE 432
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentnoyl)-3-((4-methyl-
pentyl)sulfanyl)benzohydrazide
[1472] The desired compound was prepared by substituting
3-(4-methylpentylthio)benzoic acid for o-toluic acid in Example
369.
[1473] MS(ESI) m/e 442 (M+H).sup.+;
[1474] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.83 (m, 1H), 7.66
(m, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.44 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.66 (m, 2H), 1.56 (m, 1H), 1.34 (m, 2H), 1.29-1.24 (m,
6H), 0.89 (d, 6H).
EXAMPLE 433
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(sec-buty-
lsulfanyl)benzohydrazide
[1475] The desired compound was prepared by substituting
3-(1-methylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1476] MS(ESI) m/e 414 (M+H).sup.+;
[1477] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.90 (m, 1H), 7.72
(m, 1H), 7.61 (m, 1H), 7.44 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.31 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15
(m, 1H), 1.98 (m, 1H), 1.62 (m, 2H), 1.29-1.24 (m, 9H), 1.03 (t,
3H).
EXAMPLE 434
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(neopenty-
lsulfanvl)benzohvdrazide
[1478] The desired compound was prepared by substituting
3-(2,2-dimethylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1479] MS(ESI) m/e 428 (M+H).sup.+;
[1480] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.86 (m, 1H), 7.65
(m, 1H), 7.57 (m, 1H), 7.40 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98
(m, 1H), 1.29-1.24 (m, 6H), 1.05 (s, 9H).
EXAMPLE 435
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(cyclohex-
ylsulfanvl)benzohydrazide
[1481] The desired compound was prepared by substituting
3-(cyclohexylthio)benzoic acid for o-toluic acid in Example
369.
[1482] MS(ESI) m/e 440 (M+H).sup.+;
[1483] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.90 (m, 1H), 7.72
(m, 1H), 7.60 (m, 1H), 7.43 (m, 1H), 4.49 (d, 0.3H), 4.45 (d,
0.7H), 3.78 (m, 1H), 3.25 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15
(m, 1H), 1.98 (m, 3H), 1.78 (m, 2H), 1.65 (m, 2H), 1.38 (m, 4H),
1.29-1.24 (m, 6H).
EXAMPLE 436
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((cyclohe-
xylmethyl)sulfanyl)benzohydrazide
[1484] The desired compound was prepared by substituting
3-(2-cyclohexylethylthio)benzoic acid for o-toluic acid in Example
369.
[1485] MS(ESI) mle 454 (M+H).sup.+;
[1486] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.82 (m, 1H), 7.65
(t, 1H), 7.53 (t, 1H), 7.41 (m, 1H), 4.48 (d, 0.3H), 4.44 (d,
0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.90 (d, 2H), 2.72 (t, 2H), 2.15
(m, 1H), 1.98 (m, 1H), 1.91 (m, 2H), 1.74 (m, 2H), 1.66 (m, 2H),
1.53 (m, 1H), 1.29-1.18 (m, 8H), 1.05 (m, 2H).
EXAMPLE 437
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(benzylsu-
lfanyl)benzohydrazide
[1487] The desired compound was prepared by substituting
3-(benzylthio)benzoic acid for o-toluic acid in Example 369.
[1488] MS(ESI) m/e 448 (M+H).sup.+;
[1489] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.86 (m, 1H), 7.67
(m, 1H), 7.52 (m, 1H), 7.39 (m, 1H), 7.31 (d, 2H), 7.26 (t, 2H),
7.20 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 4.22 (s, 2H), 3.77
(m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H),
1.29-1.25 (m, 6H).
EXAMPLE 438
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((2-pheny-
lethyl)sulfanyl)benzohydrazide
[1490] The desired compound was prepared by substituting
3-(2-phenylethylthio)benzoic acid for o-toluic acid in Example
369.
[1491] MS(ESI) m/e 462 (M+H).sup.+;
[1492] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.87 (m, 1H), 7.68
(m, 1H), 7.57 (m, 1H), 7.44 (m, 1H), 7.27 (t, 2H), 7.23-7.17 (m,
3H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.77 (m, 1H), 3.26 (t, 2H),
3.00 (m, 1H), 2.93 (t, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m,
1H), 1.29-1.24 (m, 6H).
EXAMPLE 439
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((3-pheny-
lpropyl)sulfanyl)benzohydrazide
[1493] The desired compound was prepared by substituting
3-(3-phenylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1494] MS(ESI) m/e 476 (M+H).sup.+;
[1495] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.84 (m, 1H), 7.67
(m, 1H), 7.51 (m, 1H), 7.41 (m, 1H), 7.25 (t, 2H), 7.15 (m, 3H),
4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.76
(t, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.96 (m, 3H), 1.29-1.24 (m,
6H).
EXAMPLE 440
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(((1,1
'-biphenyl)-4-ylmethyl)sulfanyl)benzohydrazide
[1496] The desired compound was prepared by substituting
3-(biphenylmethylthio)benzoic acid for o-toluic acid in Example
369.
[1497] MS(ESI) m/e 524 (M+H).sup.+;
[1498] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.89 (s, 1H), 7.68
(m, 1H), 7.55 (m, 5H), 7.40 (m, 5H), 7.31 (m, 1H), 4.48 (d, 0.3H),
4.44 (d, 0.7H), 4.27 (m, 2H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t,
2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
EXAMPLE 441
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-4-(methylsu-
lfanyl)benzohydrazide
[1499] The desired compound was prepared by substituting
4-(methylthio)benzoic acid for o-toluic acid in Example 369.
[1500] MS(ESI) m/e 372 (M+H).sup.+;
[1501] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 2H), 7.34
(m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.53 (s, 3H), 2.15 (m, 1H), 1.98 (m, 1H),
1.29-1.25 (m, 6H).
EXAMPLE 442
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-4-(ethylsul-
fanyl)benzohydrazide
[1502] The desired compound was prepared by substituting
4-(ethylthio)benzoic acid for o-toluic acid in Example 369.
[1503] MS(ESI) m/e 386 (M+H).sup.+;
[1504] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 2H), 7.38
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.03 (m,
3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.35 (t, 3H),
1.29-1.25 (m, 6H).
EXAMPLE 443
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(propylsu-
lfanyl)benzohydrazide
[1505] The desired compound was prepared by substituting
4-(propylthio)benzoic acid for o-toluic acid in Example 369.
[1506] MS(ESI) m/e 400 (M+H).sup.+;
[1507] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.38
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.01 (m,
3H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.72 (m, 2H),
1.29-1.24 (m, 6H), 1.06 (t, 3H).
EXAMPLE 444
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-4-(butylsul-
fanyl)benzohydrazide
[1508] The desired compound was prepared by substituting
4-(butylthio)benzoic acid for o-toluic acid in Example 369.
[1509] MS(ESI) m/e 414 (M+H).sup.+;
[1510] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.37
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.02 (m,
3H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.67 (m, 2H), 1.50
(m, 2H), 1.29-1.24 (m, 6H), 0.95 (t, 3H).
EXAMPLE 445
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(hexylsul-
fanyl)benzohydrazide
[1511] The desired compound was prepared by substituting
4-(hexylthio)benzoic acid for o-toluic acid in Example 369.
[1512] MS(ESI) m/e 442 (M+H).sup.+;
[1513] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.37
(t, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.02 (m,
3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.68 (m, 2H), 1.47
(m, 2H), 1.33 (m, 4H), 1.29-1.24 (m, 6H), 0.91 (t, 3H).
EXAMPLE 446
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isopropy-
lsulfanyl)benzohydrazide
[1514] The desired compound was prepared by substituting
4-(isopropylthio)benzoic acid for o-toluic acid in Example 369.
[1515] MS(ESI) m/e 400 (M+H).sup.+;
[1516] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.81 (m, 2H), 7.43
(dd, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.62 (m,
1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.34
(d, 6H), 1.29-1.24 (m, 6H).
EXAMPLE 447
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isobutyl-
sulfanyl)benzohydrazide
[1517] The desired compound was prepared by substituting
4-(2-methylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1518] MS(ESI) m/e 414 (M+H).sup.+;
[1519] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.38
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m,
1H), 2.92 (d, 2H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.90
(m, 1H), 1.29-1.24 (m, 6H), 1.06 (d, 6H).
EXAMPLE 448
N'-((2RS,3R)-3-arnino-2-hydroxy-5-(isopropylsulfanyl)pentnoyl)-4-((4-methy-
lpentyl)sulfanyl)benzohydrazide
[1520] The desired compound was prepared by substituting
4-(4-methylpentylthio)benzoic acid for o-toluic acid in Example
369.
[1521] MS(ESI) m/e 442 (M+H).sup.+;
[1522] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.38
(m, 2H), 4.45 (d, 0.3H), 4.41 (d, 0.7H), 3.71 (m, 1H), 3.01 (m,
3H), 2.71 (t, 2H), 2.13 (m, 1H), 1.96 (m, 1H), 1.69 (m, 2H), 1.57
(m, 1H), 1.36 (m, 2H), 1.29-1.24 (m, 6H), 0.89 (d, 6H).
EXAMPLE 449
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(sec-buty-
lsulfanyl)benzohydrazide
[1523] The desired compound was prepared by substituting
4-(1-methylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1524] MS(ESI) m/e 414 (M+H).sup.+;
[1525] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.43
(dd, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.65 (m, 2H), 1.33
(d, 3H), 1.29-1.24 (m, 6H), 1.04 (t, 3H).
EXAMPLE 450
N'-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanovl)-4-(neopenty-
lsulfanyl)benzohydrazide
[1526] The desired compound was prepared by substituting 4-(2,
2-dimethylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1527] MS(ESI) m/e 428 (M+H).sup.+;
[1528] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.79 (m, 2H), 7.42
(m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m,
3H), 2.72 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H),
1.06 (s, 9H).
EXAMPLE 451
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(cyclohex-
ylsulfanyl)benzohydrazide
[1529] The desired compound was prepared by substituting
4-(cyclohexylthio)benzoic acid for o-toluic acid in Example
369.
[1530] MS(ESI) mle 440 (M+H).sup.+;
[1531] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.80 (m, 2H), 7.41
(m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.37 (m,
1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 3H), 1.79
(m, 2H), 1.65 (m, 2H), 1.39 (m, 4H), 1.29-1.24 (m, 6H).
EXAMPLE 452
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((cyclohe-
xylmethyl)sulfanyl)benzohydrazide
[1532] The desired compound was prepared by substituting
4-(2-cyclohexylethylthio)benzoic acid for o-toluic acid in Example
369.
[1533] MS(ESI) m/e 454 (M+H).sup.+;
[1534] .sup.1 H NMR (500 MHz, CD.sub.3OD) .delta. 7.79 (m, 2H),
7.37 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00
(m, 1H), 2.91 (d, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H),
1.92 (m, 2H), 1.75 (m, 2H), 1.67 (m, 2H), 1.56 (m, 1H), 1.29-1.21
(m, 8H), 1.06 (m, 2H).
EXAMPLE 453
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(benzylsu-
lfanyl)benzohydrazide
[1535] The desired compound was prepared by substituting
4-(benzylthio)benzoic acid for o-toluic acid in Example 369.
[1536] MS(ESI) m/e 448 (M+H).sup.+;
[1537] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.77 (m, 2H), 7.39
(m, 4H), 7.28 (t, 2H), 7.22 (m, 1H), 4.48 (d, 0.3H), 4.43 (d,
0.7H), 4.27 (s, 0.7H), 4.26 (s, 0.3H), 3.77 (m, 1H), 3.00 (m, 1H),
2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.23 (m, 6H).
EXAMPLE 454
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((2-pheny-
lethyl)sulfanyl)benzohydrazide
[1538] The desired compound was prepared by substituting
4-(2-phenylethylthio)benzoic acid for o-toluic acid in Example
369.
[1539] MS(ESI) m/e 462 (M+H).sup.+;
[1540] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.82 (m, 2H), 7.41
(m, 2H), 7.28 (m, 2H), 7.21 (m, 3H), 7.27 (t, 2H), 7.23-7.17 (m,
3H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.28 (m, 2H),
3.00 (m, 1H), 2.96 (t, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m,
1H), 1.29-1.24 (m, 6H).
EXAMPLE 456
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((3-pheny-
lpropvl)sulfanyl)benzohydrazide
[1541] The desired compound was prepared by substituting
4-(3-phenylpropylthio)benzoic acid for o-toluic acid in Example
369.
[1542] MS(ESI) m/e 476 (M+H).sup.+;
[1543] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.78 (m, 2H), 7.33
(m, 2H), 7.27 (m, 2H), 7.18 (m, 3H), 4.48 (d, 0.3H), 4.44 (d,
0.7H), 3.77 (m, 1H), 3.01 (m, 3H), 2.77 (t, 2H), 2.71 (t, 2H), 2.15
(m, 1H), 1.98 (m, 3H), 1.29-1.24 (m, 6H).
EXAMPLE 457
N'-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(((1,1'-b-
iphenyl)-4-ylmethyl)sulfanyl)benzohydrazide
[1544] The desired compound was prepared by substituting
4-(biphenylmethylthio)benzoic acid for o-toluic acid in Example
369.
[1545] MS(ESI) m/e 524 (M+H).sup.+;
[1546] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.78 (m, 2H), 7.58
(d, 2H), 7.55 (d, 2H), 7.43 (m, 6H), 7.31 (m, 1H), 4.48 (d, 0.3H),
4.43 (d, 0.7H), 4.32 (s, 1.4H), 4.31 (s, 0.6H), 3.76 (m, 1H), 3.00
(m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m,
6H).
EXAMPLE 458
(2S
,3R)-3-arnino-N'-(3-chlorobenzoyl)-2-hydroxy-5-phenylpentanohydrazide
Example 458A 4-phenylbutanal
[1547] A solution of 4-phenylbutyric acid (1.64 g, 10.0 mmol),
N,O-dimethyl hydroxylamine hydrochloride (1.58 g, 16 mmol),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.06
g, 10.7 mmol), 1-hydroxybenzotriazole (1.56 g, 11.6 mmol), and
N-methylmorpholine (2.8 mL, 26 mmol) in dichloromethane (40 mL) at
room temperature was stirred for 16 hours, diluted with
dichloromethane, washed sequentially with aqueous NaHCO.sub.3,
brine, 10% KHSO4, and brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate and lithium aluminum hydride (9.0
mmol, 1 equivalent) in diethyl ether (49 mL) at room temperature
was stirred 90 minutes, treated with IM NaHSO.sub.4, diluted with
ether, washed sequentially with 10% KHSO.sub.4, and brine, dried
(MgSO.sub.4), filtered then concentrated to provide the desired
product.
[1548] MS(ESI) m/e 148 (M+H).sup.+.
EXAMPLE 458B
(2S,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-6-phenylhexanoic
acid
[1549] The desired product was prepared by substituting Example
458A for 2-ethylhexanal in Examples 236A-236C.
[1550] MS(ESI) m/e 324 (M+H).sup.+.
EXAMPLE 458C
(2S
,3R)-3-amino-N'-(3-chlorobenzoyl)-2-hydroxy-5-phenylpentanohydrazide
[1551] The desired product was prepared by substituting
3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride
and Example 458B for Example 98A in Example 98B.
[1552] MS(ESI) m/e 376 (M+H).sup.+;
[1553] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.69 (br s,
1H), 10.30 (br s, 1H), 8.24 (br s, 2H), 7.92 (m, 1H), 7.86 (d, 1H),
7.69 (d, 1H), 7.57 (t, IH), 7.24 (m, 5H), 6.62 (m, 1H), 4.21 (m,
1H), 2.60 (m, 2H) 1.90-1.55 (m, 4H).
EXAMPLE 459
(2S,3R)-3-amino-N'-(3-chlorobenzoyl)-2-hydroxy-5-(1H-indol-3-yl)pentanohyd-
razide
EXAMPLE 459A
3-(3-indolyl)propanal
[1554] The desired product was prepared by substituting
3-indolylpropionic acid for 4-phenylbutyric acid in Example
458A.
[1555] MS(ESI) m/e 174 (M+H).sup.+.
EXAMPLE 459B
(2S,3R)-3-(tert-butoxycarbonvl)amino-2-hydroxy-5-(3-indolyl)pentanoic
acid The desired product was prepared by substituting Example 459A
for 2-ethylhexanal in Examples 236A-236C.
[1556] MS(ESI) m/e 349 (M+H)+.
EXAMPLE 459C
(2S
,3R)-3-amino-N'-(3-chlorobenzoyl)-2-hydroxy-5-(lH-indol-3-yl)pentanohy-
drazide
[1557] The desired product was prepared by substituting
3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride
and Example 459B for Example 98A in Example 98B.
[1558] MS(ESI) m/e 400 (M+H).sup.+;
[1559] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.69 (br s,
1H), 10.33 (br s, 1H), 7.98 (br s, 2H), 7.90 (m. 1H), 7.85 (d, 1H),
7.68 (d, 1H), 7.56 (t, 1H), 7.34 (m, 2H), 7.17 (m, 1H), 7.08 (m,
1H), 6.98 (m, 1H), 6.67 (m, 1H), 4.23 (m, 1H), 2.80 (m, 2H), 2.27
(m, 1H), 1.91 (m, 1H).
EXAMPLE 460
(2RS,3R)-3-amino-N'-(3-(2,3-dihydroxypropoxy)benzoyl)-2-hydroxy-5-(isoprop-
ylsulfanyl)pentanohydrazide
Example 460A
methyl 3-(prop-2-enyloxy)benzoate
[1560] Methyl-3-hydroxy-benzoate (1.09 g, 4.9 mmol), allyl bromide
(0.73 g, 6.0 mmol) and potassium tert-butoxide (6.5 g, 5.8 mmol) in
DMSO (15 mL) was stirred at room temperature for 16 hours. The
mixture was poured into ice water, extracted with ether, washed
with brine, dried (Na.sub.2SO.sub.4), and evaporated to give the
title compound.
[1561] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.55 (m, 1H),
7.45 (m, 2H), 7.24 (m, 1H), 6.12-5.98 (m, 1H), 5.44-5.26 (m, 2H),
4.64 (m, 2H), 3.84 (s, 3H).
EXAMPLE 460B
methyl 3-(2,3-dihydoxypropyloxy)benzoate
[1562] A solution of Example 460A (0.3 g, 1.5 mmol),
4-methylmorpholine N-oxide (0.55 g, 4.5 mmol) and osmium tetroxide
(4 wt % solution in water 0.1 mL, 0.015 mmol) in 9:1/acetone:water
was stirred at room temperature for 48h. The reaction was quenched
with 10% Na.sub.2S.sub.20.sub.3 and stirred for 15 minutes,
extracted with ethyl acetate, washed with brine, dried
(Na.sub.2SO.sub.4), and concentrated to give the title
compound.
[1563] MS(ESI) m/e 249 (M+Na).sup.+.
[1564] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.54 (m, 1H),
7.44 (m, 2H), 7.23 (m, 1H), 4.98 (d, 1H), 4.68 (t, 1H), 4.05 (dd,
1H), 3.51 (dd, 1H), 3.85 (s, 3H), 3.8 (m, 1H), 3.55 & 3.45 (t,
2H).
EXAMPLE 460C
Methyl 3-(2,3-di(tertbutyldimethylsilyloxy)propoxv)benzoate
[1565] A solution of Example 460B (0.26 g, 1.15 mmol),
tert-butyldimethylsilyl chloride (0.44 g, 2.87 mmol) and imidazole
(0.31 g, 4.6 mmol) in DMF (10 mL) was stirred at room temperature
for 18 hours. The mixture was diluted with ether, washed with
brine, dried (Na.sub.2SO.sub.4), and concentrated to give the title
compound.
[1566] MS(ESI) m/e 455 (M+H)+.
[1567] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.58 (m, 1H),
7.47 (m, 2H), 7.26 (m, 1H), 4.09 (dd, 1H), 3.98 (dd, 1H), 3.89 (s,
3H), 3.85 (m, 1H), 3.67 (d, 2H), 0.91 (s, 9H), 0.89 (s, 9H), 0.08
(s, 6H), 0.05 (s, 6H).
EXAMPLE 460D
(2RS
3R)-3-amino-N'-(3-(2,3-dihydroxypropoxy)benzoyl)-2-hydroxy-5-(isoprop-
ylsulfanyl)pentanohydrazide
[1568] Example 460C was treated with hydrazine hydrate in ethanol
at reflux for 48h. After evaporation of the reaction mixture to
dryness, the resulting hydrazide was reacted with Example 123B as
in Example 98B.
[1569] MS(ESI) m/e 414 (M-H).sup.+.
[1570] .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.57 &
10.38 (s, 1H), 10.23 & 10.12 (s, 1H), 8.05 & 7.97 (br s,
2H), 7.48-7.38(m, 3H), 7.16 (m, 1H), 6.65 & 6.56 (d, 1H), 4.98
& 4.7 (br s, 1H), 4.39 & 4.25 (t, 1H), 4.05 (dd, 1H), 3.92
(m, 1H), 3.81 (m, 1H), 3.46 (d, 2H), 3.02-2.92(m, 1H), 2.75-2.55
(m, 2H), 2.05-1.75 (m, 2H), 1.2 (m,6H).
[1571] It will be evident to one skilled in the art that the
present invention is not limited to the forgoing illustrative
examples, and that it can be embodied in other specific forms
without departing from the essential attributes thereof. It is
therefore desired that the examples be considered in all respects
as illustrative and not restrictive, reference being made to the
appended claims, and all changes which come within the meaning and
range of equivalency of the claims and therefore intended to be
embraced therein.
* * * * *